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Abstract
CD40L is a membrane protein belonging to the tumour necrosis factor family, 
originally found on activated T cells. The CD40L-CD40 interaction is of critical 
importance in the adaptive immune response, in innate immunity and in inflammation. 
Recently, activated platelets have been found to express CD40L. Platelets can 
stimulate endothelial cells via a CD40L-CD40 interaction to upregulate adhesion 
molecule expression, tissue factor expression and cytokine production. The aim of this 
project was to investigate the role of platelet CD40L in inflammation, focusing 
particularly on the platelet-monocyte interaction. A novel assay using thrombin 
receptor agonist peptide (TRAP) was used to confirm the existence of CD40L on 
human platelets in whole blood. Using this assay it was demonstrated that resting 
platelets do not express CD40L. However, CD40L expression occurred within 
minutes of stimulation with TRAP, with the same kinetics as CD62P expression, 
suggesting that platelet CD40L is stored, pre-synthesised, in the platelet a-granule. 
Platelets adhered to both circulating monocytes and the monocytoid cell line THP-1 in 
a P-selectin dependent manner following stimulation with TRAP. Confirmation of the 
importance of P-selectin in this interaction came from experiments using blocking 
antibodies and also from experiments using blood from patients with naturally 
occurring knockouts of platelet and monocyte adhesion molecules. Platelet CD40L 
did not induce monocyte cytokine production. During the course of the investigation, 
it became clear that platelets themselves became activated in response to CD40L. 
Further experiments demonstrated that platelets constitutively express functional 
CD40 and that stimulation of platelets with CD40L causes the platelet release reaction
2
to occur. These findings have important implications in the understanding of the 
biology of human platelets in both health and disease.
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1.Introduction
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1.1 Platelets
"The existence of a constant blood particle, differing from the red and white blood 
cells, has been suspected by several authors for some time". Thus Giulio Bizzozero 
announced his discovery of the platelet to the world in 1882 (Bizzozero, 1882). In this 
first report, Bizzozero also even presented functional evidence of the importance of the 
platelet in haemostasis and thrombosis. "The more rapid coagulation of blood, flowing 
from a wound which had been open for some time, is probably due to the presence of 
aggregates of blood platelets which have formed some time after the first incision, on 
the surface of vascular lesions and the margins of incision". Bizzozero's functional 
observations were confirmed and expanded over the following years. Platelets are now 
known to be critical in the processes of haemostasis, coagulation and thrombosis. 
Within seconds of vascular injury, a primary haemostatic plug composed of aggregated 
platelets is formed. Activation of the clotting cascades by subendothelial tissue factor 
and the subsequent generation of fibrin strands from fibrinogen in blood plasma also 
depends upon components of the platelet. These fibrin strands stabilise the haemostatic 
plug, which prevents further blood loss prior to thrombus formation and eventual 
wound healing.
Recent observations now suggest that the influence of the platelet extends far beyond 
the process of haemostasis to inflammation, wound healing and vascular remodelling.
1.1.1 Morphology and ultrastructure
Platelets are anucleate cell fragments, which circulate for 7-10 days, with physiological 
levels of 150x109/L to 400xl09platelets/L. They are derived from bone marrow 
megakaryocytes and are produced by a process of cytoplasmic budding in the bone
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marrow (Wright,1910). There is now evidence to suggest they may also be produced 
by fragmentation o f circulating megakaryocytes in the pulmonary capillary bed 
(Zucker-Franklin et al, 2000). The classical description o f the shape o f the platelet is as 
an oblate spheroid, or disc, between 3-5 pm in diameter and 0.7-1 pm in thickness. 
Volume varies between 4-8 fL. Upon activation platelets undergo a shape change to a 
globular form with pseudopodia up to 5pm long [Figure 1-1].
Figure 1-1: Scanning electron micrographs of resting (A) and activated (B) 
platelets.
Reproduced from http://www.akh-wien.ac.at/biomed-research/htx/platwebl .htm
A B
The platelet has a plasma membrane composed of a phospholipid bilayer in which the 
various membrane proteins are embedded. Scanning electron microscopy reveals small 
orifices in the membrane which connect to the open canalicular system (OCS). 
Overlying the membrane is the glycocalyx, an irregular layer ranging from 10-50 nm. 
This is composed of a variety o f proteins, glycoproteins and mucopolysaccharides and 
contains a high concentration o f sialic acid.
The open canalicular system (OCS) is a network o f interconnecting channels in the 
cytoplasm which communicates with the cell surface. The OCS is in close apposition
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to storage organelles, including a-granules and dense bodies. Substances contained in 
these organelles are extruded to the surface of the platelet during the release reaction.
The marginal microtubular system consists of a single circumferential band of 
microtubules. During platelet activation, the microtubule band disappears as the tubulin 
dissociates but it re-forms as the platelet returns to its quiescent state. Actin (10-20%) 
and myosin (15-20%), the major platelet proteins, form a three-dimensional network 
through the cytoplasm of platelets. A second network of shorter actin fibres serves as a 
membrane skeleton and is responsible for the discoid shape of the resting platelet.
The cytoplasm of the platelet contains various granules, the most obvious of which are 
the a-granule and the dense body, a-granules are oval vesicular structures measuring 
300-500 nm and contain over 20 proteins, of which four are platelet-specific. The 
platelet-specific proteins are platelet factor 4 (PF-4), p-thromboglobulin, platelet- 
derived growth factor (PDGF) and thrombospondin. The membrane of the a-granule 
also contains important adhesion molecules including the P3 intregrin allbp3 and P- 
selectin (also known as CD62P). The dense bodies are round structures 50-150 nm in 
diameter. Dense granules develop from undifferentiated platelet granules by a process 
related to the uptake of 5-HT from the plasma. The dense bodies contain 5-HT, 
nucleotides, calcium ions and catecholamines [Table 1]. Other organelles include 
mitochondria, glycogen granules, lysosomes, ferritin granules and ribosomes [Figure 1- 
2].
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Table 1: contents of platelet organelles
Organelle________________ Contents
Dense body
a-granule
Dense tubular system
Peroxisomes
Lysosomes
Nonmetabolic ATP, ADP, GTP, GDP, 5-HT, histamine, 
secretable Ca2+, Mg2+
Platelet specific proteins:
PF-4, p-thromboglobulin, PDGF, thrombospondin 
Other proteins: P-selectin, anbp3, GP lb, PECAM-1, 
CD9, cationic proteins, fibrinogen, fibronectin, albumin, 
factor V, plasminogen, HMWK, vWF, vWag-II, factor 
D, piH  complement globulins, a-2 antiplasmin, a-1 
antitrypsin, a-2 macroglobulin, histidine-rich 
glycoprotein, RANTES, M IP-la, IL-1, CTAP-3, NAP-2, 
TGF-p
Arachidonic acid metabolites, prostaglandin converting 
enzymes contractile Ca2+
Catalase 
Acid hydrolases
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Figure 1-2: Schematic representation and transmission electron micrographs of 
human platelets
Schematic representation (A) and electron micrographs in transverse (B) and 
longitudinal (C) section o f the human platelet (x20,000). OCS=open canalicular 
system, M=mitochondrion, DB=dense body, G=a-granule, some o f which contain 
dense bodies, Gly=glycogen granules, EC=exterior coat (glycocalyx), 
MT=microtubules. The platelets are the author's.
M ►
1 micron
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Table 2: Im portant platelet glycoproteins
Glycoprotein Cluster
differentiation
Integrin Molecular weight Putative
function
Absent or 
dysfunctional 
in
GP Ia-IIa CD49b/CD29c a 2P i a = 167000 
P=89000
Collagen
receptor
GP Ic-IIa CD49e/CD29c a 5Pi a = l55000 
P=89000
Fibronectin
receptor
GP Ic-IIa CD49I7CD29c a 6Pi a = 140000 
P=89000
Laminin receptor
GP Ib-IX CD42ba and 
CD42bp (GP lb), 
CD42a (GP IX)
CD42ba= 143000 
CD42bp=22,000 
CD42a=22,000
VWF and low 
affinity thrombin 
receptor
Bernard Soulier 
syndrome
GP IV CD36 88000 ?thrombospondin
?collagen
GP V 82000 Forms 
multimeric 
complex with 
GP Ib-IX at 
platelet surface
Bernard Soulier 
syndrome
GP Ilbllla CD41/CD61 <XlIbP3 a = 140000 
P=105000
Fibrinogen 
receptor (other 
ligands are vWF, 
fibronectin, 
vitronectin and 
thrombospondin)
Glanzmann's
thrombasthenia
1.1.2 Platelet membrane glycoproteins
The platelet glycoproteins act as receptors for adhesion and interaction with other 
cells, including the vascular subendothelium and are critical in the process of 
haemostasis. Absence or dysfunction of these glycoproteins causes disorders of 
platelet function [Table 2]. The major glycoproteins have been designated by Roman 
numerals I to IX. Some have been assigned CD (clusters of differentiation) markers. 
Some are also members of the integrin superfamily of adhesion molecules.
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1.1.3 Platelets and haemostasis
Haemostasis is essential for the prevention of blood loss following vessel damage. It 
depends firstly on the adhesion of circulating platelets to the vascular subendothelium 
exposed after injury and subsequent platelet aggregation and secondly, activation of the 
coagulation cascade leading to the formation of fibrin, which reinforces the initial 
platelet plug. Following exposure of the vascular subendothelium by injury, platelets 
adhere to subendothelial collagen using a specific collagen receptor, the most 
important of which is probably the GPIa-IIa complex (a2pl). Following adhesion to 
the vascular subendothelium, two interactions allow platelets to remain attached to the 
vessel wall despite the shear forces generated by flowing blood. First, adherent 
platelets spread via an interaction between allbp3 and fibronectin. Secondly, the GPIb- 
IX-V complex interacts with another plasma adhesive protein, vWF, which also binds 
to collagen. GPIb-IX-V, the platelet vWF receptor, is a very abundant platelet protein, 
with approximately 25000 copies on each platelet. There is good evidence that the 
GPIb-IX-V complex interacts with the platelet cytoskeleton via an actin binding 
protein. This may be important in transducing signals leading to platelet activation and 
secretion. Whatever the mechanism, following platelet adhesion, platelet activation 
occurs with the characteristic shape change and release of granule contents, including 
ADP and thromboxane A2. ADP and thromboxane A2 then initiate platelet aggregation 
by activating other platelets. During platelet activation, allbp3 undergoes a 
conformational change which causes it to expose its high affinity ligand binding site, 
allowing the formation of fibrinogen bridges between adjacent platelets. This process is 
of critical importance in platelet aggregation and the formation of primary platelet 
plugs.
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allbp3 also binds to other adhesion molecules with the RGD peptide motif, including 
vWF, fibronectin and vitronectin. Binding to soluble fibrinogen and other ligands 
requires exposure of the allbp3 ligand binding site, which occurs upon stimulation of 
platelets by agonists such as thrombin, ADP, and collagen.
Primary platelet plugs are converted into secondary definitive plugs following 
activation of the coagulation cascade and the production of thrombin, which converts 
soluble fibrinogen in the plug into insoluble fibrin.
1.2 The coagulation cascade and the formation of thrombin
The numerous historical theories of blood coagulation were replaced in the 1960s by 
the cascade hypothesis proposed by MacFarlane (Macfarlane,1964). In this model, 
which is still generally accepted, clotting is initiated when blood comes into contact 
with “foreign” surfaces or damaged tissues. This initiates a series of enzymatic steps in 
which the enzyme formed in the first step serves as a catalyst or activator for the next 
step. There are twelve of these enzymes, or coagulation factors, which normally exist 
in the plasma as inert precursors. The coagulation factors, which are known by their 
roman numerals, thus act first as substrate and then as enzyme. The series of steps 
forms an enzyme cascade, which ends with the conversion of soluble fibrinogen by 
thrombin into insoluble fibrin and subsequent thrombus formation. Although a detailed 
discussion of this process is beyond the scope of this thesis, a brief overview is given 
here.
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Coagulation can be initiated by at least two fundamentally different mechanisms, 
contact activation and activation by tissue factor. Contact activation activates the 
intrinsic pathway of coagulation and tissue factor activates the extrinsic pathway. Both 
pathways activate factor X, which in turn activates the final steps of coagulation 
involving factor V, platelet factor 3 (PF-3), prothrombin and fibrinogen. PF-3 
represents the ability of activated platelets to accelerate the coagulation mechanism. 
These final steps are known as the common pathway [Figure 1-3].
1.2.1 Contact activation (intrinsicpathway)
Contact activation involves the adsorption of four contact sensitive coagulation factors 
(factors XII, XI, prekallikrein and HMWK) to a variety of artificial surfaces and 
biological surfaces. Activation of these coagulation factors leads to a cascade of events 
ending with the activation of factor X. Factor X is activated by an interaction with the 
Xase complex on the platelet surface, consisting of factor IXa, factor VIII, Ca2+, and 
PF-3.
1.2.2 Tissue factor (extrinsic pathway)
Tissue factor (TF) is a transmembrane glycoprotein and member of the cytokine 
receptor superfamily, which consists of three distinct sections. It has a short 
cytoplasmic domain (19 amino acids), a transmembrane domain (23 amino acids), and 
a large extracellular domain (219 amino acids). TF triggers the extrinsic coagulation 
cascade, the pathway responsible for the initiation of haemostasis and thrombosis in 
vivo. The extracellular domain binds with factor VH/VIIa in the presence Ca in 
circulating blood to form a catalytic complex that converts inactive factors IX and X to 
their active forms, IXa and Xa, with the subsequent formation of thrombin and
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deposition of fibrin [Figure 1-4]. Traditionally, activation o f the intrinsic pathway has 
been thought to require exposure of blood to a negatively charged surface. However, 
the TF-factor Vila complex can also mediate the conversion of factor IX to IXa (Bauer 
et al, 1990), directly linking the two pathways.
Intrinsic system
Contact activation
Factor Factor 
XII Xlla
I
Factor JL*. Factor 
XI Xla
Factor I  Factor
IX Ca2- r
Extrinsic system
T issu e injury 
(release of tissue 
factor)
Factor 
'  Vila
Factor VIII, 
ph osp holip ids
Factor 
X Factor Xa 
Factor Va
Ca2 '
P hospholip ids
Prothrom binase
co m p lex
Factor II 
(prothrom bin) Ca2+
„ Factor lla 
(throm bin)
Fibrinogen
Factor
Xllla
Factor
XIII
Fibrin (soluble)
Inhibition of fibrinolysis
P lasm inogen  
(fibrin surface)
Plasm in  
(fibrin surface)
*■ Fibrin (insoluble)
PAi
P lasm in ogen  
(fluid phase)
t*PA or u-PA
Plasm in  
(fluid phase)
Fibrin-degradation products
Fibrinopeptide A or B
Coagulation Fibrinolysis
Figure 1-3: The coagulation and fibrinolytic pathways
Activation of factor XII on contact with a negatively charged surface initiates the 
intrinsic coagulation system. (The activated form is indicated by "a.") The extrinsic 
pathway is activated by tissue factor. Intrinsic and extrinsic activation o f the 
coagulation cascade leads to the generation of thrombin, with subsequent cleavage of 
fibrinogen, release of fibrinopeptides and formation of fibrin. Fibrinolysis is initiated 
by tissue plasminogen activator (t-PA), urinary-type plasminogen activator (u-PA), 
and plasmin. Plasmin bound to fibrin initiates the lysis of fibrin, with the generation of 
fibrin-degradation products. The main anti-fibrinolytics are plasminogen-activator 
inhibitor type 1 (PAI-1) and a 2-antiplasmin. (Kohler et al, 2000)
28
Thus, TF both initiates coagulation through activation of factor X and provides 
amplification by activation of factor IX.
A wide variety of cells express TF upon activation, including monocytes, 
macrophages, fibroblasts, smooth muscle cells and vascular endothelial cells. Until 
recently the conventional view of activation of the TF pathway was that thrombosis 
after vascular injury was the result of exposure of subendothelial TF to factor VH/VIIa 
and platelets. This dogma has recently been challenged after observations that TF can 
be isolated from whole blood and plasma from healthy volunteers (Giesen et al, 1999).
In conclusion, TF is thought to be the initiator of coagulation in vivo, while the 
intrinsic pathway plays a critical role in thrombus propagation and growth. Initiation 
of coagulation may occur through the exposure of tissue-bound TF or by the action of 
blood-borne TF on leukocytes and microparticles. TF may also have a role outside 
coagulation in the regulation of monocyte diapedesis, cell signaling, and expression of 
growth factors.
1.2.3 Common pathway
Activated factor X (Xa) interacts with the prothrombinase complex on the platelet 
surface, consisting of factor V, Ca2+ and PF-3. Thrombin in turn converts fibrinogen to 
fibrin [Figure 1-4]. These interactions will be described in detail below.
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Figure 1-4: Platelet coagulant activity.
Assembly of coagulation protein complexes on the platelet surface. The suffix a 
indicates the activated form of the coagulation factor shown. The platelet membrane 
provides the appropriate anionic phospholipid as well as factor Va for the assembly of 
the prothrombinase complex.
Fibrinogen
Thrombin
ProthrombinaseXase complex
Fibrin
PTIXa
Xa
Villa
Va
Va
Va
alpha-granules
Va
1.2.4 Platelet factor 3
Although the process of fibrin formation is often referred to as the “soluble” phase of 
coagulation, this process actually takes place on the surface o f a number o f different 
cell types, including monocytes, endothelial cells and most importantly, activated 
platelets (Kung et al, 1994). The two most important groups o f proteins that assemble 
on the platelet surface are the Xase complex and the prothrombinase complex. 
Assembly of these complexes on the platelet surface accelerates the production o f Xa 
and thrombin by factors o f several thousand. This ability to accelerate coagulation is 
referred to as platelet factor 3 (PF-3) activity.
Platelet activation causes an increase in PF-3 activity by a flip-flop rearrangement of 
the platelet cell membrane, resulting in the presentation o f pro-coagulant anionic
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phospholipid cofactors, and the secretion of Va, part of the prothrombinase complex, 
from the platelet a-granule.
1.2.5 Fibrinogen andfibrin
Fibrinogen is a 340 kD protein coded for on chromosome 4 and synthesised by 
hepatocytes. It is composed of two identical subunits, each containing three dissimilar 
polypeptide chains (aA, pB, yG), which are linked by disulphide bonds. Thrombin 
cleaves fibrinopeptides A and B from fibrinogen, resulting in the formation of strands 
of fibrin monomer, which consists of three paired alpha, beta and gamma chains. These 
bind non-covalently and then covalently to form stable fibrin [Figure 1-5]. GPRP is a 
peptide motif occurring on the cleaved N terminus of the a  chain, which fits snugly 
into a binding site in the y chain. Addition of GPRP to whole blood prevents the 
formation of fibrin by sitting in this binding site and halting the formation of 
polymerised fibrin from fibrin monomers.
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Figure 1-5: Interactions between adjacent fibrin chains.
Thrombin cleaves the alpha chain N terminus, creating a new N terminus (the A site) 
beginning with the sequence GPR. The A site binds to the complementary "a" 
polymerization pocket in the gamma chain during the alignment of the fibrin 
protofibrils. (Pratt et al, 1997).
1.2.6 Homeostatic inhibitors of coagulation, fibrinolysis andfibrinolysis inhibitors
Physiological inhibitors of coagulation in plasma localise procoagulant activity to sites 
of injury. Antithrombin (also known as antithrombin III) is the principle inhibitor of 
thrombin, factor Xa, and the other serine proteases (Rosenberg et al, 1973). 
Antithrombin is a "pseudosubstrate" for thrombin and "traps" thrombin in an 
antithrombin-thrombin complex. In the presence of heparin, there is marked 
acceleration of the antithrombin-thrombin interaction. Heparin cofactor II is also an 
inhibitor of thrombin. Thrombin also binds to an endothelial receptor, 
thrombomodulin, which inhibits its procoagulant activity. The thrombin- 
thrombomodulin complex activates protein C to activated protein C (APC). This 
protein C/protein S pathway is an important regulatory system. Once protein C is 
converted to APC, it inhibits coagulation (Esmon,2001) by inactivating factors V and 
VIII. Protein S is an important cofactor for this reaction [Figure 1-6]. Antithrombin 
and Protein C/Protein S can also act as anti-inflammatory proteins, by modulating 
intra-cellular signalling, cytokine secretion, apoptosis, and leukocyte-endothelial
32
interactions. Once fibrin clot has formed, physiological pathways o f fibrinolysis begin 
to dissolve it. The plasma protein plasminogen binds to fibrin in the clot, where it is 
converted into plasmin by tissue plasminogen activator (tPA). Plasminogen activator 
inhibitor-1 (PAI-1) is a physiological inhibitor o f this reaction. Once formed, plasmin 
degrades fibrin into soluble fragments. A recently discovered thrombin-activatable 
fibrinolysis inhibitor (TAFI) can inhibit fibrinolysis.
Thrombomodulin
Initiation of 
coagulation
Thrombin
generation
Protein C 
activation
Cofactor
inactivation
Vessel lumen
T issu e
factor ^
Inactive
cofactors
Throm bin
Protein C Activated  
protein C
E ndothelial
m em b ran e
Active
cofactors
Endothelial I
protein C 
receptor
C ytoplasm
Figure 1-6: Endothelial activation of coagulation and the protein C pathway.
Coagulation is initiated by tissue factor and other coagulation-factor complexes on the 
surface of endothelial cells and monocytes. Activated factor X requires activated 
cofactors V and VIII to produce thrombin, which in turn forms a complex with 
thrombomodulin. Protein C is activated by an interaction between the 
thrombomodulin-thrombin complex and the endothelial protein C receptor. Activated 
protein C in the presence o f protein S inactivates the activated forms of factors V and 
VIII, thus inhibiting the generation of thrombin. Complex 1 comprises tissue factor 
and coagulation factors VII, IX, and X; complex 2 comprises factors IX and X and 
cofactor VIII; and complex 3 comprises factor X, prothrombin, and cofactor V. (Faust 
et al, 2001).
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1.3 The thrombin receptor
Thrombin triggers shape change and degranulation in platelets with the release of 
ADP, serotonin, thromboxane A2, chemokines and growth factors. It mobilises 
CD62P and CD40L to the platelet surface (Henn et al, 1998; Stenberg et al, 1985) and 
activates allbp3 (Shattil et al, 1998). Thrombin also triggers PF-3 activity on the 
platelet surface, which supports the generation of additional thrombin. These actions 
are all mediated by a specific platelet thrombin receptor.
The human platelet thrombin receptor, protease activated receptor-1 (PAR-1) is a G- 
protein coupled receptor. Activation of the receptor requires the N terminal to be 
cleaved by thrombin, which is a serine protease. This releases a 41 amino acid peptide 
and causes the formation of a tethered ligand on the receptor, which activates its own 
active site (Vu et al, 1991) [Figure 1-7]. Both the tethered ligand 
(SFLLRNPNDKYEPF) and the cleaved peptide have now been characterised. It has 
been shown that peptides containing the motif SFLLRN are capable of activating 
human platelets and cause aggregation in the absence of thrombin with an EC50 of 0.2 
pM. Peptides with a similar three-dimensional structure but with markedly enhanced 
activity have been synthesised such as the peptide AFR-Cha-RY which has an EC50 
of 0.03 pM (Feng et al, 1995). Both SFLLRN and AFR-Cha-RY were used in this 
thesis. Although both are thrombin receptor agonist peptides (TRAP), for the purposes 
of clarity in this thesis, SFLLRN will be referred to as SFLLRN and only AFR-Cha- 
RY will be referred to as TRAP.
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Figure 1-7: Mechanism of thrombin receptor activation.
Thrombin (green sphere) recognises the N-terminal domain (blue sphere) o f PAR-1. 
This interaction uses sites both N-terminal and C-terminal (pink oval) to the thrombin 
cleavage site. The latter sequence resembles the C-terminal tail o f the thrombin 
inhibitor hirudin. Thrombin cleavage unmasks a new N terminus with the sequence 
SFLLRN (yellow diamond). This tethered ligand interacts with the body of the 
receptor to effect transmembrane signalling. Synthetic SFLLRN peptide functions as 
an agonist independently of receptor cleavage. (Coughlin, 2000).
Thrombin PAR1
Since the original work on the human platelet thrombin receptor, a number of other 
PARs have been characterised [Table3]. The original receptor has been designated 
PAR-1. PAR-2 was initially found to be present on human vascular endothelial cells 
in addition to PAR-1 and is activated by trypsin and the peptide SLIGRL, which 
corresponds to the new N terminus of PAR-2 following proteolytic cleavage. PAR-2 
is not activated by thrombin. Both trypsin and SLIGRL cause endothelium dependent 
relaxations in porcine coronary arteries (Hwa et al, 1996). SLIGRL does not aggregate 
human platelets, suggesting the receptor is not present on platelets.
PAR-3 was characterised in murine platelets when knockout studies demonstrated that 
murine PAR-1 is not responsible for the activation o f mouse platelets by thrombin
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(Connolly et al, 1996). PAR-3 mRNA has been found in a number of human tissues 
including bone marrow and megakaryocytes (Ishihara et al, 1997). The putative 
tethered ligand, TFRGAP or TFRGAPPNS, however, showed no activity on calcium 
mobilisation (reflecting phosphoinositide synthesis) in Xenopus oocytes expressing 
PAR-3 even at high concentrations of 100 pM. The mechanism of activation of this 
receptor is as yet unclear and a role for it in human platelets has not been identified.
Table 3: Human tethered ligand activating peptides.
PAR-1 EC50:0.1 nM Thrombin,
l-3pM SFLLRN (Kahn et al, 1998)
PAR-2 EC50: InM Tryptase (Molino et al, 1997)
Human: SLIGKV (Ishihara et al, 1997; Molino et al, 1997)
Mouse: SLIGRL active vasodilator at 1-3 pM in rat and porcine aorta, 
inactive up to 300 pM in human platelets (Hwa et al, 1996)
PAR-3 EC50:0.2nM Thrombin, TFRGAP tethered ligand failed to activate
even at lOOpM suggesting a an alternative machanism of activation 
(Ishihara et al, 1997)
PAR-4 30nM Thrombin in mice (Kahn et al, 1998), not known in humans
300-500pM GYPGKF in human (Kahn et al, 1998)
Pharmacological studies have suggested PAR-1 independent mechanisms for 
activating human platelets may exist, revealing differential effects of SFLLRN and 
thrombin on the procoagulant effect of platelets and on production of thromboxane A2 
(Goodwin et al, 1994; Henriksen et al, 1997; Kramer et al, 1995) and recently a fourth 
protease activated receptor, PAR-4, has been described. This receptor has been found 
to be functional and responsive to thrombin both in murine and in human platelets 
(Kahn et al, 1998), suggesting a dual signalling mechanism in both species. In mice, 
platelets appear to express PAR-3 and PAR-4 and in humans, platelets express PAR-1 
and PAR-4. The putative tethered ligand for PAR-4 is GYPGKF, which activates
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human platelets with an EC50 of 300-500 pM. Activation of PAR-4 appears to have 
similar intracellular effects as activation of PAR-1, including inducing production of 
thromboxane A2 (Henriksen et al, 2002). As yet the biological importance of the two- 
receptor system is unknown.
1.4 Platelet nucleotide receptors
The purine nucleotide ADP has been known to cause induce platelet aggregation since 
1962 (Bom, 1962). It is released from injured cells and activated platelets and is of 
prime importance in haemostasis. It causes platelet shape change, a transient increase 
in intraplatelet Ca2+ levels and allbp3 activation with subsequent fibrinogen binding 
and platelet aggregation. Intact endothelium expresses an ecto-ADPase (CD39) 
(Marcus et al, 1997), which breaks down ADP and thus helps to maintain the non- 
thrombogenic nature of healthy endothelium. The actions of ADP were initially 
thought to be mediated by a unique ADP receptor termed P2(T) found only on 
platelets and antagonised by ATP. "P2(T)" responses are now thought to represent a 
combination of responses from three different P2 receptors (Daniel et al, 1998). P2 
receptors are divided into two families: P2Y receptors, which are G protein coupled 
and P2X receptors, which are ligand gated. ADP acts on two P2Y receptors, P2Yi and 
P 2 T a c  to cause platelet aggregation, with P2Yi mediating shape change. Selective 
blockade of either of these receptors inhibits platelet aggregation. The ionotropic 
receptor P2Xi allows calcium influx but has no influence on shape change or 
aggregation (Di Virgilio et al, 2001).
Many circulating cells, including neutrophils, monocytes and lymphocytes also 
constitutively express nucleotide receptors, which mediate effects as diverse as
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proliferation, differentiation, chemotaxis, release of cytokines or lysosomal 
constituents, and generation of reactive oxygen or nitrogen species (Di Virgilio et al, 
2001). Nucleotides are thus an important mediator of both leukocyte and platelet 
activation in haemostasis, thrombosis and inflammation.
1.5 Other membrane receptors
Human platelets express 012 adrenergic receptors and aggregate when exposed to 
adrenaline and noradrenaline (Kerry et al, 1985). They express a thromboxane A2 
receptor, a seven membrane spanning G protein receptor (Nusing et al, 1993), which 
mediates platelet activation, and a prostacyclin receptor (Schafer et al, 1979), which 
stimulates adenylate cyclase activity and prevents platelet activation. They also 
express ADH (Thibonnier et al, 1985) and 5 -HT2 (De Clerck et al, 1984) receptors 
which can initiate platelet aggregation in vitro but are of uncertain physiological 
significance.
1.6 Arachidonic acids and platelets
Platelets and endothelial cells have biochemical pathways which metabolise 
arachidonic acid (AA) (Kroll et al, 1989). AA is released from membrane 
phospholipids by phospholipase A2. Subsequently, cyclo-oxygenase converts AA to 
cyclic endoperoxides. The endoperoxides are converted by thromboxane synthetase to 
thromboxane A2. Thromboxane A2 is a potent agonist that induces platelet 
aggregation. Endothelial cells also contain an AA pathway. However, endothelial cells 
preferentially convert cyclic endoperoxides to prostacyclin (Cines et al, 1998), which 
is a potent inhibitor of platelet aggregation.
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1.7 Thrombin and inflammation
Thrombin is important in many conditions involving haemostasis, thrombosis, 
inflammation and vascular remodelling (Coughlin,2000). It stimulates mast cell 
degranulation with release of histamine (Razin et al, 1984), is chemotactic for 
neutrophils (Sugama et al, 1992) and enhances neutrophil adhesion (Lorant et al,
1991) and transmigration (Moser et al, 1990).
There is evidence that the chemoattractant properties of thrombin on monocytes and 
neutrophils are mediated by a non proteolytically activated receptor (Crago et al,
1995; Jenkins et al, 1995) rather than one of the PARs. Thrombin, whether 
proteolytically active or not, is chemotactic for both cell types whereas SFLLRN is 
not. Data is conflicting regarding the presence or absence of a PAR on neutrophils and 
monocytes. PAR-1 was not detectable on human neutrophils or monocytes by flow 
cytometry in one study (Howells et al, 1993). However, whereas SFLLRN did not 
cause increased calcium flux in neutrophils, both it and thrombin cause increased 
calcium flux in platelets and monocytes (Hoffman et al, 1993). This suggests the 
presence of a proteolytically activated receptor on monocytes and platelets but not 
neutrophils.
Monocytes have been shown to express PAR-1 using northern blot techniques and 
upregulate it in response to interferon-y (Naldini et al, 1998). They produce IL-1, IL-6 
and MCP-1 in response to both SFLLRN and thrombin and ID8 and TNF-a in 
response to thrombin (Colotta et al, 1994; Grandaliano et al, 1994; Hoffman et al, 
1995; Johnson et al, 1998; Naldini et al, 2000; Naldini et al, 2002).
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Neutrophils have been shown by flow cytometry to express PAR-2. SLIGRL, the 
peptide agonist, induces an increase in the forward and side light scatter after 5-10 
minutes, a small increase in the expression of the activation molecule CD1 lb and 
calcium flux (Howells et al, 1997). Additionally, neutrophils in pre-eclamptic and 
pregnant women have been reported to express PAR-1 (Wang et al, 2002), although 
the functional significance of this is not understood.
In cultured endothelial cells, thrombin causes vWF release (Hattori et al, 1989), P- 
selectin expression (Hattori et al, 1989), production of chemokines (Ueno et al, 1996) 
and platelet activating factor (Zimmerman et al, 1996)and increases in permeability 
(Lum et al, 1994). PARs are thus thought to be of critical importance in both 
haemostasis, thrombosis, inflammation and vascular remodelling (Coughlin,2000) 
[Figure 1-8 and Table 4].
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Figure 1-8: The actions of thrombin on blood cells and blood vessels.
Thrombin is generated at sites o f vascular injury. It is the most effective agonist for 
platelet activation. Thrombin also elicits responses in the vascular endothelium, 
including shape and permeability changes, mobilisation of adhesion molecules to the 
endothelial surface and stimulation of autocoid and cytokine production. Thrombin is 
chemotactic for monocytes and mitogenic for lymphocytes and mesenchymal cells. 
(Coughlin,2000)
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Table 4: Distribution of human PARs
Platelet Neutrophil Monocyte Endothelium
PAR-1 Yes Not known Yes Yes
PAR-2 No Yes Not known Yes
PAR-3 No Not known Not known Not known
PAR-4 Yes Not known Not known Not known
PAR-3 mRNA is present in human bone marrow by Northern blot (Ishihara et al, 
1997)
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1.8 Platelets and inflammation
In the last few years, platelets have emerged as critical to the process of inflammation 
as well as to haemostasis and thrombosis. In evolutionary terms, this is not surprising 
as in birds, reptiles, amphibians and fish, thrombocytes are often nucleated and 
combine both phagocytic and haemostatic functions.
In humans, platelets retain some phagocytic capacity (Meseguer et al, 2002). They can 
sequester bacteria through platelet aggregation, phagocytose latex particles and 
bacteria, and release bactericidal compounds such as p-lysin on stimulation. The role 
of platelet phagocytosis in host defence is unclear. However, in humans, platelets are 
an important link between pathways of haemostasis and host defence. Platelets can 
modulate the innate immune response by interacting with other cell types such as 
neutrophils, monocytes and endothelial cells and influence their function either 
indirectly by the release of inflammatory mediators or directly via adhesion molecule 
dependent cell-cell interactions.
The platelet a-granules are the major storage vesicle containing inflammatory 
mediators in platelets. These include the cationic proteins, C-X-C and C-C 
chemokines, IL-1 and certain adhesive proteins [see table 5]. The cationic proteins 
were originally detected in leukocyte granules and mediate induction of fever, 
increased vascular permeability, mast cell degranulation and neutrophil chemotaxis. 
The C-X-C chemokines include PF-4 and P-thromboglobulin. Both are derived by 
proteolysis from the platelet basic protein, a 15 kD precursor. From this precursor, two 
further C-X-C chemokines are formed; connective tissue activating protein 3 (CTAP-3) 
(Castor et al, 1977) and neutrophil activating peptide 2 (NAP-2) (Cohen et al, 1992).
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The C-C chemokines present are RANTES (Kameyoshi et al, 1992) and M IP-la 
(Klinger et al, 1995).Of the interleukins, only IL-1 has thus far been identified in 
human platelets (Hawrylowicz et al, 1991). The adhesive proteins with a role in 
inflammation are thrombospondin, which promotes neutrophil chemotaxis (Mansfield 
et al, 1990) and fibrinogen, which may be involved in the platelet-leukocyte interaction 
(see below). PDGF is another a-granule protein which stimulates new vessel formation 
but also activates and exerts chemotactic effects on neutrophils and monocytes (Deuel 
etal, 1984).
Dense granules contain ADP, ATP, histamine and serotonin and the dense tubular 
system is the main site of arachidonic acid metabolism. Arachidonic acid metabolites 
are synthesised either alone in platelets or in co-operation with leukocytes. These 
mediators are released upon platelet activation and all have well characterised 
inflammatory effects [see table 5].
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Table 5: Inflammatory mediators released by activated platelets and their effects
Mediator Effect
12-HETE
adenine nucleotides
cationic proteins
histamine
M IP-la
IL-ip
PAF
PDGF
PGE2, PGD2
PF-4, CTAP-3, P-TG, NAP-2
RANTES
Serotonin
TGF-p
chemotaxis
neutrophil activation and degranulation 
vascular permeability, chemotaxis 
vascular permeability, bronchoconstriction 
chemotaxis, inflammatory cell activation 
chemotaxis, inflammatory cell activation 
chemotaxis, bronchoconstriction 
vasoconstriction, neutrophil degranulation, 
chemotactic and mitogenic for smooth muscle 
cells and fibroblasts 
vasodilatation
chemotaxis, neutrophil activation, degranulation 
and adhesion
chemotaxis, basophil degranulation, enhanced 
IgG4 and IgE synthesis 
Vasoconstriction, neutrophil activation and 
adhesion, fibroblast proliferation, 
chemotaxis, fibroblast proliferation.
1.9 Platelet interactions with endothelial cells
In addition to their well-documented capacity to bind to the vascular subendothelium, 
platelets can also adhere to intact vascular endothelial cells [Figure 1-9]. Platelet 
rolling on activated vascular endothelium is dependent upon expression of endothelial 
cell P-selectin and specific counter-receptors on platelets. Two platelet receptors, the 
GP Ib-IX-V complex and PSGL-1 have been proposed as possible receptors for 
endothelial cell P-selectin (Frenette et al, 2000; Romo et al, 1999). Bombeli et al have 
also found that activated platelets adhere to endothelial cells (Bombeli et al, 1998) via 
a platelet allbp3 -dependent bridging mechanism involving bound fibrinogen, 
fibronectin and vWF. Platelet bound fibrinogen interacts with endothelial av|33 and 
ICAM-1 (D'Souza et al, 1996; Gardiner et al, 1997), fibronectin with endothelial 
avp3, and vWf with avp3 and endothelial GPIba (Bombeli et al, 1998).
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Overall, these results suggest that platelets may follow a similar vessel wall adhesion 
paradigm to leukocytes (Springer, 1994). In this model, circulating unactivated 
platelets may slow down and interact with the vessel wall by rolling on the 
endothelium. Reversible association with endothelial cell P-selectin could lead to 
platelet activation with subsequent firm adhesion via platelet allbp3 leading to shear 
resistant platelet deposition. Adherent activated platelets could provide a site for 
development of endothelial cell associated microthrombi and P-selectin mediated 
leukocyte recruitment. In support of this, knockout mice deficient in P- selectin have 
markedly prolonged skin bleeding times consistent with an abnormality in 
haemostasis (Subramaniam et al, 1996).
Once bound to the vascular endothelium, platelets can induce production of IL-6, GM- 
CSF and MCP-1 and expression of ICAM-1 by releasing IL-1 (Gawaz et al, 1998; 
Hawrylowicz et al, 1991), gene transcription of ICAM-1, IL-8 and MCP-1 by 
releasing lysophosphatidic acid (Palmetshofer et al, 1999) and vascular permeability 
(Yuan et al, 1993) and expression of selectins by releasing histamine (Lorant et al, 
1991).
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Figure 1-9: Interaction of platelets with the blood vessel wall.
Circulating platelets may interact via GPIb-IX-V or PSGL-1 with P-selectin expressed 
on activated endothelial cells, or via GPIb-IX-V with vW f in the subendothelial 
matrix. Subsequently, a llbp3 becomes activated and adhesive towards vWf. GPIb-IX- 
V may also interact with leukocyte Mac-1 integrin in the recruitment o f leukocytes. 
Berndt MC et al, 2001 (1STH conference, Paris, 2001)
1.10 Platelet-leukocyte adhesion
The ability o f platelets to bind to leukocytes has been known since Giulio Bizzozero's 
first reports in 1882. He noted that in his blood smears, many leukocytes were rosetted 
with platelets. This phenomenon once again became a focus o f research in the 1970s, 
when platelets were found to enhance the adherence of monocytes to plastic surfaces 
(Musson et al, 1979) and an increased association of platelets with phagocytic cells 
(“satellism”) was observed in autoimmune disorders (Kjeldsberg et al, 1974). 
Platelet-leukocyte interactions include direct cell-cell contact via adhesion molecules, 
exchange of inflammatory mediators and transcellular metabolism of arachidonic acid 
(Palmantier et al, 1991).
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1,10.1 Cell adhesion molecules
Platelet-leukocyte adhesion depends upon interactions between adhesion molecules 
which are expressed on the cell surface. The major families of cell adhesion molecules 
are the selectins, the immunoglobulin superfamily and integrins. The selectins are 
important for leukocyte homing to particular tissues and can be expressed on 
leukocytes (L-selectin, CD62L), vascular endothelium (P-selectin, CD62P and E- 
selectin, CD62E) and platelets (P-selectin). The immunoglobulin superfamily include 
ICAM-1, ICAM-2 and VCAM-1. Integrins are a large family of proteins that mediate 
cell adhesion, migration, activation, embryogenesis, growth and differentiation 
(Hynes,2002). Each member of the integrin family consists of a non-covalently linked 
heterodimer of an a  chain and a P chain, transmembrane glycoproteins with short 
cytoplasmic tails. They are subdivided according to the different subunits, and more 
than 20 different combinations have been recognised [Table 6]. Some bind to 
extracellular-matrix proteins and take part in the interactions between cells and the 
extracellular matrix. Others bind to cell-membrane proteins (eg, ICAM-1 and 2) and 
mediate cell-cell adhesion and cell-cell communication. In this way they are able to 
integrate the activation of the extracellular matrix and the cytoskeleton (hence the 
term "integrin"). Ligand specificity is determined by the particular ap  subunit 
combination of the integrin. Integrin ligands, including fibrinogen, use specific amino 
acid sequences as recognition motifs for receptor binding. The prototype motif is 
RGD (Humphries, 1990). However, numerous other amino acid sequences are now 
recognised as integrin ligands, some of which are much longer than the originally 
described RGD motif (Ruoslahti,1996).
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Integrins change their conformation and shape during ligand binding and activation 
(Frelinger et al, 1991; Kouns et al, 1992; Sims et al, 1991) [Figure 1-10]. This 
property allows integrins to play a role in both "outside-in" and "inside-out" 
signalling. Through the outside-in signalling pathway, binding of ligand to integrins 
alters gene expression and affects cellular proliferation and differentiation (Rosales et 
al, 1995). The "inside-out" signal pathway is important for leukocyte recruitment and 
platelet aggregation, because conformational changes in the integrin heterodimer 
expose the high affinity integrin binding site, substantially increasing the binding of 
specific ligand. Integrin intracellular signalling is poorly understood, but it is known 
to be dependent on the presence of divalent cations (Hogg et al, 1993). A number of 
antibodies exist which are known as "activation reporters", that is they bind at or very 
near the ligand binding site of the integrin. Mab 24 identifies the active site of 
CD1 lb/CD 18 (Dransfield et al, 1992) and Pac-1 identifies the active site of allbp3 
(Shattil et al, 1985). Alternatively, as fibrinogen is an integrin ligand, its binding to 
either molecule can be used as a proxy measure of activation state.
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Figure 1-10. The integrin heterodimer exists in two conformational forms.
On the left is the inactivated form. Activation may occur by binding of ligand or 
specific activating antibodies (right). This may cause "outside-in" signalling, in which 
intracellular events occur as a result o f ligand binding. Alternatively "inside-out" 
signalling may occur, changing the conformation of the integrin from inactive to 
active, exposing the ligand binding site, and making the integrin much more likely to 
bind to its ligand (shown as a triangle).
cell membrane
Inactive conformation Active conformation
Table 6. Some im portant integrins mentioned in this text and their ligands
p subunit P2 p3
aL  LFA-1
(CD 11a) CD1 la/CD18
ICAMs
aM  M ac-1
(C D llb ) CD1 lb/CD 18
ICAM-1, fibrinogen
ocX pi 50.95
(C D llc ) CD 11 c/CD 18
iC3b
aV  CD51/CD61
(CD51) vitronectin
a llb  GPIIbllla
(CD41) CD41/CD61
fibrinogen
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1.10.2 The process of platelet-leukocyte adhesion
Activated platelets bind readily to leukocytes, particularly monocytes and neutrophils, 
to form platelet-leukocyte complexes (Peters et al, 1997; Peters et al, 1999). In 1989, 
the platelet alpha granule and endothelial Weibel-Palade granule protein known as 
GMP-140, PADGEM or P-selectin was first cloned (Johnston et al, 1989). It soon 
became apparent that this protein mediated leukocyte-platelet adhesion by binding to 
leukocyte P-selectin glycoprotein ligand-1 (PSGL-1), which is preferentially 
expressed on myeloid cells. Mac-1, an important leukocyte integrin, has also been 
shown to be important in leukocyte firm adhesion and transmigration on monolayers 
of activated platelets (Diacovo et al, 1996) and in platelet-leukocyte adhesion under 
conditions of high shear stress (Evangelista et al, 1996). Mac-1 integrin activation is 
triggered by PSGL-1 mediated phosphorylation of various intracellular proteins 
following ligation of PSGL-1 by P-selectin (Evangelista et al, 1999; Piccardoni et al, 
2001).
1.10.3 P-selectin
P-selectin is functionally inert in the platelet a-granule or endothelial Weibel-Palade 
body, where it is stored pre-formed, but participates in cell adhesion upon exocytosis 
of the storage granule and incorporation into the plasma membrane during activation. 
The protein is composed of a lectin domain, an epidermal growth factor domain, a 
series of complement repeats, a transmembrane domain and a cytoplasmic tail. The 
extracellular domain is located within the lumen of the storage granule, the 
transmembrane domain inserts through the granule membrane, and the short 
cytoplasmic tail always remains within the cytoplasm and is free to interact with 
cytoplasmic proteins [Figure 1-11].
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Figure 1-11: Multicellular interactions mediated by binding of PSGL-1 to P- and 
L-selectins under flow.
Binding o f PSGL-1 to P-selectin promotes tethering and rolling of leukocytes on 
activated endothelial cells and platelets. Binding of PSGL-1 to L-selectin mediates 
tethering o f leukocytes to other leukocytes, which may amplify recruitment of 
leukocytes to the vascular wall. Activated platelets, through P-selectin-PSGL-1 
interactions, may connect additional leukocytes to sites o f inflammation or tissue 
injury. (MeEver et al, 1997)
Two studies performed shortly after P-selectin was first cloned demonstrated that it 
mediates platelet-leukocyte adhesion. In the first, fixed thrombin-activated human 
platelets, but not unstimulated platelets, formed rosettes around neutrophils in the
9 -4- • • •presence o f Ca" but this was inhibited by a monoclonal antibody to P-selectin and by 
purified P-selectin (Hamburger et al, 1990). In the second study, washed, fixed, 
thrombin stimulated and resting platelets were incubated with separated neutrophils 
and monocytes and adhesion assayed by flow cytometry (Rinder et al, 1991). Maximal 
adhesion o f stimulated platelets to neutrophils occurred within 10 minutes and to 
monocytes within 30 minutes. G l, a P-selectin blocking antibody, inhibited the 
binding of stimulated platelets to both neutrophils and monocytes. Antibodies against 
allbp3 , CD 15, CD1 lb, CD 18, thrombospondin and ICAM-1 had no effect.
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1,10,4 The ligand for P-selectin
Work now began investigating possible leukocyte ligands for P-selectin. The first 
investigation of rolling adhesion of neutrophils to immobilised activated platelets 
(Buttrum et al, 1993) indicated complete blockade of adhesion with G l, the specific 
anti P-selectin antibody, demonstrating the critical role of P-selectin. Further 
investigation of leukocyte adhesion to surface adherent platelets under flow conditions 
(Yeo et al, 1994) showed that antibodies against sialyl Lewis x could inhibit adhesion 
and that the adhesion process most likely involved two steps, depending on platelet 
and neutrophil adhesion molecules respectively.
This and other work indicated that sialylated sugar chains (of which sialyl-Lewis x, or 
SLex, is the simplest example) are critical components of neutrophil P-selectin 
ligands. Indeed, a large number of neutrophil glycoproteins (leukosialin, L-selectin, 
LAMPs, CEA-like proteins, LFA-1, etc.) have been reported to act as P-selectin 
(and/or E-selectin) ligands when purified and presented at high density in various in 
vitro assays.
However, the principal ligand for P-selectin is now thought to be P-selectin 
glycoprotein ligand 1 (PSGI^l). PSGL-1 cDNA was isolated from an HL60 cell 
cDNA library in 1993 (Sako et al, 1993) and it is present on myeloid cells, particularly 
monocytes and neutrophils (Moore et al, 1992). PSGL-1 binds selectively to P- 
selectin [Figure 1-12]. Removal by Pasturella hemolytica O-sialoglycoprotease (which 
cleaves PSGL-1) abrogates binding (Norgard et al, 1993), and blockade by specific 
monoclonal antibodies inhibits rolling of neutrophils on P-selectin-expressing vascular 
endothelium in vivo (Norman et al, 1995). PSGL-1 blockade inhibits P-selectin-
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mediated responses to activated platelets in monocytes (Weyrich et al, 1996). The 
physiological role o f PSGL-1 as a ligand for P-selectin on neutrophils has now been 
confirmed by demonstrating deficient P-selectin-mediated neutrophil rolling in 
PSGL-1 knockout mice (Yang et al, 1999).
Endothelial Cell O-Glycans Leukocyte
or Platelet
PSGL-1
Figure 1-12: Interaction between P-selectin and PSGL-1.
A P-selectin molecule is depicted binding to the two subunits o f PSGL-1. The lectin 
domain of P-selectin contacts an NfL-terminal sLex-containing, O-glycan and a 
nearby tyrosine sulphate residue in PSGL-1. Also shown are the EGF domain and the 
nine short consensus repeats in the extracellular domain o f P-selectin, and the 16 
consensus repeats in the extracellular domain of PSGL-1. The symbols on the O- 
glycans o f PSGL-1 represent sialic acid (filled diamonds), galactose (open circles), N- 
acetylglucosamine (filled boxes), and fucose (filled triangles). (McEver et al, 1997)
The current evidence thus suggests that PSGL-1 is an important P-selectin ligand. 
Whether it is the only biologically important P-selectin ligand remains to be seen. One 
study has demonstrated differential effects o f neuraminidase, a bacterial enzyme that 
causes desialylation o f glycoproteins, on the capacity for different classes of 
leukocytes to bind to platelets. Although neutrophil adhesion to activated platelets was 
reduced by 81% by pre-treatment o f neutrophils with neuraminidase, monocyte- 
platelet adhesion was only reduced by 21%, indicating the possibility o f a number o f 
different ligands for P-selectin with different levels of sialylation (Bruijne-Admiraal et
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al, 1992). Interestingly, platelets themselves express low levels of PSGI^l, which has 
been been reported to support adhesion to P-selectin expressed by activated vascular 
endothelial cells (Frenette et al, 2000).
1.10.5 A role for the integrins?
Evidence now began to accumulate that CD1 lb/CD 18, an important leukocyte 
integrin, was important in neutrophil firm adhesion and transmigration (but not 
rolling) on monolayers of activated platelets (Diacovo et al, 1996) and in platelet- 
leukocyte complex formation under conditions of high shear stress (Evangelista et al, 
1996). These results have been used to support the hypothesis of a multistep adhesion 
paradigm for the platelet-leukocyte interaction similar to that described for neutrophil 
adhesion to activated endothelial cells [Figure 1-13].
Evangelista et al have shown that ligation of PSGL-1 induces protein-tyrosine 
phosphorylation, inducing P2 integrin dependent neutrophil aggregation and platelet- 
neutrophil adhesion (Evangelista et al, 1999). Neutrophil aggregation represents 
homologous cell-cell adhesion, which is mediated by CD1 lb/CD 18 (Simon et al, 
1993). Thus most authorities now accept that platelet-leukocyte adhesion depends on a 
CD62P-PSGL-1 interaction followed by CD1 lb/CD 18 dependent firm adhesion. 
However, important questions remain regarding the precise role of the integrins. For 
example, although Evangelista et al clearly demonstrated, in their investigation of 
platelet-leukocyte complex formation under conditions of high shear stress 
(Evangelista et al, 1996), that CD1 lb/CD 18 activating antibodies were able to induce 
platelet-neutrophil adherence under flow conditions, they did not perform the crucial
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experiment using CD1 lb/CD 18 blocking antibodies to show that this effect was 
CD1 lb/CD 18 dependent. The CD1 lb/CD 18 activating antibodies (KIM 127 and 
KIM 185) are known to induce "outside-in" integrin signalling and may have more 
effects on the neutrophil than simply to promote CD1 lb/CD 18 ligand binding site 
exposure. Moreover, the platelet counter-receptor for CD1 lb/CD 18 has not been 
definitively elucidated, although evidence has been presented suggesting a role for 
GPIba (Simon et al, 2000), ICAM-2 (Diacovo et al, 1994), a llbp3 associated 
fibrinogen (Weber et al, 1997) and the junctional adhesion molecule JAM-1 (Santoso 
et al, 2002).
Figure 1-13: Proposed multistep model of platelet-leukocyte adhesion.
Platelet P selectin binds to leukocyte PSGL-1. PSGL-1 acts as a signalling molecule, 
inducing protein tyrosine phosphorylation and inside-out activation o f leukocyte 
CD1 lb/CD 18. Leukocyte CD1 lb/CD 18 binds to a number o f ligands on the platelet 
(see text) and mediates subsequent firm adhesion.
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1.11 Consequences of platelet adhesion to leukocytes
The release of inflammatory mediators from activated platelets in the vicinity of 
leukocytes causes numerous changes, as discussed above. Platelet-leukocyte adhesion 
also has a number of effects. In whole blood, a proportion of neutrophils circulates in 
association with platelets. At rest, neutrophils in such complexes exhibit a 
significantly more activated adhesion molecule profile than free neutrophils, with 
increased CD1 lb expression and activation and decreased CD62L expression. In 
addition, neutrophils in complexes have enhanced phagocytic activity and produce 
more toxic oxygen metabolites than free neutrophils (Peters et al, 1999). Stimulation 
with the platelet agonist ADP leads to further increases in neutrophil CD1 lb 
expression and activation, loss of CD62L, increased phagocytosis and toxic oxygen 
metabolite production. The CD62P blocking antibody G1 inhibits these effects to a 
variable extent. This suggests that both soluble and contact-dependent factors 
contribute to platelet-mediated neutrophil activation. Of the contact-dependent factors, 
the P-selectin-PSGL-1 interaction has been the most extensively investigated. Ligation 
of neutrophil PSGL-1 by P-selectin not only triggers protein-tyrosine 
phosphorylation-dependent CD1 lb/CD 18 adhesion as described above (Evangelista et 
al, 1999), but also activation of SRC kinases with resultant integrin clustering 
(Piccardoni et al, 2001) and superoxide anion release (Nagata et al, 1993). Ligation of 
monocyte PSGL-1 induces production of IL-lp, IL-8, MCP-1 and TNF-a (Neumann 
et al, 1997; Weyrich et al, 1996), nuclear translocation of NF-kB (Weyrich et al,
1996) and tissue factor expression (Amirkhosravi et al, 1996; Lindmark et al, 2000).
In conclusion, the platelet is a key player in the processes of haemostasis, thrombosis 
and inflammation, expressing adhesion molecules and releasing mediators, which
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permit adhesion to and functional modulation of other inflammatory cells. 
Additionally, platelets may also themselves respond to inflammatory mediators 
produced by these cells through constitutively expressed chemokine receptors 
(Clemetson et al, 2000) . This inflammatory interaction between platelets, leukocytes 
and endothelial cells is likely to be of critical importance in health and in disease 
states involving inflammation at the vascular endothelium, such as atherosclerosis, 
sepsis syndrome and vasculitis.
1.12 Defects of integrin structure and function
In this thesis, the role of the different adhesion molecules in the platelet-leukocyte 
interaction in whole blood was studied using both blocking antibodies and blood from 
human “experiments of nature” patients with inherited absence or dysfunction of the 
integrins. These are human knockouts of the common p2 chain (leukocyte adhesion 
defect type 1) and of platelet allbp3 (Glanzmann’s thrombasthenia). Platelet- 
leukocyte adhesion was also investigated in a patient with a novel disorder of integrin 
function, which was found to affect P1, P2 and p3 integrins. An overview of the 
current understanding of inherited disorders of integrin structure and function is 
therefore given below.
1.12.1 Leukocyte adhesion defect type 1 (LAD-1)
LAD-1 is an immune deficiency characterised by inability of leukocytes to emigrate 
from the intravascular space to sites of tissue inflammation. The syndrome was first 
described by Hayward et al in 1979 (Hayward et al, 1979). In its classic form, it is an 
autosomal recessive disease characterised by recurrent bacterial infections, impaired 
pus formation, abnormal wound healing and persistent peripheral blood leukocytosis.
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Delay in separation of the umbilical cord may be the first sign of the disease. It is 
caused by absence or dysfunction of CD 18. The genetic defect is at chromosome 
2 2 q21  and consists of a variety of mutations in the common p2  chain including 
splicing, frame shift, missense and initiation codon abnormalities. The aberrant CD 18 
precursor protein is either undetectable or synthesised in a mutant form unable to 
associate with its a  subunit. Expression of all three of the leukocyte p2 integrins is 
thus either completely absent or deficient.
The phenotype of this condition is variable, with disease severity correlating to a large 
extent to the levels of expression of p2 integrin. Patients with <1% expression present 
early in life, have recurrent life threatening infections and require bone marrow 
transplantation for long term survival (Fischer et al, 1983). Patients with a moderate 
phenotype having 2.5-6% of the normal levels of protein expression have 
periodontitis, delayed wound healing, skin infections and skin inflammation 
resembling pyoderma gangrenosum (Bedlow et al, 1998; van de Kerkhof et al, 1990) 
[Figure 1-14]. Delayed umbilical cord separation is not a feature of the moderate 
phenotype disorder. Heterozygous relatives of the patients have 40-60% normal levels 
of p2 integrins and are clinically normal (Anderson et al, 1985).
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Figure 1-14. Gingivitis and non-healing leg ulcers in a case of LAD-1.
(Courtesy o f Professor Nigel Klein).
Recently it has become apparent that the severity o f the moderate phenotype disease is 
dependent upon the relative binding o f the mutant CD 18 molecule to the three CD 11 
proteins. A detailed molecular analysis o f patients with CD 18 levels between 1 and 
10% o f normal expression has revealed that the specific CD 18 mutations in these 
individuals leads to markedly different levels o f CD 11 a/CD 18, CD1 lb/CD 18 and 
CD 11 c/CD 18.
1.12.2 Glanzmann’s thrombasthenia
Glanzmann's thrombasthenia is an autosomal recessive disease characterised by a 
normal platelet count, a prolonged bleeding time, poor or absent clot retraction and 
abnormal platelet aggregation. The disease was first described in 1918 (Glanzmann 
E,1918) and is now known to result from absent or defective platelet allb(33 (Nurden 
et al, 1974). A number o f mutations have been identified both in a llb  (CD41) and in 
(33 (CD61). In CD41 these mutations lead to defects in mRNA splicing (Burk et al, 
1991), mRNA stability (Kato et al, 1992), subunit association (Wilcox et al, 1995), 
intracellular trafficking (Wilcox et al, 1994), and ligand binding (Loftus et al, 1990).
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Mutations in the CD61 gene include nucleotide substitutions, splicing defects, small 
deletions, gross deletions and complex rearrangements and integrin-mediated signal 
transduction (Wang et al, 1997). The absence of allbp3 means that while activated 
platelets can bind to the subendothelium, they cannot recruit additional platelets or 
bind to intact endothelium.
Glanzmann's thrombasthenia has been classified into two types: type 1, in which 
allbp3 is completely absent, and type 2, in which 5-20% of the P3 integrin is 
expressed. Clot retraction is completely absent in type 1 and decreased in type 2. Clot 
retraction depends on conformational changes in the platelet cytoskeleton 
demonstrating that "outside-in" signalling via allbp3 is functionally important. 
However, the classification does not have any clinical relevance since, in contrast to 
the leukocyte adhesion defects, the haemorrhagic tendency in Glanzmann's 
thrombasthenia is not related to the quantity of allbp3 on the platelet surface.
1.12.3 Defects of integrin function -  LAD and Glanzntann fs variants
Defects in integrin function have been found in variant forms of Glanzmann's 
thrombasthenia. A single case has been described in which a boy with 50% normal 
levels of p3 integrin detectable by flow cytometry had a clinical syndrome 
indistinguishable from Glanzmann's thrombasthenia (Wang et al, 1997). This boy was 
also found to be a compound heterozygote with different mutations in each of his two 
p3 integrin alleles. One of these mutations resulted in a truncated protein containing 
only the first eight of the 47 amino acids normally present in the cytoplasmic domain 
whereas the other resulted in a frame shift and early termination. In this case the
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truncated cytoplasmic portion of the p3 integrin was thought to interrupt "inside-out" 
signal transduction and thus disrupt function, preventing integrin activation and thus 
preventing fibrinogen binding.
To date, four patients with nonclassical forms of LAD-1 have been described. The 
leukocytes in two cases expressed approximately 60% of the normal levels of p2  
integrins, but had no P2 integrin function (Hogg et al, 1999; Mathew et al, 2000). 
These LAD-1 variant cases are related to classical LAD-1, having a mutation in one 
allele that prevents expression and a mutation in the other allele that allows expression 
but not ligand binding. There are two reported LAD-1 variant cases in which no 
mutations in the integrin p subunit genes have been detected, one with dysfunction of 
p i and p2 integrins (Harris et al, 2001) and one with dysfunction of p2 and p3 
integrins (Kuijpers et al, 1997). These cases are likely to have a defective inside-out 
signalling of both p integrins. A speculation is that the genetic lesions in these two 
patients are individual, but may be related and potentially highlight a specific common 
pathway dedicated to integrin activation.
1.13 The CD40L-CD40 ligand-receptor pair
The CD40 antigen is a 48 kDa type I transmembrane glycoprotein with 277 amino 
acids, which belongs to the TNF receptor superfamily (TNF-R). The extracellular 
region contains four cysteine rich domains consisting of four different cysteine 
modules [Figure 1-15]. The human CD40 gene is located at chromosome 20ql2- 
ql3.2. CD40 was first described on human bladder carcinoma cells (Paulie et al, 1985) 
but is also expressed on B lymphocytes (Ledbetter et al, 1987), monocytes (Alderson
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et al, 1993), dendritic cells (Caux et al, 1994) and endothelial cells (Karmann et al, 
1995).
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Figure 1-15: Structure of CD40
A. Schematic representation of CD40 protein. The extracellular region contains four 
cysteine rich regions. Each domain may be divided into two cysteine modules (A l, 
A2, B l, B2) as indicated. B. Models of the cysteine modules, which form the cysteine 
rich regions. (Van Kooten et al, 2000)
The CD40-ligand (CD40L) is a 39kDa type II transmembrane protein, first isolated 
from activated T cells (Hollenbaugh et al, 1992). Human CD40L is a polypeptide of 
261 amino acids including a 215 amino acid extracellular domain with five cysteines 
[Figure 1-16]. The gene locus for CD40L is TNFSF5, located on the X-chromosome 
at position q26.3-q27.1. It spans over 12-13 kb and consists o f five exons. CD40L is 
expressed on activated but not on resting T cells (Korthauer et al, 1993). Mast cells, 
basophils and eosinophils express CD40L and CD40L has been demonstrated on B 
cells and B cell lines, NK cells, monocytes, macrophages and dendritic cells in certain 
conditions (Van Kooten et al, 2000). CD40L is usually expressed as a trimer but can 
exist as shorter monomeric versions of 31 kD and 18 kD (Graf et al, 1995; Mazzei et
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al, 1995). These shorter soluble forms of CD40L retain their ability to form trimers, to 
bind CD40 and to deliver biological signals, thus indicating that CD40L might also act 
as a cytokine.
Several immune functions for CD40L-CD40 have been reported, one of the most 
important o f which is isotype switching during the immune response. Mutations in the 
CD40L gene are responsible for X-linked hyper IgM syndrome, a rare 
immunodeficiency disease characterized by the absence of both class switched B cells 
and high affinity antibody production (Korthauer et al, 1993).
C 'tern iuM
Figure 1-16: Structure of CD40L.
A. Schematic representation of CD40L protein. The extracellular region shows 
structural homology with other members o f the TNF family. B. Representation o f the 
extracellular portion o f a single CD40L molecule. CD40L is a sandwich of two beta 
sheets with jelly roll topology which forms trimers in vivo and in vitro. The three 
dimensional arrangement is also similar to that described for TNF-alpha. (van Kooten 
et al, 2000).
1.13.1 CD40L in humoral and cell mediated immunity
The capacity for T cells to transmit signals to a variety o f cell types via cell-contact 
dependent mechanisms has been known for nearly two decades. In these interactions,
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pre-activation of T cells is a requirement for cell-contact dependent signalling, 
suggesting the involvement of activation-induced T cell surface proteins, which are 
now known to include CD40L. It is in the context of T cell mediated B cell activation 
that the importance of CD40L-CD40 interactions was first recognised. Monoclonal 
anti-CD40 antibodies were initially reported to react predominantly with B cells and 
to co-stimulated B-cell proliferation in the presence of interleukin-4. Subsequently, 
the ligand for CD40, CD40L or CD 154, was identified as a 39 kDa glycoprotein 
expressed on activated but not resting T cells (Noelle et al, 1992). The importance of 
CD40L-CD40 interactions in the humoral immune response were highlighted by the 
discovery that defects in the CD40L gene cause X-linked hyper IgM syndrome 
(Korthauer et al, 1993). Patients with X-linked hyper IgM syndrome have little or no 
IgG, IgA and IgE but high levels of IgM and suffer from repeated and severe bacterial 
infections, Pneumocystis carinii pneumonia, Cryptosporidium enteropathy and 
sclerosing cholangitis. Over 70 mutations of this gene have now been characterised. 
Affected boys are treated with immunoglobulin infusions and prophylactic antibiotics. 
It is also possible to correct the defect by bone marrow transplantation.
Further studies have confirmed that the interaction between CD40L on activated T 
cells with CD40 on B cells is of critical importance in immunoglobulin class 
switching, affinity maturation, rescue of B cells from apoptotic death, germinal centre 
formation and the generation of B cell memory (Van Kooten et al, 2000).
Although the initial studies on CD40 focused on its role in humoral immunity, several 
observations suggest that CD40L-CD40 interactions play a much broader role in the 
immune system. Humans and mice with defective CD40L genes have increased
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susceptibility to micro-organisms that would normally be held in check by the cell- 
mediated limb of the immune system, such as Pneumocystis carinii and 
Cryptosporidia spp (Grewal et al, 1995). CD40 is expressed on non B cells, such as 
monocytes (Alderson et al, 1993), macrophages (Caux et al, 1994) and dendritic cells 
(DC) (Peguet-Navarro et al, 1995) and it is now known that CD40L-CD40 
interactions are required for the induction of co-stimulatory activity on APCs and the 
subsequent priming and expansion of antigen-specific CD8 + cytotoxic T lymphocytes 
(Schoenberger et al, 1998). Thus CD40-CD40L interactions are critical for a 
functional host immune response against infection.
1.13.2 CD40L and inflammation
Over the last few years, it has become apparent that CD40L-CD40 interactions are 
also critically important in inflammation. CD40 ligation on monocytes causes 
upregulation of matrix metalloproteinases (Malik et al, 1996; Wu et al, 2000), 
adhesion molecules (Kiener et al, 1995), stimulatory and co-stimulatory molecules 
(Kiener et al, 1995), tissue factor (Mach et al, 1997a; Pradier et al, 1996) and 
production of pro-inflammatory cytokines, including IL-1 p, IL-6 , IL-8 , IL-12, TNF-a, 
interferon-y and MCP-1 (Alderson et al, 1993; Kato et al, 1996; Kiener et al, 1995; 
Shu et al, 1995; Stout et al, 1996). Nonhaematopoietic cells including fibroblasts, 
endothelial cells, smooth muscle cells, and certain epithelial cells also express CD40 
and up-regulate it upon exposure to IFN-y (Mach et al, 1997b). Thus CD40 is a major 
activation receptor on these cells.
CD40 ligation on endothelial cells induces cell adhesion molecule (Karmann et al, 
1995; Kotowicz et al, 2000; Yellin et al, 1995) and tissue factor expression (Miller et
65
al, 1998) and the production of potent pro-inflammatory cytokines such as IL-1, IL-6 , 
and IL-8 , MCP-1 and RANTES. (Dechanet et al, 1997; Schonbeck et al, 1997;
Thienel et al, 1999). CD40 ligation on fibroblasts and endothelial cells induces 
synthesis of cyclooxygenase-2 and production of prostaglandins (Zhang et al, 1998). 
CD40 ligation on endothelial and smooth muscle cells results in the synthesis of 
matrix metalloproteinases (Schonbeck et al, 1999). Ligation of CD40 on dendritic 
cells (Caux et al, 1994) results in activation with increased MHC Class II expression 
and production of pro-inflammatory cytokines and chemokines.
1.13.3 Platelet CD40L
There was considerable interest when Henn et al demonstrated that platelets express 
membrane-bound CD40L upon activation (Henn et al, 1998). Henn et al demonstrated 
that platelets express membrane-bound CD40L upon activation and showed that 
platelet CD40L has the capacity to bind to endothelial cell CD40 and induces these 
cells to express adhesion molecules (Henn et al, 1998) and tissue factor (Slupsky et al, 
1998) and to produce pro-inflammatory cytokines such as MCP-1, IL-6  and IL-8  
(Henn et al, 1998). Since then, it has been shown that platelet CD40L can induce 
monocytes to express tissue factor through monocyte CD40 (Amirkhosravi et al,
2002; Lindmark et al, 2000). Platelet membrane bound CD40L is likely to be 
biologically important as membrane bound CD40L is expressed as a trimer (Karpusas 
et al, 1995; Peitsch et al, 1993), which is far more active than CD40L monomer 
(Morris et al, 1999). Recent studies have demonstrated that platelet membrane bound 
CD40L is also cleaved and released as a soluble form within an hour of activation 
(Henn et al, 2001). However, the biological importance of platelet sCD40L is not fully 
understood. While Henn et al suggested that soluble CD40L derived from platelets is
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monomeric, older and more exhaustive biochemical studies demonstrated that soluble 
CD40L forms trimers (Pietravalle et al, 1996). The difference is crucial as the 
biological activity o f platelet derived sCD40L is likely to depend on whether it exists 
as a trimer or monomer.
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Figure 1-17: C urrent understanding of platelet CD40L.
Platelet activation causes upregulation o f surface bound CD40L and release of soluble 
CD40L. Platelet CD40L induces monocytes to express tissue factor, which causes 
activation of the coagulation cascade. sCD40L has a direct pro-thrombotic effect by 
binding to activated platelet allbp3 via a KGD sequence at positions 115-118. 
Membrane bound CD40L induces endothelial cells to express adhesion molecules and 
tissue factor and to produce pro-inflammatory cytokines. Platelet sCD40L binds to 
platelet CD40, inducing further cleavage and release of sCD40L. The pro- 
inflammatory effects of platelet sCD40L are not fully understood.
Recent studies with CD40L-/- mice have also demonstrated an important role for 
CD40L in platelet adhesion. This is because CD40L has a KGD integrin binding 
sequence at position 115-118, enabling it to bind directly to allbp3 and to promote 
platelet adhesion under shear (Andre et al, 2002b). As platelets are the major source of
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CD40L in the circulation and CD40L has such protean effects, some have suggested 
that platelet CD40L is likely to be a pivotal link between the processes of thrombosis 
and inflammation (Andre et al, 2002a). As such, platelet CD40L is likely to be of 
particular importance in inflammatory conditions involving the vascular endothelium 
such as sepsis syndrome, meningococcal disease, sickle cell anaemia, vasculitis and 
atherosclerosis [Figure 1-17].
1,13.4 CD40L and atherosclerosis
Atherosclerosis is now recognised to be an inflammatory disease involving multiple 
interactions between leukocytes, blood vessels and platelets. Initial studies with mouse 
models of atherosclerosis (eg, LDL receptor (LDLR) -/- and ApoE -/- mouse strains) 
emphasised the critical role of leukocytes. Double knockout mice with absent 
adhesion molecules or chemokine receptors had smaller atherosclerotic plaques 
(Bourdillon et al, 2000; Dawson et al, 1999). Further studies showed that B and T 
lymphocytes were also involved. These cells with macrophages and vascular 
endothelial cells, release cytokines and growth factors, promoting the migration and 
proliferation of smooth muscle cells and inducing the expression of leukocyte 
adhesion molecules, pro-inflammatory cytokines and tissue factor. They also induce 
the synthesis of matrix metalloproteinases, which may lead to plaque rupture.
Because many of the proteins identified in the double knockout mouse experiments 
can be induced by CD40L, it was exciting when the linkage of this protein to 
atherosclerosis was shown. Mach et al (Mach et al, 1998) found that disruption of 
CD40L function in the LDLR-/- mouse with a blocking CD40L antibody prevented
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the progression of atherosclerotic disease. Lutgens et al (Lutgens et al, 2000) targeted 
the CD40L gene in the ApoE-/- mouse, which also reduced lesion progression.
Work is ongoing to determine the precise role of platelet derived CD40L, membrane 
bound and soluble, in the pathogenesis of atherosclerotic lesions, thrombosis and 
restenosis. [Figure 1-18].
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Figure 1-18: Role of CD40/CD40L in atherosclerosis.
After an initiating event, endothelial cell activation occurs with subsequent 
interactions with platelets and leukocytes. CD40-CD40L interactions between these 
cell types may induce pro inflammatory cytokines, adhesion molecules and tissue 
factor in monocytes, endothelial cells and smooth muscle cells. The resultant 
inflammation is likely to contribute to atheroma formation and subsequent blood 
vessel occlusion. (Phipps,2000).
1.13.5 CD40L and other inflammatory diseases
In mouse models of chronic inflammatory conditions including arthritis, graft versus 
host disease, transplant rejection, lung inflammation, and multiple sclerosis, 
inflammation can be reduced by disrupting the CD40-CD40L system. Additionally, 
platelet or sCD40L is elevated in the plasma of humans with an array o f inflammatory 
conditions, such as chronic renal failure (Schwabe et al, 1999), sickle cell anemia
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(Inwald et al, 2000b) and systemic lupus erythematosus (Kato et al, 1999). However, 
it is not known if this sCD40L is derived from immune cells or from platelets. In the 
context of coronary ischaemia recent studies have demonstrated increased levels of 
sCD40L in patients with acute coronary syndromes (Aukrust et al, 1999; Garlichs et 
al, 2001a) and following cardiopulmonary bypass (Nannizzi-Alaimo et al, 2002). 
Increased levels of platelet membrane bound and soluble CD40L have also been found 
in Kawasaki disease and a relationship demonstrated between the level of platelet 
CD40L and the risk of coronary arteritis (Wang et al, 2003). As yet, the role of 
CD40L in the systemic inflammatory response syndrome (SIRS) due to sepsis has not 
been investigated. However, it seems likely that platelet CD40L will be a key link 
between thrombosis and inflammation in all these conditions.
1.14 Conclusions and plan of investigation for this thesis
In conclusion, platelet CD40L is likely to be a critical link between pathways of 
haemostasis, thrombosis and inflammation. Although platelet CD40L can induce 
monocytes to express tissue factor through monocyte CD40 (Amirkhosravi et al,
2002; Lindmark et al, 2000), the potential for platelet CD40L to induce monocyte 
cytokine production is unknown. Thus after confirming that platelets do express 
CD40L upon activation, a major focus of this thesis will be an investigation of the 
dynamics of platelet-monocyte adhesion and of the capacity of platelet CD40L to 
induce monocyte cytokine production. Additionally, the role of CD40L in platelet- 
platelet signalling is poorly understood and will also be explored in this thesis.
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1,14.1 Plan of investigation
1. Investigate the presence and subcellular localisation of platelet CD40L. The 
purpose of this part of the investigation will be to confirm that platelets do express 
CD40L upon activation, to determine the conditions necessary for CD40L expression 
and to determine the ultrastructural site of platelet CD40L. Patients with X-linked 
hyper IgM syndrome will be used as negative controls.
2. Determine the capacity and mechanisms of CD40L expressing platelets to bind to 
monocytes. The dynamics of platelet-monocyte adhesion will be investigated using a 
previously validated static whole blood model of platelet-leukocyte adhesion (Peters et 
al, 1997).The adhesion molecules critical for this process will be identified using 
blocking antibodies and by investigating platelet-monocyte adhesion in human 
“experiments of nature”, children in whom adhesion molecules are absent or 
dysfunctional.
3. Determine the capacity of platelet CD40L to stimulate monocytes. The capacity of 
platelet CD40L to stimulate monocytes will be determined by looking at both blood 
derived monocytes and a monocytoid cell line. The role of CD40L in platelet-induced 
monocyte adhesion will again be determined by using blocking antibodies and by 
looking at monocytes from children with X-linked hyper IgM sydrome.
4. Investigate platelet CD40 and the capacity of CD40L to stimulate platelets. Here, 
the capacity of CD40L to activate platelets through both constitutively expressed CD40 
and GPIIbllla will be investigated by looking at the platelet release reaction and at 
platelet integrin activation. The role of both CD40 and GPIIbllla in this process will be
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determined by using CD40 blocking antibodies and by using eptifibatide, a peptide 
inhibitor of GPIIbllla. The investigation will be enhanced by using platelets from 
patients with Glanzmann’s thrombasthenia (GPIIbllla deficiency) and X-linked hyper 
IgM syndrome.
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2. Materials and Methods
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2.1. Reagents, materials and buffers
2,1,1 General chemicals and reagents
Material Supplier
[14C]-5-HT Amersham
Acetone BDH
Adrenaline Martindale Pharmaceuticals
ADP Sigma
Arachidonic acid Sigma
Aspirin Sigma
BSA Sigma
Cellfix Becton Dickinson
Chlorimipramine hydrochloride Sigma
Citifluor UKC ChemLab
Collagen Organon Teknika
Dimethyl formamide Sigma
EDTA Sigma
FACS lysis Becton Dickinson
Fast red Sigma
FCS Helena Bioscience
Ficoll 1.077 Nycomed
FITC Sigma
Fluo-3AM Molecular probes
fMLP Sigma
Heparin CP Pharmaceuticals
HEPES Sigma
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Hirudin
Interferon-y
Levamisole
Leucoperm
Levamisole
LPS
Magnesium sulphate 
Methanol
Naphthol AS-MX phosphate (Ci9Hi8N 0 5P)
Paraformaldehyde
PBS tablets
PKH-2 Green fluorescent cell marker
Probenecid
Prostacyclin
Recombinant CD40L
Scintillation fluid
SFLLRN
Sodium chloride
Sodium citrate
Thrombin
TRAP
TRIS base
Sigma
Boehringer-Ingelheim
Sigma
Serotec
Sigma
Sigma
BDH
BDH
Sigma
Sigma
Sigma
Sigma
Sigma
GSK
Dr Richard Armitage, Amgen
BDH Laboratory Supplies
BACHEM
Sigma
Sigma
Enzyme Research Laboratories
BACHEM
Sigma
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2.1.2 General buffers and wash solutions
Solution_______________________ Contents
Cellfix 10% Cellfix in PBS
FACS wash PBS, 1% BSA, 0.1% sodium azide
FACS lysis 10% FACS lysis in water
HEPES/Tyrodes buffer 129 mM NaCl, 8.9 mM NaHC0 3 , 2.8 mM KC1,
0.8 mM KH2PO4, 5.6 mM dextrose and 10 mM 
HEPES, pH 7-4.
Phospate Buffered Saline One PBS tablet dissolved in 200 ml of deionized
water yielded 0.01 M phosphate buffer,
0.0027 M KC1 and 0.137 M NaCl, pH 7.4, at 
25 °C.
Platelet buffer 10 mM HEPES, 145 mM NaCl, 5 mM KC1,
1 mM MgSO^ pH 7.4 
Platelet fix 1 % Cellfix in PBS
Tris acetate EDTA (TAE) buffer 0.04M Tris-acetate, 0.001M EDTA, pH 8.0 
Tris buffered saline 0.625M Tris, pH 7.6 with HC1. Diluted 1:10 with
normal saline for use.
Transfer buffer 25 mM Tris, 192 mM glycine, 20% methanol
2.1.3 Primary antibodies
Antibody__________ Clone____________________Supplier
Antibody24 Ab24 Cancer Research UK
IgGl control MOPC-21 Becton Dickinson
CD 11a 38 Cancer Research UK
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C D lla B3B11
C D llb 44
C D llc 3.9
CD18 TS1/18
CD18 2E7
CD29 P5D2
CD40 M2
CD40 M3
CD40 G28.5
CD40 Mab89
CD40L TRAP-1
CD41 5B12
CD41 SZ22
CD61 Y2/51
CD61 PM6/13
CD62P AK4
CD62P G1
PSGL-1 PL-1
PSGL-1 PL-2
allbp3 activator LIBS-6
Chemicon International Ltd 
Cancer Research UK 
Cancer Research UK 
Cancer Research UK 
C Gahmberg, Helsinki, Finland 
Cancer Research UK 
Dr Richard Armitage, Amgen 
Dr Richard Armitage, Amgen 
Professor Ed Clark, Seattle, US 
Dr F Briere, Dardilly, France 
Becton Dickinson 
Dako
Beckman Coulter
Dako
Serotec
Becton Dickinson
Dr R McEver, Oklahoma, USA
Beckman Coulter
Beckman Coulter
Dr M Ginsberg, California, USA
2.1.4 Secondary antibodies
Antibody_________________________________________ Supplier
APAAP complex Dako
F(ab)2 Goat anti-mouse immunoglobulin PE/FITC Dako
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Goat anti-mouse Texas Red 
Rabbit antimouse immunoglobulin
Molecular Probes 
Dako
2,1.5 Directly conjugated antibodies
Antibody Clone Supplier
IgGl PE A112-2 BD
IgGl FITC Not known BD
IgGl PerCP X40 BD
IgG2a FITC DAK-G05 Dako
IgG2a PE DAK-G05 Dako
C D llb  FITC ICRF44 Serotec
CD14 FITC UCHM1 Serotec
CD40 FITC HB14 Caltag
CD40L PE TRAP-1 BD
CD40L FITC 24-31 Alexis
CD42a PerCP Bebl BD
CD42b PE AN51 Dako
CD45 PerCP 2 D 1 BD
CD61 PerCP RUU-PL 7F12 BD
CD62P PE AK4 BD
CD69 FITC L78 BD
Fibrinogen FITC Polyclonal rabbit anti-human Dako
FITC-conjugated control Polyclonal rabbit anti-human Dako
Glycophorin A PE R7078 Dako
IL-ipPE AS10 BD
78
IL-8 PE ASH BD
IL-12PE Cl 1.5 BD
MCP-1 PE 5D3-F7 BD
PAC-1 FITC Pac-1 BD
TNF-aPE 6401.1111 BD
2.1.6 Materials and equipment -  bacterial and cell culture 
Material___________________________________________Supplier
2 -mercaptoethanol
Amphoteracin
HBSS
HBSS with no calcium or magnesium 
Iscove's modified Dulbecco's medium (IMDM) 
L-asparigine 
L-Glutamine
MEM non-essential amino acids 
MEM vitamins
Sigma
Invitrogen
Gibco
Gibco
Gibco
Gibco
Gibco
Gibco
Gibco
Monocyte culture medium RPMI 1640, FCS 10%,
100 U/ml penicillin lOOU/ml, streptomycin 0.1 mg/ml and L-glutamine 2 mM
RPMI 1640 Gibco
RPMI 1640 without phenol red Gibco
THP-1 cell culture medium RPMI 1640,10% FCS, 2-
mercaptoethanol (2x10' 5 M), 100 U/ml penicillin lOOU/ml, streptomycin 0.1 mg/ml
and L-glutamine 2 mM
Gonococcal agar BD
Monothioglycerol Sigma
Penicillin and streptomycin Gibco
Phytohaemagglutinin Murex Diagnostics
Phorbol myristate acetate Sigma
Sodium pyruvate Sigma
Thrombopoietin Sigma
Vitox Oxoid
96 well flat bottomed plate Nunc
24 well plate Costar
6  well plate Costar
50cm tissue culture flask Nunc
0 .2  micron filters Millipore
2.1.7 Materials and equipment -  flow cytometry
Reagents and equipment____________________________ Supplier
FACScan Flow Cytometer Becton Dickinson
Cellquest software package Becton Dickinson
Solutions and buffers
Cellfix 10% Cellfix in PBS
FACS wash PBS, 1% BSA, 0.1% sodium azide
FACS lysis 10% FACS lysis in water
Platelet fix 1% Cellfix in PBS
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2.1.8 Materials and equipment -  electron microscopy
Reagents and equipment_____________________________Supplier
5 nm goat anti-mouse gold conjugate British Biocell
1200EX electron microscope JEOL
Agar 100 Agar
Copper grids Agar
Dodecanyl succinic anhydride (DDSA) Agar
Glutaraldehyde Agar
Methyl nadic anhydride (MNA) Agar
MTC6000 ultramicrotome RMC
Osmium tetroxide Agar
Propylene oxide Agar
2,4,6 Tridimethylaminomethyl phenol (DMP30) Agar
Saponin Sigma
Silver enhancing kit British Biocell
Sodium cacodylate Agar
Uranyl acetate Agar
Solutions and buffers
3% glutaraldehyde: made up in in 0.1 M sodium cacodylate and 5mM calcium 
chloride
Reynold's lead citrate: 1.76g sodium citrate and 1.33g lead nitrate added to 8 mis
0.1M sodium hydroxide and added to 50 mis distilled water 
Saponin buffer: 500mg saponin in 500mls HBSS (+Ca, +Mg) for 0.1% solution and 
add 2.5 mis of 20% sodium azide and lOmls of 0.5 M Hepes buffer
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Wash buffer: PBS and 1% w/v BSA
Resin: 1 part DMP30, 12.5 parts MNA, 8.3 parts DDSA and 19.2 parts Agar 100
2.1.9 Materials and equipment -  protein blotting
Material Supplier
30% acrylamide/0.8% bis-acrylamide stock solution Anachem
Ammonium persulphate (APS) Sigma
Bromophenol blue Sigma
Butan-l-ol BDH
Enhanced chemiluminesecence reagent Amersham International
Horseradish peroxidase conjugated sheep anti mouse Ig AmershamPharmacia
Nitrocellulose paper ("Hybond ECL") Amersham Pharmacia
Non-fat milk Marvel
Rainbow molecular weight markers Amersham International
Sodium dodecyl sulphate (SDS) Sigma
N,N,N',N'-tetramethylethylenediamine (TEMED) Sigma
Transblot Cell Bio-Rad
2.1.10 Materials and equipment -  molecular biology
Material SuDDlier
100 bp DNA ladder Invitrogen
1 kbp DNA ladder Invitrogen
Agarose Invitrogen
Chloroform BDH
dNTP solution containing dATP, dCTP, dGTP, dTTP Invitrogen
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Ethanol BDH
Ethidium bromide Sigma
Isopropanol Sigma
PCR Supermix Invitrogen
Random primer oligonucleotides Invitrogen
Reverse transcriptase Invitrogen
RNAse inhibitor Promega
TriZol Invitrogen
2.1.11 Equipment -  platelet aggregometry
Material__________________________________________ Supplier
Aggregometer Biodata
Cuvettes Biodata
Hamilton micro syringes Sigma
Micro stir bars Biodata
2.1.12 Materials -  endotoxin detection
Material__________________________________________ Supplier
E-toxate single test vials Sigma
Endotoxin standard Sigma
Endotoxin-free water Sigma
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2.2. Methods
2.2.1 Conjugation of FITC to monoclonal antibodies
The following solutions were prepared: 5.3% w/v anhydrous Sodium carbonate and 
4.2% w/v Sodium hydrogen carbonate. Solution A: 5.8 mis Sodium carbonate solution 
added to 10 mis Sodium hydrogen carbonate solution. Conjugation buffer: 1 part 
solution A with 9 parts 0.15M Sodium chloride.
1. FITC dissolved to 1 mg/ml in conjugation buffer using a whirlimixer and a small 
flea.
2. 0.3mls FITC solution added to every 1ml protein solution.
3. Incubated for 3-3.5 hours at room temperature.
4. Protein solution filtered by centrifugation at 12000g through 30,000 MW filter 
using 0.1% Sodium azide in PBS to wash off excess FITC.
Protein was resuspended at desired concentration in 0.1% Sodium azide in PBS when 
excess FITC washed off.
2.2.2 Cell separation and culture protocols
Preparation o f  PRP
1. Blood was collected, discarding the initial 2 ml of blood taken in order to limit 
artefactual platelet activation and immediately added to sodium citrate to a final 
concentration of 0.38% w/v.
2. Following centrifugation at room temperature at 150g for 10 minutes, platelet rich 
plasma was removed.
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Preparation ofpurified washed platelets
For molecular biology and protein blotting experiments, purified washed platelets
were obtained as follows.
1. 10 pi prostacyclin (3 pg/ml) was added per 1 ml PRP in a ratio (final 
concentration 30 ng/ml) to prevent platelet activation and clumping
2. The PRP was centrifuged at 800g for 5 minutes
3. The pellet was resuspended in HBSS without calcium or magnesium in the 
presence of 30 ng/ml prostacyclin as above.
4. The platelet suspension was centrifuged at 150g for 10 minutes to pellet any 
remaining contaminating cells.
5. The supernatant was removed.
6 . Steps 2,3 and 4 were repeated.
7. The platelet suspension was centrifuged at 800g for 5 minutes.
8 . The pellet was resuspended in HBSS with calcium and magnesium.
Samples of purified platelets thus prepared typically contained <0.01% contaminating
cells.
Preparation o f  blood derived monocytes
1. Blood was collected into a heparinised syringe with lOiu/ml preservative free 
heparin and then diluted 1:1 with RPMI 1640
2. 2 volumes of diluted blood were layered over 1 volume of Ficoll 1.077 at room 
temperature
3. Layered blood was centrifuged at 500g for 30 minutes with no brake
4. The PBMC layer was aspirated into a clean 50ml flask and filled with 5 volumes 
of RPMI 1640
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5. The PBMC suspension was centrifuged at 250g for 10 minutes
6 . The supernatant was discarded and the cells washed once again in RPMI 1640
7. The cells were resuspended in monocyte culture medium and seeded onto a 6  well 
plate at 0.5 x 106 cells/ml.
8 . The plate was incubated for 2 hours at 37° C in 5% carbon dioxide in air. After 2 
hours, monocytes become adherent to the well: lymphocytes did not.
9. The supernatant was removed and discarded.
10. The wells were refreshed with monocyte culture medium and incubated overnight 
prior to further experiments.
THP-1 cell line
The monocytoid cell line THP-1 (Tsuchiya et al, 1980) was a kind gift from Dr M
Harrison of the Imperial Cancer Research Fund (London, UK).
1. The cells were cultured at 37° C in 5% carbon dioxide in THP-1 culture medium 
and maintained at a concentration of 0.5x106 cells/ml by splitting twice weekly.
2. When appropriate, THP-1 cells were stimulated with interferon-y at lOOiu/ml to 
upregulate CD40 mRNA and protein expression and then washed twice in RPMI 
1640 prior to further experiments. (Francisco et al, 1996; Malik et al, 1996).
2,2.3 Bacterial culture
Neisseria meningitidis serogroup B (strain H44/76) is a clinical isolate from a case of
fatal septicemia (Holten,1979).
1. Bacteria were grown on gonococcal agar supplemented with Vitox and were used 
in stationary phase after culture for 18h.
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2. Suspensions were prepared in RPMI 1640 without phenol red and the optical 
density measured at 540nm.
3. An OD of 1 was shown to be equivalent to 109 organisms per ml. Bacteria were 
fixed in 0.5% paraformaldehyde for 15 min and washed thoroughly in RPMI prior 
to use.
2.2.4 Preparation of samples for flow cytometry
2.2.4.1 Platelet staining
Directly conjugated antibodies
5 pi of citrated blood or PRP was added to 50 pi of platelet buffer, containing
monoclonal antibodies or isotype matched control antibodies at the concentration
shown in preliminary experiments to give optimal staining.
1. Following gentle resuspension, the samples were incubated at room temperature 
for 20 minutes.
2. 250 pi of platelet fix was added.
3. Flow cytometric analysis was performed immediately.
Unconjugated antibodies
1. 5 pi of citrated blood or PRP was added to 50 pi of platelet buffer, either 
containing unconjugated monoclonal antibodies or isotype matched control 
antibodies at the concentration shown in preliminary experiments togive optimal 
staining.
2. Following gentle resuspension, the samples were incubated at room temperature 
for 20 minutes.
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3. The samples were washed once with FACS wash, resuspended and incubated with 
FITC conjugated goat anti-mouse immunoglobulin for a further 20 minutes.
4. The samples were washed once again and then resuspended in 250 pi of platelet 
fix.
5. Flow cytometric analysis was performed immediately.
2.2.4.2 Cell staining in whole blood
Directly conjugated antibodies
1. 50 pi of citrated blood was incubated with monoclonal antibodies or isotype 
matched control antibodies at the concentration shown in preliminary experiments 
togive optimal staining at room temperature for 10 minutes.
2. 250 pi of FACS lysis was then added into each tube.
3. After the red cells had completely lysed, 250 pi of platelet fix was added.
4. Flow cytometric analysis was performed within 30 minutes.
Unconjugated antibodies
1. 50 pi of citrated blood was added to unconjugated monoclonal antibodies or 
isotype matched control antibodies at the concentration shown in preliminary 
experiments togive optimal staining.
2. Following gentle resuspension, the samples were incubated at room temperature 
for 10 minutes.
3. The samples were washed once with FACS wash, resuspended and incubated with 
FITC conjugated goat anti-mouse immunoglobulin for a further 20 minutes.
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4. The samples were spun at 150g for 5 minutes, resuspended in 1 ml FACS lysis and 
incubated at room temperature until all red cells had lysed.
5. The samples were washed once again and then resuspended in 250 pi of platelet 
fix.
6. Flow cytometric analysis was performed immediately.
For cultured cells, the steps with FACS lysis were omitted and wash steps were
performed with FACS wash.
2.2.4.3 Investigation o f  platelet-leukocyte adhesion andplatelet-THP cell adhesion
The method of Peters et al (Peters et al, 1997) was used.
1. Whole blood was added to 3.8% citrate in a ratio of 9:1 (final concentration 0.38% 
w/v citrate); or equal volumes of THP-1 cell suspension and platelet suspension 
were mixed.
2. Platelet agonists were added (see Chapter 4).
3. The samples were incubated at 37°C in air with 5% CO2 for varying lengths of 
time.
4. 50 pi of blood was incubated with CD1 lb FITC (granulocyte marker) and CD61 
PerCP or CD42a PerCP (platelet markers) or isotype matched control antibody) at 
room temperature for 10 minutes; or 50 pi mixed THP-1 cells and platelets were 
incubated with CD42a PerCP or isotype matched control antibody in a similar 
fashion.
5. For blood experiments, 250 pi of FACS lysis was added into each tube.
6. 250 pi of fixative was then added.
7. Flow cytometric analysis was performed within 30 minutes.
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2.2.5 Cord blood lymphocyte stimulation
1. 1ml of cord blood was collected by aspiration of blood from the umbilical vein 
into syringes preloaded with 10 iu/ml heparin and divided into two tubes.
2. 0.5ml of culture medium, consisting of RPMI and 10% fetal calf serum was added 
to each tube.
3. Into one tube phytohaemagglutinin was added to a final concentration of 6 pg/ml 
and phorbol myristate acetate to a concentration of 20 ng/ml. This technique is the 
standard operating procedure for lymphocyte stimulation in use in the Clinical 
Immunology Laboratories at Great Ormond Street Hospital NHS Trust. The 
second tube was left unstimulated.
4. After overnight incubation at 37°C in 5% CO2, lOOpl of specimen from each tube 
was incubated for 10 minutes with directly conjugated fluorescent labelled 
monoclonal antibodies in the following combinations: IgGl FITC/CD45 PerCP, 
CD69 FITC/CD45 PerCP, CD40L FITC/CD45 PerCP. Staining with CD69 was 
performed to confirm lymphocyte activation.
5. 1 ml of FACS lysis solution was added to each tube and the samples incubated at 
room temperature for 10 minutes.
6. The samples were centrifuged at 1200rpm for 5 minutes and resuspended in 500 pi 
of cell fix.
7. Flow cytometric analysis was performed within 30 minutes.
2.2.6 Whole blood culture for intracellular cytokine staining
1. Blood was collected in lOiu/ml heparin and an equal volume of RPMI 1640 added.
2. Brefeldin A was added into the diluted blood to a final concantration of 10 
mcg/ml.
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3. Stimuli were added as reported in the text. Unstimulated samples were used a 
negative control and LPS stimulated samples were used as a positive control.
4. The samples were cultured for 6 h in flat bottomed 96 well plates at 200 pl/well.
5. 5 pi of CD 14 FITC was added to wells for 30 minutes
6. The blood was transferred to FACS tubes
7. The wells were washed with FACS lysis and incubated until monocytes detached 
from wall.
8. The remaining cells were transferred to FACS tubes.
9. 500 pi of FACS lysis was added to FACS tubes until red cells lysed.
10. The remaining cells were washed with 1 ml FACS wash for 5 minutes at 1200 
rpm.
11. The supernatant was discarded and the cells resuspended in 250 pi 4% PFA
12. The cells were fixed in the dark with 4% PFA for 30 minutes
13. The cells were washed in FACS wash as above
14. 50 pi Leucoperm permeabilisation solution was added into the FACS tubes
15. 10 pi of anti-cytokine PE Mab was added and the cells incubated for 30 minutes in 
the dark.
16. The cells were washed with 2 mis FACS wash for 5 mins 1200 rpm.
17. 250 pi Cellfix was added and the cells analysed by flow cytometry within 30 
minutes.
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2.2.7 Cell culture for intracellular cytokine staining
1. THP-1 cells or monocytes were seeded in 3 ml aliquots onto a 24 well plate at a 
concentration of 0.5x106 cells/well.
2. The culture plates were spun at 1200 rpm for 5 minutes and the supernatant 
discarded.
3. The wells were now filled with either culture medium containing 10 pg/ml 
Brefeldin A with or without platelets prepared as above at a concentration of 
1.2xl0'/ml.
4. THP-1 cells were stimulated for 24 h, harvested, washed and stained with anti­
cytokine antibodies as above prior to flow cytometry.
2.2.8 Flow cytometry
Flow cytometric analysis was performed on a Becton Dickinson FACScan using 
Cellquest software. The flow cytometer was calibrated on a weekly basis for 
fluorescence and light scatter using fluorescent beads. Data were collected on PE 
fluorescence at 580nm, FITC fluorescence at 515 nm and PerCP fluorescence at >650 
nm. Forward and side scatter measurements were made with gain settings in 
logarithmic mode for platelet studies and linear mode for studies of monocytes and 
THP-1 cells.
2.2.8.1 Platelets.
The platelet population was easily identified on forward and side scatter [Figure 2-1] 
characteristics and 10000 events were acquired from each sample.
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Figure 2-1. Flow cytometry plot of whole blood.
Physical characteristics o f platelets and other blood cells. The platelet population is 
readily identifiable. Key: SSC-side scatter, FSC-forward scatter
O
e r y t h r o c y t e s  
a n d  l e u k o c y t e s .
p l a t e l e t  g a t e
2.2.8.2 Platelet-monocyte complexes
Monocytes were identified by physical characteristics and by CD1 lb  positivity 
[Figure 2-2]. The platelet markers used were PerCP conjugated mouse anti-human 
IgGl antibodies. Antibody staining was defined as positive in cells if their 
fluorescence intensity exceeded 98% of the fluorescence intensity o f staining with an 
isotype matched monoclonal antibody. [Figure 2-3]. Then, using a PerCP conjugated 
anti-platelet Mab (here CD42a is shown), a platelet-positive population of monocytes 
can be defined using the same gate [Figure 2-4]. These monocytes were defined as 
being “platelet-monocyte complexes”.
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Figure 2-2. Monocyte population in lysed whole blood.
The monocyte population is defined by CD1 lb  positivity and side scatter 
characteristics.
n e u t r o p h i l s
m o n o c y t e  g a t e
10-
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Figure 2-3. Defining non-specific staining in platelet-monocyte complex 
experiments.
Taking only cells in the monocyte gate, PerCP conjugated antibody staining was 
defined as positive in monocytes if their fluorescence intensity exceeded 98% of the 
fluorescence intensity o f staining with an isotype matched monoclonal antibody 
(upper right quadrant).
2%
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O
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□
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Figure 2-4. Platelet-monocyte complexes shown by flow cytometry.
The same quadrant superimposed on a sample stained with a PerCP-conjugated anti- 
CD42a antibody (platelet marker) defines 42.3% of monocytes as bound to platelets. 
These cells have been defined for the purposes of this thesis as “platelet monocyte 
complexes” .
o
42.3%
o
o
o
CD11 b FITC
2.2.8.3 Intracellular cytokine experiments
The methodology of investigating intracellular cytokine production was first described 
by Sander et al, who demonstrated that it is possible to detect intracellular cytokines 
by fixation with paraformaldehyde, permeabilization with saponin and subsequent 
indirect immunofluorescent staining using fluorescence microscopy (Sander et al, 
1991). This technique has been refined by using brefeldin A, a small hydrophobic 
compound produced by toxic fungi that which is a potent inhibitor o f secretion from 
the Golgi complex (Misumi et al, 1986). This leads to an accumulation o f the cytokine 
in the Golgi complex which can be assayed using flow cytometry following 
permeabilisation and staining with fluorochrome-conjugated anti-cytokine antibodies 
(Jung et al, 1993; Prussin et al, 1995). The advantage o f this method is that there is no 
need for cell sorting or cell purification to determine cytokine producing subsets in
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heterogeneous cell populations. The method allows cytokine production in individual 
cells to be assessed.
Monocytes were identified by side scatter characteristics and CD 14 positivity [Figure 
2-5]. THP-1 cells were identified by forward and side scatter characteristics (not 
shown). Anti-cytokine Mabs used in these experiments were PE conjugated mouse 
IgG l. Thus non specific binding was defined as above using a PE conjugated isotype 
matched control antibody [Figure 2-6]. An example o f TNF Mab staining in 
unstimulated whole blood monocytes and whole blood monocytes stimulated with 10 
ng/ml LPS is shown [Figure 2-7]. 2500 CD14+ events or THP-1 cells were collected 
from each sample.
Figure 2-5. Defining the monocyte population in the intracellular cytokine 
experiments.
Figure 2-6. Defining non-specific antibody staining in the intracellular cytokine 
experiments.
Specific staining is defined as staining in excess o f or equal to the upper 2% of 
staining with an isotype matched PE conjugated control antibody (upper right 
quadrant).
Figure 2-7. TNF production in monocytes in whole blood.
A: unstimulated -  only 2.7% cells stain positively with PE conjugated anti-TNF mab. 
B: stimulated with 10 ng/ml LPS for 6 hours -  98.8% cells stain positively.
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2.2.8.4 Lymphocytes
The lymphocyte population was easily identified on forward and side scatter 
characteristics [Figure 2-8]. 3000 events o f the CD45+ population were acquired from 
each sample.
Figure 2-8. Flow cytometry' plot of lysed whole blood showing lymphocyte 
population.
l y m p h o c y t e
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2.2.9 Microscopy
Smears were made of blood and bone marrow aspirates into sylane coated glass 
slides. Washed cell suspensions were adjusted to a concentration of 3-5 x 105 /ml and 
cytocentrifuge preparations were made onto sylane coated glass slides using 50 pi 
aliquots.
2.2.9.1 Fluorescent microscopy protocol
1. Slides were air dried overnight and fixed in methanol.
2. Slides were transferred into PBS and cells rehydrated for 1-5 minutes.
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3. Primary monoclonal antibody added (10 pg/ml in PBS), either unconjugated or 
directly conjugated to FITC, and incubated for 30 minutes.
4. The slides were washed three times in PBS.
5. The second layer antibody added if necessary (goat anti-mouse texas red or goat 
anti-mouse FITC) added and incubated for 30 minutes.
6. The slides were washed three times in PBS.
7. The slides were mounted in Citifluor and immediately examined with fluorescent 
microscope.
2.2.9.2 APAAP protocol
Alkaline phosphatase substrate: 2 mg naphthol AS-MX phosphate on 0.2 mis dimethyl 
formamide. 9.8 mis of Tris buffer was added, the pH was adjusted to 8.2 and the 
solution mixed well. 40 pi of 1M levamisole was added. Immediately before staining, 
10 mg Fast Red salt was added. The solution was filtered through a 0.2 pm filter 
directly onto the slide.
1. Slides were air dried overnight and fixed in methanol.
2. Slides were transferred into TBS and cells rehydrated for 1-5 minutes.
3. Primary monoclonal antibody (10 pg/ml in TBS) was added and the slides were 
incubated for 30 minutes at room temperature.
4. The slides were washed three times in TBS.
5. Rabbit antimouse (1:20 in TBS) was added and the slides were incubated for 30 
minutes at room temperature.
6. Slides were washed three times in TBS.
7. APAAP (1:40 in TBS) complex was added and incubated for 10 minutes.
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8. Steps 4,5,6 and 7 were repeated
9. Slides were washed three times in TBS.
10. Alkaline phosphatase substrate was added and incubated for 20 minutes.
11. Slides were washed three times in TBS.
12. Slides were counterstained in Harris heamotoxylin for 5 minutes and washed in 
running tap water.
13. Slides were air dried and mounted in apathy's mounting medium and examined 
immediately with light microscope.
2.2.9.3 Immunoelectron microscopy protocol
Staining
1. Washed platelets were prepared as per protocol.
2. For plain non-immunostained transmission electron micrographs, steps 3-16 were 
omitted.
3. Platelets were spun down at 2400 rpm and resuspended and fixed in 2% 
paraformaldehyde for 30 minutes at room temperauture.
4. Platelets were washed 3 times in PBS containing 50mM glycine to quench 
aldehydes.
5. Platelets were protein blocked in PBS +1%  BSA + 10% NGS + 0.1% Na azide, 
pH 7.4 for 30 minutes at room temperature.
6. Platelets were washed twice in wash buffer.
7. The sample was resuspended in saponin buffer and spun immediately at 2400 rpm 
for 5 minutes.
8. The sample was incubated with primary antibody in PBS + 1% BSA + 0.1% 
Tween + 0.1% saponin +1%  NGS for 1 hour.
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9. The sample was washed three times in buffer as per (7), incubated with 1 nm gold 
conjugate in incubating buffer (as 7) for 1 hour and then washed three times in 
PBS.
10. The sample was fixed in 1% glutaraldehyde in PBS for 15 minutes and then 
washed twice in distilled water.
11. Silver enhancement was performed as per manufacturer's instructions for 5 
minutes.
12. The platelets were washed twice in distilled water to stop enhancement and 
remove silver solutions and left in 1% glutaraldehyde overnight.
13. The sample was washed twice in distilled water.
14. Incubated with 1% aqeous osmium tetroxide for 2 hours.
15. Washed twice with distilled water.
Dehydration and resin embedding -  the sample was:
16. Incubated in 70% alcohol for 10 minutes
17. Incubated in 90% alcohol for 10 minutes
18. Incubated in 100% alcohol for 10 minutes (repeated x3)
19. Incubated with propylene oxide for 10 minutes (repeated x l)
20. Incubated with propylene oxide/resin 1:1 mix for 30 minutes
21. Incubated with neat resin overnight
22. Polymerised at 60°C overnight
23. Ultra-thin sections were cut on the ultramicrotome using a diamond knife. 
Sections collected onto naked 300 copper mesh grids
24. Electron microscopy was performed.
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2.2.10 Protein blotting
2.2.10.1 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE was performed according to the method of Laemmli (Laemmli,1970).
1. Polyacrylamide gels of the indicated percentage were prepared from a 30% 
acrylamide/0.8% bis-acrylamide stock solution in 375 mM Tris pH 8.8 containing
0.1% SDS and polymerised with 0.04% APS and 1/500 TEMED.
2. The separating gels were overlaid with a 3% polyacrylamide stacking gel prepared 
from the acrylamide/bis-acrylamide stock solution in 125 mM Tris pH 6.8 
containing 0.1% SDS and polymerised with APS and TEMED as above.
3. Proteins for electrophoresis were boiled for 5 min in sample buffer (125 mM Tris 
pH6.8, 25% glycerol, 2% SDS, 0.02% bromophenol blue) before loading onto the 
gels.
4. Rainbow coloured protein molecular weight markers in the range 14.3 kDa-220 
kDa were run on each gel as standards.
5. Electrophoresis was carried out in an Atto Dual Mini Slab Chamber containing 
electrophoresis running buffer (25 mM Tris base, 192 mM glycine, 0.1% SDS) at 
90 volts through the stacking gel and 180 volts through the separating gel.
2.2.10.2 Protein blotting
Following separation by SDS-PAGE, western blotting was performed as follows:
1. Proteins were transferred onto Hybond ECL nitro-cellulose membrane in a 
Transblot Cell using transfer buffer for 75 min at 60 volts.
2. To minimise non-specific antibody binding, membranes were blocked overnight at 
4°C in 5% milk powder in PBS-A/0.1% Tween 20.
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3. The membranes were incubated for 1 hour at RT with the primary antibody diluted 
in PBS/0.1% Tween 20 followed by a 1 hour incubation at RT with the HRP- 
conjugated secondary antibody diluted 1:50000 in PBS/0.1% Tween 20.
4. After each antibody incubation the membranes were washed three times for 5 min 
with PBS-A/0.1% Tween 20.
5. Bound antibody was detected by chemiluminescence using ECL Western blotting 
detection reagents.
2,2,11 Molecular biology
2.2.11.1 Ol igonucleotides
Primers used for amplification were obtained from Sigma-Genosys and have been 
previously described (Sugimoto et al, 1999).
CD40 sense nucleotides 41-61
5-CCTCGCCATGTTCGTCTGCC-3'
CD40 antisense nucleotides 761-780
5'-AGCC AGG AAG ATCGTCGGGA-3'). 
p-actin sense nucleotides 578-609
5'-ATCTGGCACCACACCCTTCTACAATGAGCTGCG-3' 
P-actin antisense nucleotides 1415-1384
5 '-CGT CAT ACTCCT GCTT GCCTGATCC AC AT CT GC-3'
2.2.11.2 mRNA separation protocol 
Cell homogenization
q  n1. 10 washed platelets or 10 washed THP-1 cells were prepared as a pellet
2. 1 ml Trizol was added and the cells were lysed by repetitive pipetting
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3. The lysate was transferred to a 1.5 ml Eppendorf
Phase separation
4. The lysate was incubated for 5 minutes at room temperature
5. 0.2 mis chloroform was added per 1 ml Trizol
6. The sample was shaken vigorously for 15 seconds and then incubated at room 
temperature for 2-3 minutes
7. The sample was centrifuged at 12000g for 15 mins at 5°C
RNA precipitation
8. The aqeous phase of the sample was transferred to a fresh 1.5 ml Eppendorf
9. RNA was precipitated by adding 0.5ml isopropyl alcohol per 1ml Trizol used for 
the initial homogenisation.
10. The sample was incubated at room temperature for 10 minutes and then 
centrifuged at 12000g for 10 minutes at 5°C.
RNA Wash
11. The supernatant was removed and discarded.
12. The RNA pellet was washed once with 1ml 75% ethanol per 1 ml original Trizol,
mixed by vortexing, centrifuged at 7500g for 5 minutes at 5°C.
13. The supernatant was removed and discarded.
Redissolving RNA
14. The RNA pellet was air dried for 5 minutes and redissolved in 50 pi RNAse free 
water.
15. RNA concentration was estimated using a spectrophotometer.
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2.2.11.3 Reverse transcription
cDNA was synthesised as follows:
1. 1 pg RNA was mixed with 1.5pg random primer oligonucleotides, 2pl of 1 OmM 
dNTP solution, 400 units of reverse transcriptase, 40 units of RNAse inhibitor, 
lOpl buffer and 24pi RNAse free water. Total reaction volume was 50 pi RNA.
2. Random primers were mixed first and heated to 96°C for 3 minutes.
3. The remaining reaction mix was added and heated to 37°C for one hour and then 
to 65°C for 10 minutes prior to cooling on ice.
2.2.11.4 PCR o f cDNA
1. PCR of cDNA was performed in a final volume of 48pl containing 45pl PCR 
Supermix, 2pl cDNA and 0.5pi of sense and antisense primers at a final 
concentration of 0.4pM.
2. The amplification cycles were 94°C for 1 minute, 55°C for 1 minute and 72°C for 
2 minutes.
2.2.11.5 Agarose gel electrophoresis
The PCR products were separated by electrophoresis on a 1% agarose gel after 35
cycles and visualised with ethidium bromide. Amplification of human P-actin served
as a control for sample loading and integrity. Gels were prepared as follows:
1. 1.5g of agarose was added to 100 mis of TAE buffer and heated in a microwave 
(700W, 30 seconds to 2 minutes depending on volume) until the agarose had 
completely dissolved
2. 1 pg/ml ethidium bromide was added to agarose solution
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3. The gel was poured when cooling
4. The gel was covered in TAE buffer when set
5. 5 pi of PCR product, 5 pi of TAE buffer and 2 pi of 6x loading buffer were mixed
and loaded onto the gel.
6. 2 pi 100 bp DNA ladder and 10 pi TAE buffer were mixed and loaded onto the 
gel to estimate the size of DNA strands obtained.
7. The gel was run at 100V for 30 minutes
8. The bands were visualised with long wave ultraviolet light and photographed
using a video camera system.
2.2.12 Platelet aggregometry
1. PRP was prepared as above
2. Remaining blood was centrifuged at 3500 rpm to prepare platelet poor plasma 
(PPP)
3. PPP and PRP was mixed to adjust platelet concentration to 250 x 109/L.
4. The aggregometer was switched on and warmed to 37°C.
5. The stir speed was set to 900 rpm.
6. 100% light transmission was set using PPP.
7. 0.2 mis PRP was placed into cuvettes and cuvettes were inserted into the 
aggregometer.
8. Platelet agonist was drawn up into Hamilton syringes and added to cuvettes.
9. Light transmission was recorded onto thermosensitive profiler paper.
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2.2.13 Platelet intracellular calcium flux
Calcium flux was determined by a fluo-3 method (Storey et al, 2000):
1. Aliquots (2 ml) of PRP were incubated with 20pl 500pM fluo-3 AM (final 
concentration 5pM) and 80pl 62.5mM probenecid (final concentration 
2.5mM) for 30 min at 37°C. Probenecid inhibits fura-2 leakage from cells and 
is essential to get good fluo-3 signals from platelets.
2. Aliquots (10 pi) of labelled PRP were added to 1ml HT buffer at 37°C 
containing lOpl lOOmM CaCh (final concentration ImM).
3. An aliquot (250 pi) of diluted PRP was applied to the flow cytometer to 
measure the baseline fluorescence.
4. A further 450pl aliquot of diluted PRP was added to a tube containing 50pl 
ImM SFLLRN (final concentration lOOpM).
5. The fluorescence of the sample was then measured after 5, 15, 30, 60 and 
120 s and 15 and 30 minutes on a flow cytometer. The median fluorescence 
intensity was determined for each time point.
6. Data are presented as mean percentages of the maximum fluorescence 
obtained with SFLLRN as an agonist.
2.2.14 Platelet granule release
Platelet granule release was determined by looking at release of radiolabelled
serotonin from platelets (Heptinstall et al, 1980).
1. 6pl 1.85MBq/ml [14C]-5-HT (final concentration 0.521 pM; 1.11 kBq/ml) was 
added to lOmls PRP and the tubes were incubated at 37°C in a waterbath for 
30 minutes.
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2. 20pl 25pM chlorimipramine (final concentration 1 pM, to prevent 5-HT 
reuptake) was then added to 440pl PRP containing [14C]-5-HT-labelled 
platelets and the sample was incubated at 37°C for 2 min.
3. Agonist was added and samples were incubated at 37°C for a further 30 
minutes.
4. The reaction was terminated by placing on ice and adding 50pl 13.35mM 
aspirin (final concentration 1.26mM).
5. Samples were centrifuged at 1500g for 10 min and 50pl samples of the 
supernatant plasma were placed in separate scintillation tubes that were then 
filled with 4 mis scintillation fluid, capped and mixed.
6. Sample radioactivity was counted in a scintillation counter in counts per 
minute.
7. One hundred per cent release was estimated using 50pl samples of a saline 
solution of [14C]-5-HT at the same concentration as that added to the PRP.
8. a-granule release was assessed by determining platelet p-thromboglobulin 
release in the supernatant plasma from these experiments using a commercially 
available ELISA according to the manufacturer’s instructions (Roche 
Diagnostics, Lewes, UK).
2.2,15 Limulus amoebocyte lysate (LAL) assay for endotoxin
1. Endotoxin standard was prepared in doubling dilutions from 0.25EU/ml to
0.015EU/ml to determine the endotoxin level in the test reagent.
2. The test samples, water and endotoxin standard dilutions were added to each vial
as indicated.
108
3. Each vial was briefly vortexed to ensure homogeneity and were then incubated 
undisturbed for 1 h at 37°C.
4. Vials were observed for the presence of gelation.
5. A test was considered positive only if a hard gel had formed which was not 
disrupted by complete inversion of the tube.
2.3 Statistical analysis
Unless otherwise stated, each experiment was performed on at least 3 occasions. T- 
tests, paired or unpaired as appropriate, were used to determine if differences between 
groups of data were statistically significant.
2.4 Patients
2.4.1 X-linked hyper IgM patients
Patient Year of birth Mutation
1 1988 deletion exon 5
2 1998 Q174R
3 1985 G38R
4 1990 T254M
5 1987 T254M
6 1987 Unknown
7 1994 L155P
8 1985 L155P
9 1988 341-347delAAGAAAA
10 1988 W140G
11 1987 256-262del
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2.4.2 Patients with absence or dysfunction of integrins
All patients with Glanzmann’s thrombasthenia had complete absence of allbp3. 
Patient_____________Condition__________ Year of birth Mutation
1 Glanzmann’s 1987 Not known
2 Glanzmann’s 1991 Not known
3 Glanzmann’s 1996 Not known
4 Glanzmann’s 1988 Not known
5 (Shaw etal, 2001) LAD-1 1982 CD18:A27C
6 LAD-1 1999 Not known
7 LAD-1 1986 Not known
8 LAD-1 1999 Not known
9 Combined defect 1998 Not known
2.5 Ethics and consent
All human studies performed in this thesis were approved by the local research ethics 
committee. Informed consent was taken from adult participants and from parents of 
participating children.
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3. Expression of platelet CD40L
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3.1 Introduction
Henn et al demonstrated that platelets express membrane-bound CD40L upon 
activation and showed that platelet CD40L has the capacity to bind to endothelial cell 
CD40 and thus to induce expression of adhesion molecules (Henn et al, 1998) and 
tissue factor (Slupsky et al, 1998) and production of pro-inflammatory cytokines such 
as MCP-1, IL-6 and IL-8 (Henn et al, 1998). Henn et al showed that preformed 
CD40L is stored in unstimulated platelets but is rapidly mobilised to the platelet 
surface after platelet stimulation. CD40L expression was demonstrated on platelets by 
both flow cytometry and by protein blotting. The flow cytometry method used 
separated, thrombin stimulated, fixed platelets and a biotinylated anti-CD40L 
antibody. Platelets were stained with streptavidin-PE prior to flow cytometry. 
Separated platelets were used in order to avoid the problems arising from clot 
formation, which occurs when thrombin is added to whole blood.
In this chapter, the expression of CD40L on the platelets in whole blood is confirmed 
using directly conjugated antibodies. A whole blood assay is developed using TRAP 
rather than thrombin to stimulate platelets. Addition of this peptide to whole blood 
causes platelet activation directly through stimulation of PAR-1 (as evidenced by 
rapid up-regulation of surface CD62P), but as it has no serine protease activity, 
fibrinogen is not converted to fibrin and clot formation does not occur (Feng et al, 
1995).
The presence of CD40L on activated platelets is also confirmed using fluorescence 
microscopy and its ultrastructural location identified with immunoelectron 
microscopy.
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3.2 Methods
3.2.1 Subjects
10 healthy adult volunteers, under 35 years of age, and 10 patients with a known 
diagnosis of X-linked hyper IgM syndrome (CD40L deficiency) were recruited 
following informed consent. None of these subjects had taken any drug affecting 
platelet function for the preceding 2 weeks. Additionally, three X-linked hyper IgM 
patients were investigated after bone marrow transplantation. Neonatal cord blood was 
obtained from the umbilical veins of placentas of healthy newborn term infants.
3.2.2 Fluorescence microscopy
The primary monoclonal antibodies used were anti CD40L (clone TRAP-1), anti 
CD62P (clone AK4) and an isotype matched control antibody. The second layer 
antibody was a goat anti-mouse Texas red antibody.
3.2.3 Immunoelectron microscopy
Immunoelectron microscopy is a technique to determine the ultrastructural location of 
antigens within cells. In platelets it has previously been performed by permeabilisation 
to allow the entry of primary antibody into the platelet and by on-section staining of 
frozen sections (Hovig et al, 1988; McLaren et al, 1982; Stenberg et al, 1984).
Because of the technical difficulties involved with on section staining of frozen 
sections, in this study a permeabilisation technique was used, in which platelets are 
permeabilised using a saponin buffer. This permeabilises the plasma membrane to 
allow the passage of primary and secondary gold conjugated antibody into the platelet. 
5nm gold particles can pass into cells but not the more easily visualised lOnm or
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20nm particles. A silver enhancement step was required in order to visualise the 5nm 
particle with the electron microscope. In this step, the platelets are incubated in silver 
containing buffer, which coats the gold particle in silver, making it larger and hence 
more readily visualised in the electron microscope. The advantage of this technique is 
that it is relatively simple to perform and the specimen can be processed normally 
through osmium and graded alcohols prior to embedding in resin, cutting and 
microscopy. Samples were prepared using the same primary antibodies as in the 
fluorescent microscopy protocol.
3.3 Results
3.3.1 Stimulation of platelets with TRAP causes rapid mobilisation of CD62P and 
CD40L to the platelet surface
Addition of TRAP to whole blood resulted in a rapid increase in platelet surface 
expression of CD62P, reflecting a-granule secretion. A titration and time course was 
performed in whole blood from healthy adult volunteers to determine the optimal 
concentration of TRAP for platelet activation, using CD62P expression as an end 
point. The minimal concentration needed for maximal activation was found to be 
lp,M. Expression of both CD62P and CD40L was maximal at 5 minutes [Figure 3-1].
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Figure 3-1. Dose response curve and time course of platelet CD62P and CD40L 
expression with TRAP.
Dose response curve o f platelet CD62P and CD40L expression with TRAP for 5 
minutes (A) and time course of CD40L and CD62P expression with 1 pM TRAP (B) 
Maximal activation occurs at 1 pM at 5 or 30 minutes. Representative results from 2 
experiments are shown.
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Addition o f ADP and adrenaline at differing concentrations to whole blood caused 
platelet activation, as evidenced by CD62P expression, but not to the same extent as 
TRAP. CD40L expression was unaltered by these stimuli [Figure 3-2]
Figure 3-2. Platelet CD62P and CD40L expression with adrenaline and ADP
Platelet CD62P and CD40L expression following addition o f increasing 
concentrations of adrenaline (A) and ADP (B) to whole blood for 5 minutes. Although 
there is a dose response curve for CD62P, CD40L is not convincingly upregulated by 
either agonist. Representative results from 2 experiments are shown.
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3.3.2 CD40L is not expressed on platelets from  patients with X-linked hyper-IgM  
syndrome (CD40L deficiency).
Whole blood from 10 patients with a known diagnosis o f X-linked hyper IgM 
syndrome and 10 immunocompetent controls was stimulated with TRAP for 5 
minutes at room temperature. Platelets expressed CD40L in immunocompetent 
controls but not in patients with X-linked hyper IgM syndrome [Figure 3-3]. Effective 
stimulation of platelets from both patients and controls was confirmed by upregulation 
o f surface CD62P in all samples following addition o f thrombin receptor agonist
Figure 3-3. Flow cytometry plots of TRAP stimulated platelets and PHA/PMA 
stimulated lymphocytes.
i) Platelets: Upregulation by thrombin receptor agonist peptide o f CD62P seen in all 
samples and CD40L in immunocompetent control and cord blood but not in patient 
with CD40L deficiency, ii) Lymphocytes: Upregulation of CD69 seen in all samples 
and of CD40L in immunocompetent control but not in cord blood or in patient with 
CD40L deficiency. □  CD40L (unstimulated), CD40L (stimulated),
  activation reporter: CD62P (platelets), CD69 (lymphocytes). Representative
plots from n separate experiments are shown.
i) Platelets
1. Immunocompetent (n= 10) 2. Cord blood (n=3) 3. XLHIGM (n=10)
peptide.
1 0 * 1 0 *
ii) Lymphocytes
1. Immunocompetent 2. Cord blood 3. XLHIGM
1 0 ' 10*
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3.3.3 CD40L is expressed on neonatal platelets but not lymphocytes following 
stimulation
Investigation of three cord blood specimens using the activated platelet and activated 
lymphocyte technique was performed in order to compare the potential of the two 
assays for neonatal screening. Neonatal platelets revealed levels of CD40L similar to 
adult levels following stimulation. However, CD40L expression on activated 
lymphocytes was sub maximal when compared to adult controls. [Figure 3-3].
3.3.4 CD40L is expressed on platelets from individuals with hyper-IgM syndrome 
following bone marrow transplantation.
Three X-linked hyper IgM patients were investigated after bone marrow 
transplantation. Two were found to have reconstituted CD40L on platelets as well as T 
lymphocytes. 24% of platelets were positive for CD40L following stimulation in one 
patient and 31% in another, a reconstitution to normal levels. These two patients also 
had normal lymphocyte expression of CD40L. In contrast, in the remaining patient 
only 4% of platelets were positive for CD40L following stimulation. In this patient, 
engraftment had been confirmed by DNA analysis but lymphocytes also expressed 
low levels of CD40L post transplant, suggesting a problem with gene transcription, 
translation or protein synthesis (results not shown).
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Figure 3-4. Platelet CD40L dem onstrated by fluorescence microscopy.
Panel A: stained with the anti-CD40L Mab TRAP-1. Panel B: stained with isotype 
matched control Mab.
3.3.5 CD40L demonstrated on platelets by fluorescence microscopy
Fluorescent microscopy demonstrated the presence o f CD40L on activated platelets 
spun down onto cytocentrifuge slides. No staining was observed in samples prepared 
with isoptype matched control antibody [Figure 3-4].
3.3.6 Ultrastructural location o f  platelet CD40L is the a-granule membrane
CD40L and CD62P antigen were visualised using the immunoelectron microscopy 
technique [Figure 3-5]. In resting platelets, both CD62P and CD40L are seen on the 
cellular side o f the a-granule membrane. However, in platelets that have become 
activated during the separation process, both CD62P and CD40L are seen at the 
surface o f the platelet near the pseudopodia formed upon activation.
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Figure 3-5. Immunoelectron microscopy of platelet CD40L and CD62P
Immunoelectron microscopy o f platelets showing location o f CD62P and CD40L in 
unstimulated (A) and stimulated (B) platelets. Both CD62P and CD40L are located in 
the a-granule membrane in resting platelets, whereas in activated platelets they can be 
seen at the platelet surface and in the open canalicular system (OCS). No staining with 
isotype matched control antibody (IgGl).
B CD62PA CD62P
A CD40L B CD40L OCS
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3.4 Discussion
The data presented here confirm that CD40L is expressed on the surface of platelets 
within minutes of activation. CD40L is upregulated with the same time course as 
CD62P. This is consistent with CD40L having the same ultrastructural site as CD62P, 
the platelet a-granule.
10 patients with a known diagnosis of X-linked hyper IgM syndrome had defective or 
absent expression of platelet CD40L as well as lymphocyte CD40L. Two patients 
were investigated post bone marrow transplant and had reconstituted CD40L both on 
PMA/PHA activated T cells and on platelets. The use of blood from these human 
knockouts provided an important negative control and helped to confirm the presence 
of CD40L on platelets from immunocompetent controls.
CD40L expression was also demonstrated on neonatal platelets, making the whole 
blood assay developed here suitable for neonatal and potentially antenatal screening. 
Previous reports that neonatal platelets are less reactive than adult platelets to 
physiological agonists in whole blood (Kestin et al, 1993) were confirmed. Decreased 
levels of CD62P and CD40L expression in neonatal platelets were found compared to 
adult platelets in response to stimulation with TRAP. Previous reports of near-absent 
expression of CD40L on activated T cells obtained from healthy neonatal cord blood 
(Nonoyama et al, 1995) were also confirmed, demonstrating that the lymphocyte 
assay is unsuitable for neonatal screening [Figure 3-3].
In spite of the different antibody clones used in the activated platelet and the activated 
lymphocyte technique, there were no conflicting results. This is probably because both
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the TRAP-1 clone, used in the platelet work, and the 24-31 clone, used in the 
lymphocyte work, are thought to bind near the active site of the CD40L trimer rather 
than near its cytoplasmic tail.
Thus, it might be possible to use the assay developed here for clinical diagnosis of X- 
linked hyper IgM syndrome. Until now a diagnosis of X-linked hyper IgM syndrome 
was dependent on a failure to demonstrate the molecule on the surface of T cells 
obtained from whole blood and activated in vitro or by gene sequencing. These assays 
are time consuming, typically taking 6-24 hours to complete. In contrast, the flow 
cytometric technique described here takes less than 20 minutes to perform and may be 
used for the assessment of CD40L expression on activated platelets. The assay may be 
useful in neonatal screening, evaluation of patients in whom a diagnosis of X-linked 
hyper IgM syndrome is suspected and to confirm marrow reconstitution post bone 
marrow transplant. However, some patients with X-linked hyper IgM syndrome 
express mutated CD40L, which is detected by some monoclonal antibodies but not 
others (Seyama et al, 1998). Thus if a patient is strongly suspected of having a 
diagnosis of X-linked hyper IgM syndrome, CD40L gene sequencing should also be 
performed. There is also an autosomal recessive form of the syndrome in which 
CD40L expression is normal but there are abnormalities in B cell signalling following 
ligation of CD40 (Conley et al, 1994). Patients with this form of the condition will 
clearly not be detected by either of the techniques described here.
The presence of platelet CD40L was confirmed by both fluorescent microscopy and 
by immunoelectron microscopy. Immunoelectron microscopy showed both CD62P 
and CD40L in the a-granule membrane in resting platelets. In activated platelets
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CD62P and CD40L were both seen at the platelet surface and in the open canalicular 
system (OCS). Taken together, the electron microscopy and flow cytometry data 
suggest that platelet CD40L is stored in the platelet a-granule and is rapidly 
translocated to the platelet surface following activation. This data is in contrast to that 
of Hermann et al, who have reported differential expression of platelet CD62P and 
CD40L when using collagen rather than TRAP as a platelet agonist (Hermann et al, 
2001). To explain this, Hermann at al suggested that platelet CD40L is stored 
preformed in the platelet cytoplasm rather than the a-granule. They attempted to 
confirm this hypothesis by looking at CD40L staining patterns on platelets by 
immunofluorescence microscopy. However, fluorescence microscopy is not a reliable 
method to investigate the subcellular location of antigens, particularly antigens such as 
CD40L, of which only about 300 molecules are present in any one platelet (Hermann 
et al, 2001). At the very least, confocal microscopy should have been used. In 
contrast, the immunoelectron microscopic images presented here show clearly the 
subcellular location of both platelet CD40L and CD62P in unstimulated and 
stimulated platelets. Henn et al have recently demonstrated that platelet CD40L is 
cleaved and released as an 18 kDa form shortly after platelet activation and that the 
release of the soluble form is an important mechanism by which membrane bound 
CD40L is downregulated following activation after a period of 1-2 hours (Henn et al, 
2001). This possibility was not specifically investigated here, but clearly the capacity 
for membrane bound platelet CD40L to be rapidly cleaved into a soluble form may 
have confounded the results of the study of Hermann et al, who also looked at platelet 
CD40L in subcellular platelet fractions. However, this still does not adequately 
explain the differential expression of CD40L and CD62P following platelet activation 
with collagen. While the immunoelectron microscopy images presented in this thesis
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are convincing, there is also evidence of tissue degradation, almost certainly caused by 
the saponin based permeabilisation buffer. Thus further immunoelectron microscopy, 
preferably using frozen sections, is required to confirm the findings presented here.
In conclusion, the presence of platelet CD40L was confirmed by flow cytometry, 
fluorescence microscopy and immunoelectron microscopy. The dynamics of CD40L 
expression on the platelet surface following stimulation with TRAP, combined with 
the immunoelectron microscopy data, suggest that CD40L is stored preformed in the 
platelet a-granule and rapidly translocates to the platelet surface upon activation. 
These findings were underlined by the use of human CD40L knockouts, patients with 
X-linked hyper IgM syndrome, as negative controls for platelet CD40L expression.
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4. Platelet-monocyte adhesion
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4.1 Introduction
For CD40L on activated platelets to be of biological importance, close contact will be 
necessary between platelets and CD40 expressing cells. Monocytes constitutively 
express CD40 (Alderson et al, 1993) and activated platelets bind readily to 
leukocytes, particularly monocytes and neutrophils, to form platelet-leukocyte 
complexes (Peters et al, 1997; Peters et al, 1999). The molecular determinants of 
platelet-leukocyte adhesion were investigated in detail here.
4.2 Methods
4.2.1 Platelet-monocyte interaction in whole blood
Platelet agonists were added to citrated whole blood at the following concentrations: 
ADP at 10 pM and TRAP at 1 pM. The neutrophil agonist fMLP was used at 1 pM. 
Blood was incubated at 37°C in 5% CO2 for varying lengths of time. “Activation 
reporter” Mab, which bind to the integrin ligand binding site which is only exposed 
upon activation, were also used. The allbp3 activation reporter Mab, Pac-1 FITC, was 
used to determine the activation state of the platelet p3 integrin. The Mac-1 activation 
reporter Mab, Ab24, conjugated to FITC, was used to determine the activation state of 
the leukocyte p2 integrin.
4.2.3 Blocking antibodies
The adhesion molecule blocking antibodies used were the PSGL-1 Mabs, PI and P2 
(blocking and non-blocking respectively), the CD62P blocking Mab G1 and the 
CD1 lb/CD 18 blocking Mab IB4.
125
4.2.4 Patients and controls
Human “experiments of nature”, individuals in whom adhesion molecules were absent 
or dysfunctional were used to determine the contribution of CD1 lb/CD 18 and CD61 
and other p integrins to platelet-monocyte adhesion (see Methods 2.4.2).
4.3 Results
4.3.1 Platelet activation following addition of agonists to whole blood
The effect of addition of 10 pM ADP, 1 pM fMLP or 1 pM TRAP or a combination 
of ADP and fMLP to whole blood was investigated in healthy adult controls (n=4), 
[Figure 4-1]. Pac-1 binding was maximal at 1 minute and CD62P positivity was 
maximal at 10 minutes. Data from these time points only are presented. When 
unstimulated, Pac-1 MFI was 37.0 + 4.2. This rose to 52.6 +1.6 (p=0.001) with ADP 
and to 107.8 + 4.7 (p=0.0006) with TRAP. fMLP caused no change, MFI being 36.9 + 
4.8 (p=0.98). When unstimulated, % CD62P+ platelets was 12.3 +4.1. This rose to
52.4 ± 10.0 (p=0.02) with ADP, to and to 85.1 ± 4.6 (p=0.0002) with TRAP. fMLP 
caused no change, %CD62P+ platelets being 12.3 + 4.9 fMLP (p=0.99).
4.3.2 Monocyte activation following addition of agonists to whole blood.
The effect of addition of 10 pM ADP, 1 pM fMLP or 1 pM TRAP to whole blood 
was investigated in healthy adult controls (n=5), [Figure 4-2]. When unstimulated,
CD1 lb MFI was 22.3 + 1.9. This rose to 46.6 + 6.7 (p=0.008) with ADP, to 104.6 +
26.2 with fMLP (p=0.03) and to 81.1 ± 14.3 (p=0.03) with TRAP. When 
unstimulated, Mab24 MFI was 16.1 + 2.4. This rose to 29.9 + 7.2 (p=0.1) with ADP, 
to 80.1 + 6.2 with fMLP (p=0.003) and to 83.4 +1.4 (p=0.001) with TRAP. Clearly,
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monocyte activation following addition of platelet agonists here could be a direct 
effect o f the agonists upon monocytes, or an indirect effect mediated by platelets.
Figure 4-1. Platelet activation following addition of agonists to whole blood.
Effect o f addition of 10 pM ADP, 1 pM fMLP or 1 pM TRAP to whole blood in 
healthy adult controls (n=4) on platelet Pac-1 binding at 1 minute (A) and CD62P 
expression at 10 minutes (B)
A
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Figure 4-2. Monocyte activation following addition of agonists to whole blood.
Effect o f addition o f 10 pM ADP, 1 pM fMLP or 1 pM TRAP on CD1 lb  expression 
(A) and Mab24 binding (B) to whole blood in healthy adult controls (n=5).
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4.3.1 Adhesion of activated platelets to monocytes -  platelet activation is the crucial 
step
The effect of addition of ADP, fMLP or TRAP or a combination of ADP and fMLP to 
whole blood for 10 minutes at 37°C was investigated in healthy adult controls (n=10). 
When unstimulated, 26.3 + 3.7% monocytes were found to be in platelet-monocyte 
complexes. This rose to 65.6 + 5.4% (p<0.0001) with ADP, to 77.9 + 5.3% (p<0.001) 
with ADP and fMLP and to 93.9 + 2.1% (pO.OOOl) with TRAP [Figure 4-3]. fMLP 
had a non-significant additive effect when combined with ADP. fMLP alone had no 
effect [Figure 4-4].
ADP and TRAP both cause platelet P-selectin expression and p3 integrin activation 
and some degree of leukocyte activation whereas fMLP is a specific leukocyte agonist 
which causes p2 integrin activation, as shown by binding of Mab24 to the Mac-1 
ligand binding site [Figure 4-2]. fMLP did not cause the formation of platelet- 
monocyte complexes. Additionally, as ADP and fMLP together did not cause 
significantly greater platelet-monocyte adhesion than with either agonist alone, 
platelet activation seems to be more important than leukocyte activation in platelet- 
monocyte adhesion in the whole blood model presented here.
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Figure 4-3.Platelet-monocyte complex in whole blood
Whole blood was stimulated with TRAP for 10 minutes at 37°C. This 
photomicrograph was taken from a film prepared from the sample.
Figure 4-4. Platelet-monocyte adhesion in whole blood with different agonists.
Effect o f addition o f 10 pM ADP, 1 pM fMLP or 1 pM TRAP or a combination o f 
ADP and fMLP to whole blood for 10 minutes at 37°C in normal controls (n=10). 
Both ADP and TRAP induced platelet-monocyte adhesion. fMLP had a non­
significant additive effect when combined with ADP. fMLP alone had no effect.
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4.3.2.2 Experiments with blocking antibodies
Further experiments using blocking antibodies were performed in order to dissect the 
pathway of platelet-monocyte adhesion in more detail. Blocking antibody experiments 
were performed with G1 (P-selectin blocking antibody), PI and P2 (blocking and non- 
blocking PSGL-1 antibodies respectively), IB4 (Mac-1 blocking antibody) and 
eptifibatide (platelet P3 integrin blocking peptide).
10 pM ADP was added to whole blood for 10 minutes at 37°C and platelet-monocyte 
adhesion was assessed. ADP increased % platelet-monocyte complexes from 16.4 + 
2.9% to 68.9 ± 3.4% (p=0.003, n=4). Platelet-monocyte adhesion was completely 
abrogated by preincubation with 10 pg/ml of P-selectin blocking antibody G1 
(p=0.0005) and the PSGL-1 blocking antibody PI (p=0.0003). The non-blocking 
PSGL-1 antibody P2 and the Mac-1 blocking antibody IB4 had no effect. P3 integrin 
blockade with 2 pg/ml eptifibatide enhanced platelet-monocyte adhesion (p=0.004).
These experiments demonstrate that blockade of the P-selectin-PSGL-1 interaction 
with G1 or with PI completely inhibited the formation of platelet-monocyte 
complexes. At the same time, Mac-1 blockade had no effect. p3 integrin blockade 
enhanced platelet-monocyte adhesion [Figure 4-5]. Thus the P-selectin -  PSGL-1 
interaction is critically important to platelet-monocyte adhesion in the whole blood 
model. In contrast, the p2 and P3 integrins appear to be making minimal contribution 
to adhesion between these two cell types.
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Figure 4-5. Platelet-monocyte adhesion is critically dependent upon a P-selectin- 
PSGL-1 interaction.
10 \xM ADP was added to whole blood for 10 minutes at 37°C and platelet-monocyte 
adhesion was assessed. ADP induced platelet-monocyte adhesion was completely 
abrogated by the P-selectin blocking antibody G1 and the PSGL-1 blocking antibody 
PI. The non-blocking PSGL-1 antibody P2 and the Mac-1 blocking antibody IB4 had 
no effect. p3 integrin blockade with eptifibatide enhanced platelet-monocyte adhesion.
The findings presented here are consistent with previous workdemonstrating that
to monocyte PSGL-1.
4.3.2.3 Platelet-monocyte adhesion in Glanzmann’s thrombasthenia 
In order to further investigate the contribution of the platelet P3 integrin to the 
adhesive interaction between platelets and monocyte, whole blood from children with 
Glanzmann's thrombasthenia was examined under the same experimental conditions. 
The effect o f addition o f ADP, fMLP or TRAP or a combination o f ADP and fMLP to
to 1 0 0
critical initial event in platelet-monocyte adhesion is the binding of platelet P-selectin
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whole blood in normals (n=10) or Glanzmann’s thrombasthenia (n=3) was examined. 
ADP caused 65.6 + 5.4% monocytes to form platelet-monocyte complexes in normals 
but 90.6 + 4.5% form complexes in individuals with Glanzmann’s thrombasthenia 
(p=0.007). There were no significant differences in platelet-monocyte adhesion with 
other agonists.In spite of complete absence o f allbp3 which has been proposed as a 
potential ligand for monocyte CD1 lb/CD 18 (Weber et al, 1997) platelet-monocyte 
adhesion was not impaired. In fact, as with eptifibatide, platelet-monocyte adhesion 
was enhanced with ADP [Figure 4-6].
Figure 4-6. Formation of platelet-monocyte complexes in patients with 
G lanzm ann’s thrombasthenia.
Effect o f addition of 10 pM ADP, 1 pM fMLP or 1 pM TRAP or a combination o f 
ADP and fMLP to whole blood in normals (n=10) or Glanzmann’s thrombasthenia 
(n=3). ADP caused significantly more formation of platelet-monocyte complexes in 
individuals with Glanzmann’s thrombasthenia than in controls. There were no 
significant differences in platelet-monocyte adhesion with other agonists.
□ normal 
m Glanzmanns
The likely explanation o f this phenomenon is that in the absence o f allbp3 , there is no 
homotypic platelet adhesion (ie platelets do not bind to other platelets), meaning that
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more are available for heterotypic adhesion to monocytes and neutrophils. 
Examination of the forward scatter/side scatter profile of whole blood stimulated with 
ADP in both normals and in patients with Glanzmann's thrombasthenia confirmed the 
extent of platelet-platelet adhesion in normals and its complete absence in 
Glanzmann's thrombasthenia [Figure 4-7]. Further analysis of the forward scatter 
profile revealed that the "sword" like profile between the neutrophils and monocytes 
does indeed consist of platelet aggregates. These platelet aggregates were present in 
all samples of normal individuals when stimulated with ADP but were never present 
in individuals with Glanzmann's thrombasthenia.
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Figure 4-7. FACS plots of platelet-monocyte complexes in whole blood.
Neutrophils and monocytes are clearly seen in FACS plots o f lysed whole blood in a 
normal individual and an individual with Glanzmann’s thrombasthenia. A “sword” is 
seen between the neutrophil and monocyte population in the normal individual 
following addition of 10 pM ADP. This “sword” has been gated as R l. Further 
analysis o f the population in the Rl gate in the histogram reveals intense staining for 
CD42a (shaded area) with minimal control antibody binding (clear area). This 
demonstrates that the population consists of platelet aggregates. Such aggregates 
require homotypic platelet adhesion via allbp3, which does not occur in Glanzmann’s 
thrombasthenia.
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4.3.2.4 Platelet-monocyte adhesion in LAD-1
In order to further examine the contribution of the leukocyte p2 integrin (Mac-1 or 
CD1 lb/CD 18), whole blood from children with leukocyte adhesion defect type 1 
(LAD-1) (with absent CD1 lb/CD 18 expression) was examined under the same 
experimental conditions. In spite of complete absence of CD1 lb/CD 18 in LAD-1, 
platelet-monocyte adhesion was not impaired [Figure 4-8]. In fact, again, platelet- 
monocyte adhesion was enhanced with ADP. ADP caused 65.6% + 5.4 monocytes to 
form platelet monocyte complexes in controls but 85.4% + 3.9 formed complexes in 
LAD-1 patients (p=0.005). One explanation for this is that in normal individuals, 
platelet-dependent monocyte activation may cause enhanced homotypic binding of 
monocytes to monocytes (Konstantopoulos et al, 1998), thus removing them from the 
pool available for binding to platelets or resulting in aggregates so large as to be 
invisible to the flow cytometer. This effect will not occur in patients with LAD. This 
again suggests that adhesion molecules other than CD1 lb/CD 18 may be important in 
both platelet-monocyte and monocyte-monocyte adhesion.
136
Figure 4-8. Platelet-monocyte adhesion in LAD-1.
Effect o f addition of 10 pM ADP, 1 pM fMLP or 1 pM TRAP or a combination o f 
ADP and fMLP to whole blood in normals (n=10) or LAD-1 (n=3). A. Platelet- 
monocyte adhesion. ADP caused significantly more formation of platelet-monocyte 
complexes in LAD-1 than in normals. There is no significant difference in platelet- 
monocyte adhesion with other agonists. B and C. C D llb  and Mab24 expression. As 
expected, CD1 lb and Mab24 expression are significantly reduced in all conditions in 
LAD-1.
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4.3.2.5 Platelet-monocyte adhesion in a patient with dysfunctional ft integrins 
As both platelets and monocytes express other important p integrins, the possibility of 
these being of importance in platelet-monocyte adhesion was considered. The 
investigation of this possibility was facilitated by the identification o f a patient who 
had dysfunctional p i ,  p2 and p3 integrins (patient 9 in Methods 2.4.2, see Chapter 5). 
When whole blood from this patient was stimulated with ADP, fMLP, ADP and fMLP 
or TRAP, platelet-monocyte complexes formed in similar numbers to control blood 
[Figure 4-9]. This suggests that in the model of platelet-monocyte adhesion presented 
here, p integrin activation with subsequent ligand binding is not essential for platelet- 
monocyte adhesion.
Figure 4-9. Platelet-monocyte adhesion in patient 9.
Effect o f addition of 10 pM ADP, 1 pM fMLP or 1 pM TRAP or a combination o f 
ADP and fMLP to whole blood in normals (n=10) or patient FM (n=3 separate 
experiments). There is no significant difference in platelet-monocyte adhesion with 
any of the agonists investigated.
□ normal
□ Patient 9
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4.4 Discussion
In the whole blood model investigated here, it was demonstrated that platelet- 
monocyte complex formation is critically dependent upon platelet activation and upon 
the platelet P-selectin—»monocyte PSGL-1 interaction. ADP, a specific platelet 
agonist, caused the formation of platelet-monocyte complexes in a P-selectin 
dependent manner. The p2 and p3 integrins appeared to be minimally involved as 
experiments with blocking antibodies and with natural human knockouts of CD 18 and 
allbp3 showed no reduction in the number of platelet-monocyte complexes compared 
to normal controls with any agonist studied. In fact, absence or blockade of p2 or P3 
integrins was associated with increased platelet-monocyte adhesion.
There are a number of explanations for the observation that P2 and p3 integrins do not 
play a role in platelet-leukocyte adhesion in whole blood under static conditions, 
whereas under conditions of shear stress, as shown by several other groups, P2 
integrins become critically important.
Firstly, integrins may require some shear for optimal function. Platelet adhesion to 
immobilised fibrinogen has been reported to be optimal with shear rates > 300s’1 
(Bonnefoy et al, 2000). The presence of shear may highlight high-affinity rather than 
low affinity adhesive cell-cell interactions. Indeed, platelet adhesion to leukocytes has 
been found to be Mac-1 dependent in a whole blood model with shear rates as low as 
100 s*1 (Konstantopoulos et al, 1998).
139
A further explanation of the difference in the findings between the static whole blood 
model (P2 integrins of no importance) and previously reported work looking at 
platelet-leukocyte adhesion in cell suspensions (P2 integrins of critical importance) is 
that in some previously reported work there has always been an element of P3 integrin 
blockade, either with CD61 antibodies (Konstantopoulos et al, 1998) or with RGDS 
peptide (Evangelista et al, 1996). This Chapter has shown that P3 integrin blockade or 
dysfunction enhances platelet-monocyte adhesion, probably as platelet-platelet 
adhesion is absent. Similarly, absence of Mac-1 function enhances platelet-monocyte 
adhesion, probably due to reduced monocyte-monocyte adhesion, although further 
work is required to confirm this. When p i, P2 and p3 integrins were all dysfunctional, 
as in the patient investigated here, these effects appeared to cancel each other out, 
suggesting that in the complete absence of homotypic adhesion, heterotypic adhesion 
occurs with normal dynamics in static conditions, again depending on platelet P- 
selectin-monocyte PSGL-1 interactions.
Taken together, the data presented here suggest that whatever their role in neutrophil 
transmigration across the vascular endothelium, damaged or otherwise, the integrins 
are not required in the adhesion of platelets to leukocytes in the static whole blood 
model. Further work is required to dissect out the pathways of adhesion further and to 
determine the reasons for the profound differences found between the static model 
used here and models in which adhesion occurs under shear.
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5. A novel form of integrin dysfunction 
involving pi, 02, and 03 integrins
141
5.1 Introduction
The integrins are a widely expressed family of noncovalently linked a  and p subunits 
that mediate cell-cell and cell-extracellular matrix interactions. The integrins on 
circulating leukocytes and platelets bind minimally to their ligands, buttheir adhesive 
capacity can be increased by stimulation of intracellular signaling pathways, for 
example by chemokines and bacterial peptides, triggering of the T cell receptor 
complex, or artificially, with phorbol esters. This mechanism of integrin activation has 
been termed inside-out signaling. It is also possible to activate integrins with divalent 
cations such as Mg and Mn or with special anti-integrin Mabs. These agonists act 
directly on the integrin ectodomain and stimulate adhesion to ligand (Stewart et al, 
1996).
Inside-out signaling induces two major forms of alteration to integrins that enable 
efficient ligand binding: integrins can undergo conformational change leading to 
higher affinity receptors and can diffuse laterally in the membrane to form higher 
avidity clusters. Once activated (and ligand bound), the integrin signals back into the 
cell, and this is termed outside-in signaling.
Active p i and p2 integrins play a crucial role in the extravasation of leukocytes from 
the circulation to sites of injury or infection and in the homing of lymphocytesto 
tissues. Specifically, integrins a4p i and LFA-1 mediate firm adhesion of the 
leukocytes and transendothelial migration. Neutrophils and monocytes are the first 
cells to be recruited to inflammatory sites making use of p2 integrins (CD11/CD18), 
LFA-1, Mac-1, and p i50,95. The platelet integrin allbp3 is stimulated to bind 
fibrinogen by agonists such as thrombin and ADP, released at sites of vascular injury.
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This event is pivotal to the aggregation of platelets the formation of the platelet plug 
and the clotting of blood.
In humans, two inherited autosomal recessive diseases result from germline mutations 
in the genes encoding integrins specific to cells of hematopoietic origin. These 
disorders are leukocyte adhesion deficiency-1 (LAD-1) and Glanzmann 
thrombasthenia (GT) (see Introduction). The hallmark of these disorders is lack of 
expression of the affected integrin. LAD-1 is caused by mutations in the p2 subunit of 
the leukocyte integrins. The bleeding disorder GT is usually caused by mutations in 
either the a  or p subunit of the platelet integrin allbp3 (CD41/CD61).
Here, an unusual patient with clinical features of both LAD-1 and GT is described. 
The results suggest that the patient has a novel form of integrin dysfunction in which 
the p i, p2, and p3 integrins are expressed on the cell surface at normal levels but 
cannot be stimulated to bind ligand by intracellular signaling pathways.
5.2 Methods
5,2.1 Investigation of integrin expression on platelets and leukocytes 
Experiments looking at integrin expression and activation on leukocytes were all 
performed in whole blood. Experiments looking at integrins and integrin activation on 
platelets were all performed in PRP. Primary antibodies used were: IB4 (P2); Ab38 
(otL); ICRF44 (aM); 3.9 (ocX); TS1/18 (P2),P5D2 (pi), 5B12(ccIIb) and Y2/51 (P3).
143
5.2.2 Protein blotting
Primary antibodies used were SZ22 (allb blotting) and PM6/13 (p3 blotting); Ab38 
(aL blotting), 2E7 (P2 blotting) and B3B11 (pi blotting).
5.2.3 Investigation of integrin activation in whole blood and PRP 
Platelet agonists were added to citrated whole blood or PRP at the following 
concentrations: ADP at 10 pM and SFLLRN at 100 pM. The neutrophil agonist fMLP 
was used at 1 pM. The samples were incubated at 37°C in air with 5% CO2 for 
varying lengths of time. The Mac-1 activation reporter Mab, Ab24, conjugated to 
FITC, was used to determine the activation state of the leukocyte P2 integrin. The 
allbp3 activation reporter Mab, Pac-1 FITC, was used to determine the activation 
state of the platelet P3 integrin.
Binding of soluble fibrinogen was determined using FITC conjugated polyclonal 
rabbit anti-human anti-fibrinogen. In the platelet experiments, non specific binding 
was determined by pre-incubating the samples with 20 pg/ml eptifibatide, which 
blocks fibrinogen binding to the allbp3 binding site. In the monocyte experiments, 
non-specific binding was determined using a control antibody.
5.3 Results
5,3,1 Patient clinical characteristics
The patient was bom at term by elective Caesarean section to non-consanguineous 
Maltese parents. She had two female siblings, of whom one was 7 years old and well, 
whereas the other died within hours of birth with widespread bruising and bleeding. In
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spite of her atraumatic delivery, the patient was noted to have extensive bruising and 
petechiae within hours of birth. She had an antenatal intraventricular haemorrhage and 
later required insertion of a ventriculo-peritoneal shunt for post-haemorrhagic 
hydrocephalus. A platelet count and routine clotting screen performed at this point 
were in the normal range. The umbilical cord separated normally at one week of age. 
At three months of age she was referred for investigation of prolonged bleeding 
following minor trauma.
The platelet count, thrombin time, activated partial thromboplastin time, prothrombin 
time, and fibrinogen levels were all within the normal range. However, platelet 
aggregation was absent in response to ADP, collagen and arachidonic acid. In 
contrast, platelets from both parents aggregated normally in response to these 
agonists. Flow cytometry revealed that the patient's platelets had normal expression of 
GPIb and allbp3. These results suggested a diagnosis of Type 2 Glanzmann’s 
thrombasthenia with dysfunctional, rather than absent, platelet allbp3. She was 
managed with tranexamic acid and platelet transfusions as required.
From 5 months of age the patient developed recurrent bacterial infections and at 11 
months she developed leg ulcers and was commenced on prophylactic antibiotics. She 
was found to have leukocytosis (38.4xl09/l; normal range 5-15xl09/l) suggestive of a 
leukocyte adhesion defect, but had normal expression of the leukocyte integrin aL, 
aM, aX  and p2 subunits and the selectin ligand sialyl Lewis x. She had normal 
humoral immune responses to Tetanus toxoid and Haemophilus influenza, neutrophil 
phagocytosis of Staphylococcus aureus and oxidative burst. Her lymphocyte count, 
however, was high (15.7xl09/l; normal range of 1.5-4x109/l). Her T cell mitogenic 
activity to PHA was reduced by 50% compared to healthy age matched controls. The
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patient is now 3 years old and has undergone a successful bone marrow transplant. 
There is no family history of either LAD-1 or GT- type disorders.
5.3,2 Integrin expression on the patient*s platelets and monocytes 
Because the patient displayed symptoms indicative of both leukocyte and platelet 
integrin dysfunction, the cell surface expression of the major integrins on platelets and 
monocytes was analysed by flow cytometry. The overlapping profiles in Figure SI 
show that the expression of the allb  and P3 subunits on platelets and the aL, aM, aX, 
P1 and p2 subunits on monocytes was similar for the patient and a control donor.
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Figure 5-1. Integrin expression on patient and control platelets and monocytes.
Expression of (a) a llb  and P3 subunits on platelets, (b) aL, aM , aX , pi and P2 
subunits on monocytes from control individual (black line) and patient (grey region). 
Background binding is indicated (dotted line) and was similar for control and patient. 
Representative histograms (n = 2) are shown.
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To determine whether the patient’s integrins were abnormally processed or post- 
translationally modified, cell lysates were subjected to SDS-PAGE and Western 
blotting for the relevant integrin subunits. No differences were detected in the 
electrophoretic characteristics of the a llb  or p3 integrin subunits o f platelet lysates or
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the aL , p i or p2 subunits of T cell lysates [Figure 5-2] prepared from the patient and a 
control donor. Therefore the patient's integrins resembled normal controls in both 
expression and biochemical characteristics.
Figure 5-2. Electrophoretic characteristics of integrin subunits from patient and 
control platelets and T cells.
(a) Platelet lysates from a control donor (C) and the patient (P) blotted for a llb  and P3
subunits, (b) T cell lysates from a control donor (C) and the patient (P) blotted for aL ,
p2, and p 1 subunits. Representative blots (n = 2) are shown.
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5.3.3 Functional analysis o f a l lb/33 on the patient's platelets
Although the patient had normal cell surface expression of the three classes of 
integrins tested, it was possible that her symptoms were due to the inability o f these 
integrins to function normally. The function of the platelet integrin allbp3 was 
assessed by aggregometry. Although control platelets responded to 5pM ADP as 
expected, the patient's platelets did not aggregate [Figure 5-3a]. We next assessed the 
ability o f two standard platelet agonists, ADP and TRAP, which signal through two 
distinct platelet receptors, to cause platelets to bind soluble fibrinogen [Figure 5-3b]. 
Both stimuli induced binding of control platelets to fibrinogen and this was inhibited
148
by the allbp3 antagonist, eptifibatide; however, the patient’s platelets failed to bind 
soluble fibrinogen under any circumstances of inside-out stimulation. These agonists 
induced upregulation of a-granule contents, such as P-selectin, indicating platelet 
activation was normal (data not shown). Another way to activate integrins is to use 
mAbs, such as LIBS-6, which stimulate allbp3 by direct activation of the ectodomain 
(termed outside-in signalling) (Frelinger et al, 1991). LIBS-6 induces expression of 
the allbp3 activation epitope recognised by the mAh PAC-1 (Shattil et al, 1985). Here 
LIBS-6 induces the PAC-1 epitope on both patient and control platelets [Figure 5-3c].
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Figure 5-3. Comparison of integrin a llb p 3  function in patient and control 
platelets.
(a) Platelet aggregation in response to 5 pM ADP (single experiment performed in 
duplicate), (b) Binding of FITC-conjugated antifibrinogen to platelets in the presence 
(black line) or absence (gray region) o f 20 pg/ml eptifibatide. Platelets were either 
unstimulated or stimulated for 20 minutes with 10 pM ADP or 1 pM TRAP. Data are 
representative o f four separate experiments, (c) Binding o f mAb Pac-1 to platelets 
stimulated with 10 pg/ml p3 integrin mAb LIBS-6 in the presence (black line) and 
absence (grey region) o f eptifibatide. Representative data (n = 2) are shown.
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5.3.4 Functional analysis o f  Mac-1 on the patient's monocytes
The function of the p2 integrin Mac-1 was examined by inducing monocyte binding to 
soluble fibrinogen in whole blood. FMLP, a potent "inside-out" monocyte integrin 
agonist, caused control monocytes to upregulate surface CD1 lb  expression and to 
expose the Mac-1 ligand binding site, thus allowing binding of soluble fibrinogen. In 
contrast, the patient’s monocytes upregulated surface CD1 lb  but failed to bind to 
soluble fibrinogen in response to fMLP [Figure 5-4].
Figure 5-4. Comparison of Mac-1 function in patient and control monocytes.
Monocytes were either unstimulated or stimulated with 1 pM fMLP for 10 minutes. 
Binding of CD1 lb  FITC and FITC-conjugated antifibrinogen is shown. While patient 
monocytes upregulated surface CD1 lb  to near normal levels upon stimulation, 
fibrinogen binding (indicating Mac-1 activation with exposure o f the ligand binding 
site) was impaired. Data are representative o f two separate experiments.
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5.3.5 Further analysis
Further investigation was undertaken by Dr A McDowall at Cancer Research UK and 
included investigation of P 1 integrin function on lymphocytes and in depth
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investigation of p2 integrin function on neutrophils (McDowall et al, 2003). This 
demonstrated that “inside-out” signalling pathways leading to integrin activation were 
defective and that this was associated with abnormal clustering of p 1 and p2 integrins. 
The integrins themselves were intact and capable of function following extracellular 
stimulation.
5.4 Discussion
A patient with a novel form of inherited integrin dysfunction is described, in which the 
p2 integrins were expressed on the leukocyte cell surface at normal levels, but could 
not be stimulated to bind ligand by intracellular signaling pathways. Similar findings 
were demonstrated by McDowall et al regarding the pi integrins. The defect also 
affected the integrin allbp3, because the patient’s platelets could not be induced to 
bind soluble fibrinogen or to aggregate by platelet agonists. However, in joint work 
performed with McDowall et al, we demonstrated intact outside-in signalling, of the p 
integrins, that is they could function when activated directly from outside the cell 
(McDowall et al, 2003).
Characteristically LAD-1 patients lacking P2 integrins have elevated numbers of 
circulating neutrophils and fail to clear bacterial infections because these cells have 
restricted ability to traffic into infected tissue. The patient described here also had an 
abnormally elevated number of circulating lymphocytes, a feature that is not evident in 
classical LAD-1. This was probably due to the lack of function of both the p i and p2 
families of integrins, resulting in impaired responses of both myeloid cells and 
lymphocytes to inflammatory signals.
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To date, four patients with nonclassical forms of LAD-1 have been described. The 
leukocytes in two cases expressed approximately 60% of the normal levels of 132 
integrins, but had no 132 integrin function (Hogg et al, 1999; Mathew et al, 2000). 
These LAD-1 variant cases are related to classical LAD-1, having a mutation in one 
allele that prevents expression and a mutation in the other allele that allows expression 
but not ligand binding. Similar GT patients have been described who have allbp3 
expression but no function (Loftus et al, 1990).
There are two reported LAD-1 variant cases in which no mutations in the integrin p 
subunit genes have been detected. The first case had the clinical indicators of LAD-1 
and the p2 integrins were expressed but non-functional (Kuijpers et al, 1997). After 
some years, defects in p3 integrin function also became apparent; but, in contrast to 
our patient, p i integrins were not affected. For the second patient, there were problems 
with p2 and pi integrin function, and a bleeding problem then developed that was not 
explored experimentally (Harris et al, 2001). A speculation is that the genetic lesions 
in these two patients and the patient described here are individual, but may be related 
and potentially highlight a specific common pathway dedicated to integrin activation.
Because the activities of at least three integrin families were affected in the patient 
described here and outside-in signalling was intact, it is unlikely that the dysfunction 
was due to mutations in the integrin subunits themselves. It is more probable that the 
faulty gene encoded a protein critical for integrin function. Moreover, the expression 
of the affected gene product is predicted to be confined to hematopoietic cells or have
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redundant function in other cell types. The fact that murine p i integrin knockouts are 
embryonic lethal (Fassler et al, 1995) implies that the patient would not have survived 
if p 1 integrin functioning was universally affected. The results demonstrating that 
other leukocyte and platelet functions were relatively normal provide evidence that the 
lesion was confined to a component of a key pathway dedicated to integrin activation.
In summary, a defect in the activation of integrins on leukocytes and platelets was 
dissected in a unique patient with clinical features of both Glanzmann’s 
thrombasthenia and LAD-1. The patient had normal expression of p i, P2 and P3 
integrins, but all were dysfunctional. This is the first description of a dysfunction 
affecting three classes of integrins. The defect is likely to be caused by a lesion in an 
intracellular factor or signalling pathway essential for integrin activation in 
haematopoietic cells and results in lack of regulation of clustering, an essential 
component of integrin-mediated adhesion. A key observation in the joint work 
performed with McDowall et al was that the p2 and pi leukocyte integrins were 
constitutively clustered (McDowall et al, 2003) and it is speculated that the lack of 
regulation of this clustering leads to a defect in the ability of the integrins to function 
correctly and, in turn, to the LAD-1- and Glanzmann’s thrombasthenia-like symptoms 
of this unique patient.
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6. The role of CD40L in platelet- 
monocyte interactions
155
6.1 Introduction
Activated platelets have the capacity to stimulate monocytes to express tissue factor 
and to produce the cytokines IL-la, IL-ip, IL-8, MCP-1 and TNF-a in vitro (Aiura et 
al, 1997; Amirkhosravi et al, 1996; Neumann et al, 1997; Weyrich et al, 1996). 
Monocytes constitutively express CD40 (Alderson et al, 1993) and ligation of 
monocyte CD40 by CD40L or anti-CD40 antibodies can induce cell surface expression 
of ICAM-1, MHC Class 2, CD86, tissue factor, matrix metalloproteinases, CD40 and 
production of the cytokines IL-lp, IL-6, IL-8, IL-12, TNF-a, interferon-y and MCP-1 
(Alderson et al, 1993; Kato et al, 1996; Kiener et al, 1995; Mach et al, 1997a; Malik et 
al, 1996; Stout et al, 1996).
Platelets express membrane bound CD40L, as demonstrated in Chapter 3, and release 
soluble CD40L upon activation (Aukrust et al, 1999; Henn et al, 2001; Phipps et al, 
2001). As CD40 is constitutively expressed on monocytes (Alderson et al, 1993), this 
raises the possibility that platelets may have the capacity to activate monocytes through 
a CD40L-CD40 interaction. Indeed, there is already evidence that platelets can induce 
monocyte tissue factor expression through a CD40L-CD40 interaction (Amirkhosravi 
et al, 2002; Lindmark et al, 2000).
Here the capacity of platelet derived CD40L and sCD40LT to induce monocyte 
cytokine production was investigated.
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6.2 Methods
6.2.1 Investigation of CD40L expression on platelet-monocyte complexes 
CD40L expression was examined on platelet-monocyte complexes using a 
modification of the methodology described in Methods 2.2.4.3. Three-colour staining 
was performed, using FITC conjugated CD 14 Mab, PE conjugated CD40L Mab, and 
PerCP conjugated CD61 Mab. Flow cytometry was performed as Methods 2.2.8.2 
although monocytes were identified using CD 14 positivity and side scatter rather than 
CD1 lb positivity and side scatter.
6.2.2 Investigation of platelet-THP-1 cell adhesion
Platelet-THP-1 cell adhesion was investigated according to Methods 2.2.4.3. The P- 
selectin blocking antibody G1 was used azide free at a concentration of 10 pg/ml. 
Isotype matched control antibody was used at the same concentration.
6.2.3 Phenotyping of monocytes and THP-1 cells
Two layer staining of monocytes and THP-1 cells for flow cytometry was performed 
using the following antibodies: UCHM1 (CD14), Mab89 (CD40), G28.5 (CD40), 
Ab38 (CD1 la), Ab44 (CD1 lb), Ab3.9 (CD1 lc), TS1/18 (CD18), PL-1 (PSGL-1) and 
a goat anti-mouse second layer antibody. Isotype matched control antibody was used 
in all experiments to determine non-specific antibody binding.
6.2.4 Intracellular cytokine assay
Cytokine production following co-incubation with activated platelets was investigated 
in both blood-derived monocytes and in THP-1 cells. Intracellular cytokine production 
was assessed according to Methods 2.2.8.3 for monocytes in whole blood and THP-1
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cells in culture. LPS was used as a positive control in whole blood work and killed 
meningococci (Methods 2.2.3) in separated cells and THP-1 cells.
6.2.5 Limulus amoebocyte lysate assay for endotoxin
All reagents were tested for contamination with endotoxin with the limulus
amoebocyte lysate assay.
6.3 Results
6.3.1 Platelet-monocyte complexes have high levels of CD40L 
CD40L expression was examined in platelet-monocyte complexes in whole blood 
from immunocompetent adults. Addition of 1 pM TRAP into citrated whole blood for 
10 minutes at 37°C caused expression of platelet CD40L and formation of platelet- 
monocyte complexes with high levels of CD40L expression [Figure 6-1].
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Figure 6-1. Platelet monocyte complexes express CD40L.
FACS plot showing staining of CD 14+ monocytes for CD61 (platelet marker) and 
CD40L in citrated whole blood before (A) and after (B) adding 1 pM TRAP for 10 
minutes at 37°C. Control antibody binding falls within the lower left quadrant. 
Following stimulation with TRAP, platelets attach to monocytes to form platelet- 
monocyte complexes with high levels of surface bound CD40L. % of the total 
population in each quadrant is shown. A representative plot from 16 experiments is 
shown.
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6.3.2 Platelet-monocyte complex formation is not impaired in patients with CD40L 
deficiency
Platelet-monocyte complex formation and CD40L expression on platelet-monocyte 
complexes was investigated in citrated whole blood following stimulation with 1 pM 
TRAP for 10 minutes at 37°C. Increase in platelet monocyte complexes was seen in 
controls (p<0.001, n=16) and in X-linked hyper IgM patients (p<0.001, n=10). CD40L 
increased only in controls (p<0.001) [Figure 6-2]. Thus patients with X-linked hyper 
IgM had normal platelet-monocyte adhesion but the complexes formed have no 
CD40L present, demonstrating that the CD40L-CD40 interaction is not required for 
adhesion under the low shear conditions in the whole blood model.
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Figure 6-2. Platelet CD40L is not required for platelet-monocyte adhesion
Platelet-monocyte complex formation (A) and CD40L expression (B) on platelet- 
monocyte complexes in citrated whole blood following stimulation with 1 pM TRAP 
for 10 minutes at 37°C. Increase in platelet monocyte complexes seen in controls 
(n=16) and in X-linked hyper IgM patients (n=10). CD40L increased only in controls. 
Means +SEMs are shown.
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6.3.3 Blood derived monocytes constitutively express CD40.
Flow cytometry revealed that circulating monocytes constitutively express CD40 
[Figure 6-3], as previously described (Alderson et al, 1993).
Figure 6-3. CD40 expression on blood monocytes.
Blood monocytes constitutively express CD40 at low levels. Black unfilled histogram: 
isotype matched control antibody, grey filled histogram: anti-CD40 MAb binding. 
Two-layer flow cytometry was performed using the primary antibodies shown 
followed by a Goat anti-mouse FITC. Representative plots from 3 separate 
experiments are shown.
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6.3.4 Effect of platelet and soluble trimeric CD40L on cytokine production in whole 
blood monocytes
Addition of TRAP to whole blood from immunocompetent individuals caused 
production of MCP-1 (pO.OOl, n=T7) but not IL-ip, IL-8, IL-12 or TNF-a 
[Figure 6-4]. Experiments with patients with X-linked hyper IgM syndrome revealed 
similar levels of monocyte MCP-1 production following addition of TRAP to whole 
blood (pO.OOl, n=7), demonstrating that platelet CD40L was not required to induce 
monocyte MCP-1. Further experiments with the P-selectin blocking antibody G1 
demonstrated no inhibition of MCP-1 production (p=0.5, n=7). Taken together, these 
results suggest that in whole blood either TRAP itself or a released platelet product 
other than CD40L was responsible for induction of monocyte MCP-1 production 
following stimulation with TRAP. A role for P-selectin was excluded by the 
experiments with G1.
Further experiments were performed to investigate intracellular cytokine production in 
whole blood monocytes following incubation of whole blood with lpg/ml sCD40LT 
for 6 hours. These experiments demonstrated no increase in production of IL-1 p, IL-8, 
IL-12, MCP-1 or TNF-a over baseline (not shown).
Blood derived monocytes in culture upregulated surface CD40 in response to IFN-y, 
but also produced pro-inflammatory cytokines in response to both thrombin and IFN-y 
(results not shown). Because of these limitations, further experiments investigating the 
effect of platelet and soluble trimeric CD40L in blood derived monocytes in culture
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could not be performed and experiments with the monocytoid cell line THP-1 were 
performed instead.
Figure 6-4. Platelet activation in whole blood induces monocyte MCP-1 
production.
Heparinised blood was stimulated with lpM  TRAP for 6h at 37°C in the presence of 
the Golgi blocker brefeldin A. No reduction of TRAP induced MCP-1 production by 
10 pg/ml control antibody, 10 pg/ml of P-selectin blocking antibody G1 and in 
patients with X-linked hyper IgM syndrome (CD40H). 10 ng/ml E.coli LPS was used 
as a positive control. Means + SEMs of at least 7 separate experiments performed for 
each condition.
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6.3.5 THP-1 cells constitutively express CD40 and upregulate it in response to 
interferon-y
The first requirement for THP-1 cells to be a useful model in which to investgate 
platelet CD40L-monocyte CD40 interactions is that these cells express CD40. Flow 
cytometry experiments demonstrated that THP-1 cells constitutively expressed CD40.
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CD40 was upregulated when the cells were co-cultured with interferon-y, as 
previously described (Alderson et al, 1993; Francisco et al, 1996) [Figure 6-5].
Figure 6-5. CD40 expression on THP-1 cells.
THP-1 cells constitutively express CD40 at low levels. This is upregulated following 
stimulation with 100 iu/ml interferon-y. Black unfilled histogram: isotype matched 
control antibody, grey filled histogram: resting cells anti-CD40 MAb binding, black 
dotted line: stimulated with lOOiu/ml interferon-y for 72h. Two-layer flow cytometry 
was performed using the primary antibodies shown followed by a Goat anti-mouse 
FITC. A representative plot from 3 separate experiments is shown.
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6.3.6 THP-1 cell adhesion molecule expression
The second requirement for THP-1 cells to be a useful model is that they express the 
same adhesion molecules as those expressed by circulating blood monocytes. Further 
flow cytometry experiments were therefore performed which revealed constitutive 
expression of PSGL-1, CD 18, CD 11 a, CD 11 c and low levels o f CD 11 b on TH P-1 
cells [Figure 6-6].
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6.3.7 Platelet-THP-1 cell adhesion
The third requirement for THP-1 cells to be a useful model is that they have the 
capacity to adhere to platelets and that this adhesion is through a PSGL-1—»P-selectin 
interaction. Experiments were therefore performed to examine the adhesion of 
activated platelets to THP-1 cells. 1 pM TRAP added to 1.2xl08/ml platelets with
Figure 6-6. Adhesion molecule expression on THP-1 cells.
Two-layer flow cytometry was performed on THP-1 cells using the primary 
antibodies shown followed by a Goat anti-mouse FITC. Unshaded area=control 
antibody binding. A representative experiment (n=3) is shown.
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0.5x106/ml THP-1 cells for 6h at 37°C caused platelet-THP-1 cell adhesion. This was 
completely abrogated by the P-selectin blocking antibody G1 (p=0.007) but not by 
control antibody [Figure 6-7], demonstrating that a platelet P-selectin-^THP-1 cell 
PSG-1 interaction is critical for platelet adhesion to THP-1 cells, just as it is for blood 
derived monocytes.
Figure 6-7. Formation of THP-l-platelet complexes depends on platelet P-selectin 
expression.
1 pM TRAP added to a coculture of platelets with THP-1 cells for 6 hours at 37°C 
caused platelet-THP-1 cell adhesion. This was inhibited by 10 pg/ml o f P-selectin 
blocking antibody G1 but not by control antibody. Means + SEMs of four experiments 
are shown.
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6.3.8 Effect o f  sCD40LT on cytokine production in THP-1 cells
Cytokine production in THP-1 cells following stimulation with sCD40LT was 
investigated before and after prestimulation of cells for 72h with 100 iu/ml interferon- 
y. Production of the cytokines IL-ip, IL-8, IL-12, MCP-1 and TN F-a was not induced 
when THP-1 cells were co-cultured with lpg/ml sCD40LT before prestimulation with 
interferon-y (not shown). When THP-1 CD40 expression was upregulated by pre­
incubation with interferon-y for 72h, sCD40LT induced a minor but significant 
increase in production of IL-8 (p=0.037, n=7) and TNF-a (p=0.009, n=7) but not the 
other cytokines studied [Figure 6-8].
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Figure 6-8. THP-1 cell cytokine production following stimulation with sCD40LT.
Cytokine production in THP-1 cells following stimulation with 1 pg/ml sCD40LT is 
shown before and after prestimulation of cells with interferon-y. sCD40LT increased 
production of IL-8 and TNF-a only after prestimulation o f cells with interferon-y. 
Effect o f wild type N. Meningitidis at 107/ml for comparison (WT). Means +/- SEMs 
o f 7 separate experiments shown.
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6.3.9 Effect o f  platelet CD40L on cytokine production in THP-1 cells
The IL-8, MCP-1 and TNF-a were investigated. Co-cultures o f 0.5x106/ml THP-1 
cells and 1.2xl08/ml TRAP-activated platelets induced production of IL-8 (p=0.001, 
n=4) and TN F-a (p=0.045, n=4) but not MCP-1. Pre-incubation with the CD40L 
blocking antibody TRAP-1 and the P-selectin blocking antibody G1 did not inhibit the 
response to activated platelets, suggesting it was dependent on the presence of 
released platelet products rather than on platelet CD40L or P-selectin. Importantly, 
TRAP alone had no effect. When these experiments were repeated following pre­
stimulation with interferon-y for 72 h, prestimulated THP-1 cells produced low but 
significant amounts o f IL-8 (p=0.006, n=4) and TNF-a (p=0.013, n=4) but not MCP-1
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in response to activated platelets. This response was attenuated in comparison to that 
of resting THP-1 cells. However, even following pre-treatment with interferon-y for 
72 h, neither TRAP-1 nor G1 had any inhibitory effect. This indicates that cytokine 
production caused by activated platelets was independent of platelet CD40L or P- 
selectin even in the context of enhanced CD40 expression [Figure 6-9].
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Figure 6-9. Cytokine production in THP-1 cells co-cultured with activated 
platelets.
A=resting THP-1 cells, B=prestimulated with interferon-y for 72 h. P=activated 
platelets. Effect o f wild type N. meningitidis at 107 organisms/ml shown for 
comparison (WT). Induction of IL-8 and TNF by activated platelets is not inhibited by 
10 pg/ml o f CD40L blocking antibody TRAP-1 or P-selectin blocking antibody G l. 
Isotype matched control antibody had no effect (not shown). Note reduced 
responsiveness of THP-1 cells to activated platelets and N. meningitidis following 
prestimulation with interferon-y. Means + SEMs of 4 experiments shown.
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6.4 Discussion
Here, a differential effect of platelet derived and sCD40LT was observed on the 
induction of monocyte cytokine production both in a monocytoid cell line and in 
blood monocytes. Whole blood monocytes and THP-1 cells were unresponsive to 
platelet CD40L. In contrast, sCD40LT stimulated cytokine production in THP-1 cells 
but only under conditions in which CD40 expression was enhanced.
There are a number of possible explanations for the differential effects of platelet 
derived CD40L and sCD40LT upon monocytes and THP-1 cells. Firstly, platelet 
CD40L may not be expressed in the quantity or conformation required to successfully 
stimulate monocytes to produce pro-inflammatory cytokines. Upon activation, 
platelets express membrane bound trimeric CD40L (Henn et al, 1998). This 
membrane bound form is capable of inducing endothelial cells, which constitutively 
express CD40 (Hollenbaugh et al, 1995; Kotowicz et al, 1997), to express adhesion 
molecules (Henn et al, 1998) and tissue factor (Slupsky et al, 1998) and to produce 
pro-inflammatory cytokines (Henn et al, 1998). However, it is possible that platelet 
surface CD40L is expressed at levels insufficient to effectively stimulate monocytes 
through CD40. Additionally, monomeric platelet derived sCD40L, released by 
cleavage of the membrane bound form following platelet activation (Henn et al, 
2001), may act as a competitive inhibitor for the trimeric membrane bound form. 
Secondly, monocytes with differing states of activation differ in their capacity to 
respond to CD40L. Here, while circulating monocytes constitutively expressed CD40, 
they did so at low levels and in the circulation, were unresponsive to CD40L in any 
form. Under conditions in which THP-1 cell CD40 expression was enhanced, THP-1 
cells became responsive to recombinant trimeric sCD40L. Even so, a response was
170
seen only at concentrations of sCD40LT 1000 times higher than that required to 
induce endothelial cells to upregulate adhesion molecules (Kotowicz et al, 2000). My 
observations that monocytoid cells are hyporesponsive to CD40 ligation unless pre­
stimulated with interferon-y are in concordance with previous findings that activation 
with interferon-y is required to sensitise monocytes to activating anti-CD40 antibodies 
(Francisco et al, 1996). Indeed, all previous studies demonstrating that ligation of 
monocyte CD40 induces cytokine production have been performed in cell culture, in 
which the cells are likely to have taken on a macrophage like phenotype with 
enhanced CD40 expression (Alderson et al, 1993; Kato et al, 1996; Kiener et al, 1995; 
Stout et al, 1996). Three out of four of these previous studies used second signals in 
addition to CD40L to induce monocyte cytokine production, including IL-3, 
interferon-y and GM-CSF (Alderson et al, 1993), MHC mismatched T cells (Stout et 
al, 1996) and antigen presenting T cells (Kato et al, 1996).
The three studies demonstrating that activated platelets can stimulate monocytes to 
produce the cytokines IL-la, IL-ip, IL-8, MCP-1 and TNF-a in vitro (Aiura et al, 
1997; Neumann et al, 1997; Weyrich et al, 1996) also used separated monocytes in 
cell culture. In the first of these, no attempt was made to neutralise the proteolytic 
effect of thrombin. In the second, the authors reported that their method of monocyte 
purification still left 5-10% contaminating cells. It is therefore not possible to know 
which cell type produced the cytokines under study. The third and most diligent study 
was by Weyrich et al (Weyrich et al, 1996). In this study, blood derived monocytes 
were co-cultured with unfixed thrombin stimulated platelets. The proteolytic activity 
of thrombin was neutralised by the addition of hirudin into the platelet suspension, 
prior to co-culturing the platelets with monocytes. Expression and secretion of MCP-1
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and IL-8 was demonstrated by ELISA of cell free culture supernatants. This depended 
on both engagement of monocyte PSGL-1 by platelet P-selectin and the presence of 
RANTES, a chemokine released from platelets during the release reaction. We found 
that adding TRAP to whole blood induced monocyte production of MCP-1 but found 
that this was P-selectin independent. We also did not demonstrate IL-8 production in 
monocytes in whole blood when stimulated with TRAP. These discrepancies may be 
due to a difference in phenotype of monocytes in whole blood and adherent 
monocytes in culture or may indicate that the intracellular cytokine assay is not as 
sensitive as ELISA in detemining monocyte cytokine production.
In conclusion, it is clear that the relative contributions of platelet derived surface 
CD40L and soluble CD40L to CD40 mediated cellular activation is complex. If 
platelets come into direct contact with endothelial cells, this results in cellular 
activation (Henn et al, 1998; Slupsky et al, 1998) whilst release of platelet sCD40L 
does not elicit an inflammatory response (Henn et al, 2001). Here, platelet derived 
CD40L, even in the membrane bound form, did not induce monocyte cytokine 
production. This means that, in spite of the capacity of soluble trimeric CD40L to 
induce production of cytokines in monocytoid cells in some conditions, it is possible 
that platelet derived CD40L may not be an important cause of monocyte activation in 
health and disease. Further work with blood derived monocytes in cell culture is 
required to determine if this is the case.
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7. Platelets express functional CD40
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7.1 Introduction
It was observed during work described in Chapter 6 that platelet-monocyte adehesion 
increased in whole blood cultured with sCD40LT. These preliminary experiments 
suggested that sCD40LT might be causing increased platelet-monocyte adhesion, 
suggesting that platelet activation was occurring in the presence of sCD40LT. Clearly, 
after a six hour incubation of whole blood, this could be a secondary phenomenon 
occurring as a result of activation of another cell type and subsequent release of 
platelet agonists.
However, one explanation for the observation is that platelets are directly activated by 
sCD40LT. Platelet activation by sCD40LT might occur via two distinct mechanisms. 
Firstly, platelets might express CD40. Secondly, as CD40L has a potential integrin 
binding sequence, KGD, at position 115-118, sCD40LT could bind to and activate 
platelets through interactions with the constitutively expressed p3 integrin GPIIbllla 
and subsequent outside-in signalling(Andre et al, 2002b). Further investigations were 
therefore performed to elucidate the phenomenon.
7.2 Methods
7.2,1 Platelet expression of CD40 protein
For flow cytometry, the unconjugated antibodies used were G28.5 (CD40) and Mab89 
(CD40) with a goat anti-mouse FITC as a second layer. Directly conjugated antibodies 
used were phycoerythrin conjugated TRAP-1 (CD40L) and FITC conjugated HB14 
(CD40). Isotype matched controls were used in all experiments. In some experiments 
SFLLRN, thrombin agonist peptide 1-6, was used to stimulate platelets through the 
thrombin receptor PAR-1. The TRAP used in the first part of this thesis could no
174
longer be used as it has gone out of production. SFLLRN has 1% of the potency of the 
original TRAP (Feng et al, 1995), and was therefore used at a final concentration of 
100 pM rather than 1 pM. This concentration of SFLLRN caused platelets to express 
CD40L and CD62P in an identical manner to that described caused by TRAP in 
Chapter 3.
7.2.2 Megakaryocyte CD40 expression
Megakaryocyte CD40 expression was examined by APAAP in bone marrow aspirates 
taken routinely from immunocompetent children in remission from cancer 
chemotherapy. The antibodies used were Mab89 (CD40), Y2/51 (CD61) and isotype 
matched control.
7.2.3 Platelet granule release
PRP was prepared as above and stimulated with sCD40L trimer (sCD40LT) at the 
final concentration and for the times shown. SFLLRN 100 pM was used as a positive 
control for stimulation. Blocking antibodies against CD40 (M2 and M3) and CD40L 
(TRAP-1) were employed to determine the specificity of the response to sCD40LT. 
The P-selectin blocking antibody G1 was also used in experiments looking at platelet- 
leukocyte adhesion. These blocking antibodies were all azide free and used at a final 
concentration of 10 pg/ml. Isotype matched controls were used in all experiments. 
Eptifibatide, a commercially available allbp3 antagonist, was used to determine the 
contribution of outside-in integrin signalling to platelet activation caused by 
sCD40LT. Platelets were stained with phycoerythrin conjugated CD62P antibody 
(AKA) and isotype matched control to determine the degree of platelet activation.
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7.2.4 Platelet J33 integrin activation
PRP was stained with FITC conjugated Pac-1 antibody, which binds to the allbp3 
ligand binding site, which is exposed upon integrin activation. Eptifibatide, which 
blocks this antibody binding, was used as a negative control in selected experiments.
7.3 Results
7.3.1 Platelet expression o f CD40 protein
7.3.1.1 Flow cytometry
Platelet CD40 expression was investigated by two-layer antibody staining and flow 
cytometry o f platelets in PRP. Typical flow cytometry plots are shown, demonstrating 
that CD40 is constitutively expressed on platelets [Figure 7-1].
Figure 7-1. Platelet CD40 expression demonstrated by flow cytometry.
Platelet CD40 expression is demonstrated by indirect staining using the CD40 
antibody clones shown and a second layer goat anti-mouse FITC antibody. Unfilled 
histogram=isotype matched control antibody binding, filled histogram=test antibody. 
Representative plots from 5 separate experiments are shown.
Mab89 FITC
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7.3.1.2 Western blotting
Platelet CD40 expression was confirmed by immunoblotting. Interferon-y treated 
THP-1 cells were used as a positive control in the protein blot [Figure 7-2].
Figure 7-2. Expression of platelet CD40 confirmed by immunoblotting.
Lysates from platelets (P) and interferon-y stimulated THP-1 cells (T) were blotted 
with Mab89. 48kDa CD40 protein is clearly visible. Interferon-y stimulated THP-1 
cells were used as a positive control for the presence of CD40 protein. Platelet 
preparations for blotting typically contained <0.01% contaminating cells.
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7.3.1.3 Platelet activation does not cause an increase in CD40 expression.
Following stimulation with SFLLRN there was a minor increase in CD40 expression 
from a median fluorescence intensity (MFI) of 10.9 + 0.3 to 15.8 + 0.6 (p=0.003, 
n=5). SFLLRN stimulation also increased CD40L expression as previously described 
resulting in co-expression of CD40 and CD40L on 23.1 + 2.3% of platelets compared 
to 7.5 + 0.4 % in unstimulated controls (p=0.002, n=5).
7.3.2 Platelets do not contain CD40 mRNA
In spite o f the fact that platelets do not contain a nucleus, there is good evidence that 
they contain the machinery for protein synthesis. The contain mRNA for numerous 
cytokines and factor XI (Martincic et al, 1999; Power et al, 1995; Soslau et al, 1997) 
and protein translation has been demonstrated (Roth et al, 1989).
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However, reverse transcription polymerase chain reaction (rt-PCR) demonstrated that 
platelets do not contain CD40 mRNA, suggesting that CD40 protein is probably 
produced in bone marrow megakaryocytes during platelet production [Figure 7-3].
Figure 7-3. Platelets do not contain mRNA for CD40.
Reverse transcription polymerase chain reaction in lysates o f platelets and interferon-y 
stimulated THP-1 cells for (a) CD40 mRNA (739bp) and (b) p-actin mRNA (837bp). 
Although CD40 mRNA is not present in platelets, platelets do contain P-actin mRNA, 
a “housekeeping” gene. Interferon-y stimulated THP-1 cells contain mRNA for both 
CD40 and P-actin. The presence of P-actin mRNA was used as a positive control to 
confirm sample loading and integrity and water was used as a negative control. The 
gel shown is representative o f two separate experiments.
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7.3.3 CD40 demonstrated on bone marrow derived MKs by immunohistochemistry.
Immunohistochemistry of bone marrow aspirates demonstrate low levels o f CD40 
expression on bone marrow derived megakaryocytes [Figure 7-4].
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Figure 7-4. CD40 demonstrated on bone marrow MKs by the APAAP technique.
Bone marrow aspirates were obtained from children in remission with various cancers. 
Primary antibodies used were an isotype matched control (IgGl), a CD40 antibody 
and a CD61 antibody as a positive control. There is a hint o f pink with CD40 staining 
suggesting low level expression o f protein, but it is not comparable to that seen with 
CD61 staining of either megakaryocytes or platelets. A lymphocyte with positive 
CD40 staining is also shown for comparison.
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7.3.4 Platelet CD62P expression is induced by sCD40LT and abrogated by CD40L- 
CD40 blockade.
Platelet activation with the agonists ADP, SFLLRN or collagen results in expression 
of a-granule proteins such as P-selectin (CD62P). sCD40LT was similarly found to 
induce CD62P expression on platelets. A dose response curve is shown [Figure 7-5]. 
Incubation of platelets with 1 pg/ml sCD40LT increased the percentage of CD62P 
positive cells from 15.2 + 0.9 to 46.7 + 2.8 (p=0.0002, n=5). This was completely 
abrogated by the CD40L blocking antibody TRAP-1 (p=0.0002) and the CD40 
blocking antibodies M2 (p=0.0001) and M3 (p=0.0001). There was no inhibition by 
isotype matched control antibody [Figure 7-6].
Figure 7-5. Dose response curve of CD40L induced platelet CD62P expression.
A dose response curve shows platelet CD62P expression in response to stimulation 
with trimeric sCD40LT at a range of concentrations for 30 minutes at 37°C.
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These results are consistent with platelet activation caused by ligation of CD40 by 
CD40L. However, CD40L has the integrin binding sequence KGD and Andre et al
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have recently reported that sCD40L can bind to platelets through interactions with the 
constitutively expressed P3 integrin allbp3 (Andre et al, 2002b). To investigate the 
possibility that sCD40LT induced platelet activation is mediated by outside-in 
signalling through the p3 integrin, sCD40LT mediated platelet CD62P expression was 
investigated in the presence of the allbp3 blocking peptide eptifibatide. In these 
experiments, there was no reduction in the level of CD62P expression induced by 
sCD40LT [Figure 7-6]. Additionally, platelets from a patient with Glanzmann's 
thrombasthenia with complete absence of allbp3 were normally responsive to 
SCD40LT [Figure 7-7].
Figure 7-6. sCD40LT induced platelet CD62P expression is abrogated by CD40 
blockade.
Platelet CD62P expression in response to 1 pg/ml of sCD40LT is abrogated by pre­
incubation with 10 pg/ml of CD40L blocking antibody TRAP-1 or CD40 blocking 
antibodies M2 and M3 but not isotype matched control antibody. The a llbp3 blocking 
peptide eptifibatide did not inhibit CD62P expression caused by sCD40LT. 
Eptifibatide alone had no effect. Effect of stimulation with 100 pM SFLLRN is 
shown for comparison. Means + SEMs of 5 representative experiments shown.
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Figure 7-7. Response of Glanzmann’s platelets to sCD40LT.
Complete absence of GPIIbllla does not prevent sCD40L (1 mcg/ml) from inducing 
P-selectin expression in platelets derived from a patient with Glanzmann's 
thrombasthenia. The response is abrogated by pretreatment with the CD40L blocking 
antibody TRAP-1 (10 mcg/ml). Effect of 1 pM thrombin receptor agonist peptide 
shown for comparison (TRA). Single experiment performed in triplicate; means + 
SEM shown.
7.3.5 a-granule and dense granule release
sCD40LT caused both platelet dense granule and a-granule release in a CD40 
dependent manner. sCD40LT increased p-thromboglobulin release from platelet a - 
granules from 2258 ±151 iu/ml to 3692 ±211 iu/ml (p=0.002, n=5) [Figure 7-8A]. 
This response was inhibited by the CD40 blocking antibodies M2 (p=0.002) and M3 
(p=0.01) and the CD40L blocking antibody TRAP-1 (p=0.01) but not by isotype 
matched control antibody or by the allbp3 blocking peptide eptifibatide .Eptifibatide 
alone had no effect. sCD40LT increased 14C-5HT release from platelet dense 
granules from 3.8 ± 0.2% to 8.9 +_1.1% (p=0.03, n=5) [Figure 7-8B]. This response 
was inhibited by the CD40 blocking antibodies M2 (p=0.04) and M3 (p=0.04) and the
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CD40L blocking antibody TRAP-1 (p=0.04) but not by isotype matched control 
antibody or by the otIIbp3 blocking peptide eptifibatide. Eptifibatide alone had no 
effect.
Figure 7-8. a  and dense granule release.
Platelet p-thromboglobulin release from ct-granules (A) and 14C-5HT release from 
dense granules following stimulation with sCD40LT for 30 minutes at 37°C. Both P- 
thromboglobulin and 14C-5HT release are abrogated by pre-incubation with 10 pg/ml 
o f CD40L blocking antibody TRAP-1 or CD40 blocking antibodies M2 and M3 but 
not isotype matched control antibody. The allbp3 blocking peptide eptifibatide did 
not inhibit granule release caused by sCD40LT. Eptifibatide alone had no effect. 
Effect o f maximal stimulation with 100 pM SFLLRN is shown for comparison in the 
14C-5HT experiments. As SFLLRN stimulation caused secretion of 5-fold higher 
amounts o f p-thromboglobulin, the SFLLRN data is not shown for these experiments. 
Means + SEMs of 5 representative experiments shown.
7.3,6 Platelet-leukocyte complexes
As shown in Chapter 4, in whole blood, CD62P expressed on platelets binds to 
neutrophils and monocytes, which express the specific counter-receptor, PSGL-1. This 
adhesive interaction activates leukocytes and allows the formation of platelet- 
leukocyte complexes (Peters et al, 1999), which are important in the recruitment of 
leukocytes to sites of thrombosis and tissue injury (McEver et al, 1997). Since 
sCD40LT preferentially causes platelet CD62P expression rather than allbp3 
activation, the capacity of sCD40LT to cause the formation of platelet-neutrophil 
complexes in whole blood was investigated. Without platelet activation, 14.1 + 0.6% 
of neutrophils formed complexes with adherent platelets. This increased to 31.6 + 
4.3% following stimulation with sCD40LT (p=0.02, n=5). Platelet-neutrophil complex 
formation was inhibited by the CD40L blocking antibody TRAP-1 (p=0.02), the 
CD40 blocking antibodies M2 (p=0.03) and M3 (p=0.03) and by the CD62P blocking 
antibody G1 (p=0.01) but not by control antibody showing that the effect requires a 
CD40L-CD40 interaction and that it depends on expression of platelet CD62P [Figure 
7-9]. Similar results were obtained with platelet-monocyte complexes (not shown).
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Figure 7-9. Platelet-leukocyte complex formation.
A significant increase in platelet-neutrophil complex formation from unstimulated (A) 
was observed following addition o f 1 pg/ml sCD40LT to whole blood for 30 minutes 
at 37°C (B). Isotype matched control antibody at lOpg/ml did not inhibit complex 
formation (C). This was abrogated by pre-incubation with 10 pg/ml of CD40L 
blocking antibody TRAP-1 (D) and CD40 blocking antibodies M2 and M3 (E and F) 
and by the CD62P blocking antibody G1 at 10 pg/ml (G). Stimulation with 100 pM 
SFLLRN is shown for comparison (H). A representative FACS plot from 5 separate 
experiments is shown. The neutrophil population has been gated and CD42a PerCP is 
used as a platelet marker to identify platelet-neutrophil complexes. Control antibody 
binding falls within the lower right quadrant (not shown). The % of the total 
population in the upper right quadrant (% neutrophils bound to platelets) is shown.
Forward scatter
7.3.7 Platelet shape change
Electron microscopy revealed that platelet activation by sCD40LT also induced 
pseudopodia formation and other morphological changes typically associated with 
activation [Figure 7-10].
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Figure 7-10. Platelet shape change.
Electron micrographs o f unstimulated platelets (A) and platelets stimulated with 1 
pg/ml sCD40LT (B) for 30 minutes at 37°C. Stimulated platelets lose the uniform 
discoid shape o f resting platelets, becoming heterogeneous and forming pseudopodia. 
These changes are typical o f activated platelets.
7.3.8 CD40 ligation does not induce intracellular calcium flu x
sCD40LT did not induce intracellular calcium flux, in contrast to SFLLRN, which is 
known to cause calcium flux via activation o f the G protein-coupled thrombin receptor 
PAR-1 [Figure 7-11].
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Figure 7-11. Intracellular calcium flux.
sCD40L did not induce intracellular calcium flux, in contrast to SFLLRN, which is 
known to cause calcium flux via activation of the G protein-coupled thrombin receptor 
PAR-1. Means + SEMs of 3 separate experiments shown. The error bars are too small 
to be visible for many data points.
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7,3.9 p3 integrin activation
Platelet activation with the agonists ADP, SFLLRN or collagen results in a 
conformational change in the constitutively expressed p3 integrin <xllbp3, causing it to 
expose its high affinity ligand binding site which is recognised by the monoclonal 
antibody Pac-1 (Shattil et al, 1985). Here, sCD40LT caused a small but significant 
increase in Pac-1 antibody binding from a median fluorescence intensity of 19.9+ 1.8 
to 28.1 + 2.9 (p=0.004, n=5). This was inhibited by the CD40L blocking antibody 
TRAP-1 (p=0.03) and the CD40 blocking antibodies M2 (p=0.04) and M3 (p=0.06). 
There was no inhibition by isotype matched control antibody [Figure 7-12A].
To determine if sCD40LT can induce platelet aggregation, normal platelets were 
exposed to sCD40LT and aggregation measured in an aggregometer. Despite the
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modest increase in platelet surface Pac-1 binding indicating allbp3 activation, 
sCD40LT did not induce aggregation of platelets [Figure 7-12B]. Furthermore, 
sCD40LT did not alter the capacity of both ADP and arachidonic acid to induce 
platelet aggregation at a range of concentrations (not shown) and CD40L blocking 
antibody TRAP-1 had no effect on aggregation of platelets from normal controls (not 
shown). Moreover, platelets from patients with CD40L deficiency, which, as shown in 
Chapter 3, do not express CD40L upon stimulation (Inwald et al, 2000a) aggregated 
normally [Figure 7-12B]. These experiments demonstrate that CD40L is not involved 
in homotypic platelet adhesion via allbp3 at the low shear rates encountered in an 
aggregometer.
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Figure 7-12. P3 integrin activation.
A. Pac-1 binding. A small but significant increase in Pac-1 binding is observed 
following stimulation with 1 pg/ml sCD40LT. This response is abrogated by pre­
incubation with 10 pg/ml o f CD40L blocking antibody TRAP-1 and CD40 blocking 
antibodies M2 and M3 but not by isotype matched control antibody. Means + SEMs 
of 5 representative experiments shown.
B. Platelet aggregation. Platelet aggregation at low shear is not modulated by 
sCD40LT. Aggregometry plots are shown from a normal individual (CD40L+) and a 
patient with X-linked hyper-IgM syndrome (CD40L-) showing normal aggregation in 
response to 5 pM ADP and 1 pg/ml collagen. This suggests that platelet CD40L- 
CD40 interactions are not adhesive in nature. Additionally, platelet aggregation is not 
induced by ligation o f CD40 as no aggregation is observed with platelets from a 
normal individual in response to addition of 1 pg/ml sCD40LT. Representative plots 
from 3 separate experiments are shown.
CD40L -/•CD40L+/+
collagen
sCD40L
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7.4 Discussion
Platelets are important mediators of inflammation as well as haemostasis. They 
possess adhesion molecules, which facilitate cell-cell interactions with neutrophils, 
monocytes and endothelial cells, and can activate these cells through direct contact or 
through the release of soluble mediators from platelet granules. Platelets express the 
transmembrane signalling protein CD40L within seconds of activation (Henn et al, 
1998) and following platelet activation with thrombin, ADP or collagen a soluble 18 
kDa form of CD40L is also released. Work reported by Henn et al (at the time the 
work described in this thesis was being performed) demonstrated that platelets express 
CD40 (Henn et al, 2001) and that soluble CD40L, released upon platelet activation, 
binds to platelet CD40, leading to further cleavage of membrane bound CD40L and 
release of a soluble form of CD40L, which does not have an inflammatory effect on 
endothelial cells. Platelet soluble CD40L was proposed as a homeostatic regulator of 
the endothelial inflammatory response to activated platelets (Henn et al, 2001). 
However, thus far platelet activation via CD40 has not been described.
In this present study it is shown for the first time that platelets can be activated 
through ligation of constitutively expressed CD40.
Ligation of platelet CD40 by sCD40LT caused platelet CD62P expression, a-granule 
and dense granule release, morphological changes typically associated with activation 
and modest increases in allbp3 activation.
Platelets constitutively express CD40 and upon stimulation with SFLLRN, 23.1 % are 
induced to co-express CD40L. Other cells also have the capacity to co-express CD40L 
and CD40, including vascular endothelial cells and macrophages in vitro (Mach et al,
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1997b; Reul et al, 1997) and in vivo in the context of atherosclerosis (Mach et al, 
1997b). SFLLRN mimics the physiological action of thrombin and therefore platelet 
CD40L-CD40 interactions should occur during thrombus formation -  an everyday 
event in healthy individuals. Co-expression of CD40 and CD40L has been 
demonstrated in human thrombus (Henn et al, 2001) and platelet activation with 
CD40L expression occurs even in the absence of thrombus formation in conditions 
such as sickle cell disease (Inwald et al, 2000b), acute coronary syndromes (Garlichs 
et al, 2001a) and hypercholesterolemia (Garlichs et al, 2001b). Platelet derived 
CD40L may have the capacity to stimulate resting platelets by binding to CD40 
during direct cell-cell contact or, as platelets are a major source of soluble CD40L, via 
release of soluble CD40L. Concentrations of sCD40L of up to 50 ng/ml have been 
reported in peripheral blood in humans in disease states (Kato et al, 1999; Viallard et 
al, 2002). Although the dose response curve demonstrates that this is at the lower end 
of the range required for platelet activation in vitro, much higher concentrations than 
this may be generated at sites of platelet activation and tissue injury.
The soluble CD40L used in this investigation was a trimeric form held together by an 
isoleucine zipper motif. This trimeric form of sCD40L is far more active than sCD40L 
monomer (Morris et al, 1999). Molecular modelling (Peitsch et al, 1993) and 
crystallography (Karpusas et al, 1995) suggest that CD40L on the cell surface exists as 
a trimer but it has been suggested that platelet derived soluble CD40L is monomeric 
(Henn et al, 2001). Although these results suggest that membrane bound CD40L 
trimer is likely to have the capacity to cause platelet activation, the role of platelet 
derived CD40L is not clear and requires further investigation to establish its biological 
function.
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Andre at al demonstrated that at high shear (1000/s) and during the formation of 
arterial thrombus in an animal model, CD40L can bind to the platelet allbp3 ligand 
binding site via the KGD integrin binding sequence, and promote platelet spreading 
and thrombus formation respectively (Andre et al, 2002b). However, CD40L had no 
effect on aggregation at low shear. All aggregometry experiments were also conducted 
at low shear (100/s) and the results indicate that CD40LT does not modulate platelet 
aggregation under these conditions. However, sCD40LT caused a modest increase in 
platelet allbp3 activation. The increase in allbp3 activation caused by sCD40LT was 
abrogated by both CD40 and CD40L blocking antibodies, indicating that activation 
was occurring as a result of a CD40L-CD40 interaction. This is an additional 
mechanism for CD40L induced allbp3 activation to that proposed by Andre et al and 
may also become important at high shear rates.
The principal effects of platelet CD40 ligation were to induce platelet shape change 
and alpha and dense granule release with minimal P3 integrin activation. This pattern 
of activation is distinct from that seen with other platelet agonists. An explanation for 
this observation may be that ADP, thrombin and thromboxane A2 are G-protein 
coupled receptors, while CD40 is not. p3 integrin activation requires G-protein 
mediated inside-out signalling, which is always associated with intracellular calcium 
flux (Shattil et al, 1998). In contrast, CD40 signals through protein kinase cascades, 
including protein kinase C (PKC) (Park et al, 1999). PKC signalling also occurs in 
platelets but usually in combination with increases in cytosolic calcium. Interestingly, 
phorbol esters, which induce PKC signalling alone, have been reported to cause 
platelet secretion without raising cytosolic calcium levels and take several minutes to
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induce a weak aggregation response (Rink et al, 1983; (Stafford et al, 2001; Watson et 
al, 1989). The pattern of platelet activation caused by CD40, with substantive granule 
release but minimal (33 integrin activation could be consistent with platelet CD40 
signalling via PKC. The finding that sCD40LT does not induce calcium flux is also 
consistent with this explanation. However, further work is required to clarify the 
signalling pathways activated by CD40 ligation in the platelet.
The biological importance of platelet CD40 mediated platelet activation is likely to 
stem from the release of alpha and dense granule release, the contents of which have a 
number of biological properties including leukocyte activation (Piccardoni et al,
1996). The a-granule adhesion molecule CD62P is also of critical importance in the 
recruitment of leukocytes to sites of thrombosis and inflammation and in the 
formation of circulating platelet-leukocyte complexes (Hamburger et al, 1990; Peters 
et al, 1999). These complexes represent a sub-population of neutrophils and platelets 
primed for adhesion, phagocytosis and bacterial killing (Peters et al, 1999) and their 
significance has been demonstrated in a number of clinical conditions including 
angina, multiple organ failure and SIRS. The enhancement of platelet-leukocyte 
adhesion caused by ligation of platelet CD40 and the pro-inflammatory stimulus 
caused by the release of granule contents may be particularly important where 
platelets are in close proximity to cells expressing CD40L, such as platelets in 
thrombi, and T cells, macrophages and endothelial cells in atherosclerotic plaques 
(Phipps,2000). Induction of platelet-leukocyte adhesion through CD40 mediated 
platelet CD62P expression is likely to provide a mechanism whereby leukocytes can 
be directed to sites of thrombosis, inflammation or tissue injury and in the initiation 
and propagation of atherosclerosis. The findings presented here suggest that CD40
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mediated platelet activation is likely to provide a pivotal link between thrombosis and 
inflammation.
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8. General discussion and future 
developments
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Platelets are critical in haemostasis, coagulation and thrombosis but the influence of 
the platelet is now recognised to extend far beyond haemostasis to inflammation, 
wound healing and vascular remodelling. Platelet CD40L may be a key player in all of 
these processes. Platelet CD40L has the potential to interact with CD40 bearing cells 
including monocytes, endothelial cells, and, as has been demonstrated in this thesis, 
platelets. Andre et al (Andre et al, 2002b) have also recently demonstrated that CD40L 
also has the capacity to contribute directly to the thrombotic process by binding to the 
ligand binding site of allbp3.
At the beginning of this thesis, there was no information on the subcellular location of 
platelet CD40L or on the capacity of platelet CD40L to interact with and activate 
monocytes. CD40 had not been recognised to be constitutively expressed on platelets 
and the potential of CD40L as a platelet agonist was unknown. Throughout this thesis, 
these questions have been investigated in experiments using both blocking antibodies 
and naturally occurring human knockouts of both CD40L (X-linked hyper IgM 
syndrome) and p integrins (Leukocyte adhesion defect type 1 and Glanzmann’s 
thrombasthenia).
While it is now beyond dispute that platelets do express CD40L upon stimulation, 
when the work in Chapter 3 was performed, CD40L had been demonstrated upon 
platelets by only a single group (Henn et al, 1998). In Chapter 3 the presence o f 
CD40L on platelets was further investigated and the subcellular location found to be 
the a-granule membrane. The work in Chapters 4 and 5 has provided valuable insights 
into the mechanism of platelet-monocyte adhesion and into P integrin function in 
haematopoietic cells. Additionally, the work investigating platelet-monocyte adhesion
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poses important questions as to the role of the integrins in this process. In the whole 
blood model used in this thesis, the integrins were found to be redundant in the process 
of platelet-monocyte adhesion. However, previous work looking at platelet-leukocyte 
adhesion under shear has shown that the integrins are critically important. Further work 
is required to determine exactly how shear contributes to this process. In Chapter 6, the 
capacity of platelet derived and soluble trimeric CD40L to induce monocyte cytokine 
production was investigated. This work demonstrated that blood monocytes, in spite of 
constitutively expressing CD40, do not respond to CD40L. The reason for this may be 
related to the level of CD40 expression on the monocyte, the capacity of the monocyte 
to respond to CD40 ligation or the activation status of the monocyte. Unfortunately, 
further work looking at blood derived monocytes in cell culture was not possible due to 
the difficulty of controlling for the confounding effect of thrombin in inducing the 
production of pro-inflammatory cytokines. Thus further investigation was performed 
using THP-1 cells, a monocytoid cell line derived from a child with acute myeloid 
leukemia. These cells also constitutively express CD40 and also did not respond to 
sCD40L or platelet under resting conditions. Following co-culture with interferon-y, 
which upregulated surface CD40 in THP-1 cells, sCD40L induced production of IL-8 
and TNF-a. MCP-1 was not induced. Taken together, these findings are important as 
they may indicate a limited role for platelet CD40L in the induction of monocyte 
cytokine production. However, the importance of the findings in THP-1 cells is unclear 
as the cells are an immortalised cell line and therefore may not be representative of the 
behaviour of healthy blood monocytes in vivo. Further work is therefore required to 
determine if blood derived monocytes behave in the same way as THP-1 cells. This 
work would involve separating blood monocytes to obtain a pure population and then 
stimulating with interferon-y prior to experiments to look at the effects of thrombin-
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stimulated platelets. Work would be required to find the best way of neutralising the 
effect of thrombin on both platelets and monocytes following stimulation in order to 
remove thrombin as a confounding variable. Previous work has used hirudin for this 
purpose. Hirudin is a leech derived protein which antagonises the serine protease 
activity of thrombin. Since the experiments described in this thesis were performed, 
endotoxin free recombinant forms of hirudin have been commercially produced which 
may enable the proposed experiments to be performed. In Chapter 7, platelets were 
found to constitutively express CD40 and to become activated following ligation of 
CD40 with CD40L. This work was performed contemporaneously with the work of 
Henn et al, who also found that platelets constitutively express CD40 but did not 
demonstrate platelet activation following CD40 ligation (Henn et al, 2001). The novel 
work presented here opens up the possibility for platelet-platelet cross talk via a 
CD40L-CD40 interaction. However, an important limitation of the work was that it 
looked only at the effect of soluble trimeric CD40L on platelets. As yet, the capacity of 
platelet derived CD40L to stimulate platelets is not clear. Platelet derived CD40L may 
have the capacity to stimulate resting platelets by binding to CD40 during direct cell­
cell contact or, as platelets are a major source of soluble CD40L, via release of soluble 
CD40L. The biological activity of platelet sCD40L is likely to depend not only on 
local concentration but also on whether it exists as a trimer or monomer. The soluble 
CD40L used in this investigation was a trimeric form held together by an isoleucine 
zipper motif, which is far more active than sCD40L monomer (Morris et al, 1999). 
While Henn et al suggested that 18 kDa platelet sCD40L is monomeric, other workers 
have found that 18 kDa sCD40L sediments on a sucrose gradient with an apparent 
molecular mass of 56 kDa (Pietravalle et al, 1996), suggesting that it spontaneously 
forms trimers. As molecular modelling (Peitsch et al, 1993) and crystallography
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(Karpusas et al, 1995) suggest that membrane bound CD40L is trimeric, membrane 
bound CD40L trimer is likely to have the capacity to cause platelet activation.
Thus further work is necessary to determine the role of platelet CD40L, both 
membrane bound and soluble, in platelet-platelet cross talk. In acute inflammatory 
conditions other than atherosclerosis, the role of CD40L remains largely 
uninvestigated. Work is currently underway to investigate the role of platelet CD40L 
in a number of clinical conditions, which involve inflammation and injury of the 
vascular endothelium, including sickle cell anaemia and meningococcal sepsis. 
Bacterial sepsis should be the next important condition to investigate in this context as 
numerous studies have identified platelets as central to the pathophysiology of 
bacterial sepsis. In meningococcal disease (MD), the paradigm of acute bacterial 
sepsis, there is devastating activation of inflammatory cells and coagulation mediators, 
leading to overt disseminated intravascular coagulation (DIC) with microvascular 
thrombosis, hypoperfusion, and multiple organ failure. There is now considerable 
evidence to show that platelets are important in the induction of endothelial injury in 
MD (Hawrylowicz et al, 1991; McEver,2001; Peters et al, 2003). Thrombocytopenia 
reflects the extent of endothelial activation and damage as platelets adhere to activated 
endothelial cells and to exposed sub-endothelial matrices and activate coagulation 
factors, accelerating disseminated intravascular coagulopathy. Thrombocytopenia is a 
clinically useful prognostic factor in MD and thrombosed vessels are prominent on 
histological examination of skin lesions (Faust et al, 2001; Peters et al, 2001). The 
mechanisms of the coagulopathy of severe systemic inflammation have been 
extensively investigated and known key elements include: activation of the tissue 
factor (TF) pathway by endothelial and monocyte TF expression, consumption or
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inhibition of endogenous anti-coagulant (e.g. anti-thrombin III, protein C), decreased 
fibrinolytic capacity due to increased plasminogen activator inhibitor-1 (PAI-1) and 
reduced activation of protein C (Esmon,2001; Opal et al, 1999). All these processes 
lead to increased thrombin production, which is a profound stimulus to platelet 
activation and causes platelets to mobilise CD40L (Henn et al, 1998). As platelet 
CD40L is a major pro-inflammatory (Henn et al, 1998) and pro-thrombotic (Slupsky 
et al, 1998) stimulus to vascular endothelial cells, and as sCD40L is known to 
promote arterial thrombosis by binding to activated allbp3 (Andre et al, 2002b), it 
seems likely that platelet CD40L will be a key link between thrombosis and 
inflammation in bacterial sepsis.
The work presented here is an important addition to the current understanding of the 
pro-inflammatory effects of platelet CD40L. However, further work must be done to 
refine the understanding of the role of platelet CD40L in inflammation both in vitro 
and in vivo before clinical studies looking at blocking the effect of platelet CD40L can 
be performed. As CD40L binds to the ligand binding site of activated allbp3 and thus 
promotes platelet spreading and adhesion (Andre et al, 2002b), the possibility of 
blocking this interaction with allbp3 blocking agents such as eptifibatide and 
abciximab is raised. It might also be possible to block CD40L-CD40 interactions with 
CD40 or CD40L blocking antibodies. Once the role of platelet CD40L in inflammation 
is more fully understood, future clinical studies are likely to focus on investigating 
such strategies in conditions as diverse as acute coronary events, stroke, vasculitis and 
sepsis syndrome.
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